var title_f40_57_41872="Mometasone: Patient drug information";
var content_f40_57_41872=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Mometasone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/4/7236?source=see_link\">",
"       Mometasone (nasal): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/30/7654?source=see_link\">",
"       Mometasone (oral inhalation): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/61/13268?source=see_link\">",
"       Mometasone (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10877 Version 27.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-C5FDE4D645-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41872=[""].join("\n");
var outline_f40_57_41872=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/4/7236?source=related_link\">",
"      Mometasone (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?7/30/7654?source=related_link\">",
"      Mometasone (oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?12/61/13268?source=related_link\">",
"      Mometasone (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_57_41873="Absorption of laser and light by various tissues";
var content_f40_57_41873=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F77528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F77528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Absorption of laser and light by various tissues",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 436px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41873=[""].join("\n");
var outline_f40_57_41873=null;
var title_f40_57_41874="Pseudofolliculitis barbae - hair loop";
var content_f40_57_41874=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudofolliculitis barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pseudofolliculitis barbae. A loop of hair exiting and entering the skin is visible at the site of the erythematous papule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41874=[""].join("\n");
var outline_f40_57_41874=null;
var title_f40_57_41875="Drugs that elevate the serum creatinine concentration";
var content_f40_57_41875=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Drugs that elevate the serum creatinine concentration",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     Lesley A Inker, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     Ronald D Perrone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41875/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/57/41875/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 5, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An elevation in the serum creatinine concentration (SCr) usually reflects a reduction in the glomerular filtration rate and is associated with a concomitant rise in the blood urea nitrogen (BUN). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=see_link\">",
"     \"Assessment of kidney function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are, however, a variety of settings in which the SCr can increase acutely independent of the GFR, and therefore, in which there is no true change in overall kidney function. This may be due to one of three factors: decreased creatinine secretion; interference with the serum assay; or enhanced creatinine production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DECREASED SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, approximately 15 percent of the urinary creatinine is derived from secretion in the proximal tubule. This value can rise to as high as 50 percent in patients with advanced kidney disease and accounts for the overestimation of the true GFR by the creatinine clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"     \"Calculation of the creatinine clearance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Creatinine is an organic cation in the physiologic pH range and is secreted by the organic cation secretory pump that can be inhibited by other organic cations. Commonly used drugs that can interfere with creatinine secretion and, therefore, result in a self-limited and reversible rise in the SCr by as much as 0.4 to 0.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (35 to 44",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    without changing the true GFR include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antimicrobial",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"       trimethoprim",
"      </a>",
"      (which is most often given in combination with sulfamethoxazole) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The antiarrhythmic drug",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/3/5176?source=see_link\">",
"       dronedarone",
"      </a>",
"      (which is used in some patients with atrial fibrillation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The H2-blocker",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       cimetidine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/4,5\">",
"       4,5",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       Ranitidine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"      , which are other commonly used H2-blockers, have a much less prominent effect on creatinine handling [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/5\">",
"       5",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The effect of cimetidine has been used clinically to improve the accuracy of the creatinine clearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/4,6,7\">",
"       4,6,7",
"      </a>",
"      ]. By competitively inhibiting creatinine secretion, the creatinine clearance becomes a more accurate measure of the true glomerular filtration rate. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=see_link\">",
"       \"Calculation of the creatinine clearance\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      disoproxil fumarate (TDF), a drug used to treat chronic hepatitis B infection and HIV infection, has been reported to acutely increase the serum creatinine, thereby decreasing the estimated GFR. It is not clear whether this is due to an effect on creatinine secretion or on filtration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/8-11\">",
"       8-11",
"      </a>",
"      ]. There is no direct evidence that TDF inhibits creatinine secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INTERFERENCE WITH THE SERUM ASSAY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum creatinine is most often measured by the alkaline picrate method. This colorimetric assay can recognize other compounds as creatinine chromagens, particularly acetoacetate in diabetic ketoacidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/12\">",
"     12",
"    </a>",
"    ]. In this setting, the SCr can rise by 0.5 to 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or more (44 to 176",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    a change that is rapidly reversed with insulin therapy.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     Cefoxitin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    are other drugs that can produce a similar effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Ektachem (Eastman Kodak Co., Rochester, New York) method, using the enzyme creatinine iminohydrolase, and the creatinine PAP method (Boehringer Mannheim, Mannheim, Germany), using the enzymes creatininase, creatinase, and sarcosine oxidase, yield creatinine values comparable to those obtained using the kinetic alkaline picrate method. In general, these methods appear to have less interferences than the alkaline picrate methods, but there are reports of interfering substances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/15\">",
"     15",
"    </a>",
"    ]. As an example, the antifungal agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    interferes with the Ektachem measurement; it may increase the value by as much as 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It seems likely in the future that more specific assays for creatinine will eliminate the problem of drug interference. One possible method is the use of an artificial receptor that is specific for creatinine and that undergoes a color change when creatinine is bound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENHANCED CREATININE PRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The SCr varies during the day, rising by as much as 0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (44 to 88",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    after a large cooked meat meal (since muscle contains creatine, which is converted to creatinine by the heat from cooking) and then returning slowly to the baseline level [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been suggested that the serum creatinine concentration rises more rapidly with rhabdomyolysis (up to 2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or 220",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    per day) than with other causes of acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/21\">",
"     21",
"    </a>",
"    ]. Release of preformed creatinine from injured muscle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    release of creatine that is then converted into creatinine in the extracellular fluid have been proposed to explain this finding. However, neither of these mechanisms appears to account for the increase in the serum creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/22\">",
"     22",
"    </a>",
"    ]. An alternative explanation is that rhabdomyolysis often affects men with a high muscle mass and a higher rate of creatinine production than seen in frequently ill patients with other forms of acute renal failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Creatine supplements are increasingly used in health and disease. For most people, this will not lead to increases in serum creatinine levels (or declines in estimated GFR). One randomized control trial of patients with diabetes showed no effect on GFR measured using (51)Cr-EDTA clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41875/abstract/23\">",
"     23",
"    </a>",
"    ], despite higher muscle phosphoryl creatine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/19/9529?source=see_link&amp;anchor=H16909042#H16909042\">",
"     \"Non-hormonal performance enhancement\", section on 'Creatine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22322751\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small number of drugs affect the serum creatinine level. There are two primary mechanisms for this. The drug may compete with the secretion of creatinine at the level of the kidney tubule or may interfere with the assay. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Decreased secretion'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Interference with the serum assay'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/1\">",
"      Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/2\">",
"      Berg KJ, Gjellestad A, Nordby G, et al. Renal effects of trimethoprim in ciclosporin- and azathioprine-treated kidney-allografted patients. Nephron 1989; 53:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/3\">",
"      Duncker D, Oswald H, Gardiwal A, et al. Stable cystatin C serum levels confirm normal renal function in patients with dronedarone-associated increase in serum creatinine. J Cardiovasc Pharmacol Ther 2013; 18:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/4\">",
"      Hilbrands LB, Artz MA, Wetzels JF, Koene RA. Cimetidine improves the reliability of creatinine as a marker of glomerular filtration. Kidney Int 1991; 40:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/5\">",
"      Rocci ML Jr, Vlasses PH, Ferguson RK. Creatinine serum concentrations and H2-receptor antagonists. Clin Nephrol 1984; 22:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/6\">",
"      Kemperman FA, Silberbusch J, Slaats EH, et al. Follow-up of GFR estimated from plasma creatinine after cimetidine administration in patients with diabetes mellitus type 2. Clin Nephrol 2000; 54:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/7\">",
"      Tangri N, Alam A, Edwardes MD, et al. Evaluating cimetidine for GFR estimation in liver transplant recipients. Nephrol Dial Transplant 2010; 25:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/8\">",
"      Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/9\">",
"      J&uuml;lg BD, Bogner JR, Crispin A, Goebel FD. Progression of renal impairment under therapy with tenofovir. AIDS 2005; 19:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/10\">",
"      Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007; 21:1431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/11\">",
"      Vrouenraets SM, Fux CA, Wit FW, et al. Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity. AIDS 2011; 25:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/12\">",
"      Molitch ME, Rodman E, Hirsch CA, Dubinsky E. Spurious serum creatinine elevations in ketoacidosis. Ann Intern Med 1980; 93:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/13\">",
"      Saah AJ, Koch TR, Drusano GL. Cefoxitin falsely elevates creatinine levels. JAMA 1982; 247:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/14\">",
"      Mitchell EK. Flucytosine and false elevation of serum creatinine level. Ann Intern Med 1984; 101:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/15\">",
"      Myers GL, Miller WG, Coresh J, et al. Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program. Clin Chem 2006; 52:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/16\">",
"      Smith CH, Landt M, Steelman M, Ladenson JH. The Kodak Ektachem 400 Analyzer evaluated for automated enzymic determination of plasma creatinine. Clin Chem 1983; 29:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/17\">",
"      Noble MA, Harper B, Grant AG, Bernstein M. Rapid determination of 5-fluorocytosine levels in blood. J Clin Microbiol 1984; 20:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/18\">",
"      Herrington D, Drusano GL, Smalls U, Standiford HC. False elevation in serum creatinine levels. JAMA 1984; 252:2962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/19\">",
"      Bell TW, Hou Z, Luo Y, et al. Detection of creatinine by a designed receptor. Science 1995; 269:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/20\">",
"      Payne RB. Creatinine clearance: a redundant clinical investigation. Ann Clin Biochem 1986; 23 ( Pt 3):243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/21\">",
"      Hamilton RW, Gardner LB, Penn AS, Goldberg M. Acute tubular necrosis caused by exercise-induced myoglobinuria. Ann Intern Med 1972; 77:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/22\">",
"      Oh MS. Does serum creatinine rise faster in rhabdomyolysis? Nephron 1993; 63:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41875/abstract/23\">",
"      Gualano B, de Salles Painelli V, Roschel H, et al. Creatine supplementation does not impair kidney function in type 2 diabetic patients: a randomized, double-blind, placebo-controlled, clinical trial. Eur J Appl Physiol 2011; 111:749.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2361 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-2E861B2D37-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41875=[""].join("\n");
var outline_f40_57_41875=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22322751\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DECREASED SECRETION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INTERFERENCE WITH THE SERUM ASSAY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENHANCED CREATININE PRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22322751\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/45/36570?source=related_link\">",
"      Assessment of kidney function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/23/35190?source=related_link\">",
"      Calculation of the creatinine clearance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/19/9529?source=related_link\">",
"      Non-hormonal performance enhancement",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_57_41876="Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds";
var content_f40_57_41876=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Physiologic and pharmacologic maneuvers in the differential diagnosis of heart murmurs and sounds",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41876/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41876/contributors\">",
"     Kanu Chatterjee, MB, FRCP, FCCP, FACC, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41876/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41876/contributors\">",
"     Catherine M Otto, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41876/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41876/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/57/41876/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac auscultation is one of the most useful investigative tools to detect alterations in cardiovascular anatomy and physiology. Physiologic maneuvers during auscultation (dynamic auscultation) may sufficiently alter the systemic hemodynamics to change the character, behavior, and intensity of heart sounds and murmurs, thereby improving the diagnostic accuracy of the physical examination (",
"    <a class=\"graphic graphic_figure graphicRef61744 \" href=\"mobipreview.htm?16/62/17391\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The most common maneuvers used during auscultation will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef69748 \" href=\"mobipreview.htm?25/56/26508\">",
"     table 1",
"    </a>",
"    ). Concerns about the use of these maneuvers are that they may be difficult to interpret and may not be reproducible, particularly when performed by nonexperts, and their diagnostic utility has rarely been validated.",
"   </p>",
"   <p>",
"    In current clinical practice, echocardiography is the standard for establishing the cause of a murmur. The 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of patients with valvular heart disease included recommendations for the use of echocardiography in patients with symptomatic and asymptomatic murmurs (",
"    <a class=\"graphic graphic_table graphicRef50108 \" href=\"mobipreview.htm?36/4/36939\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41876/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A full discussion of cardiac auscultation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RESPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Venous return to the right ventricle increases during normal inspiration resulting in an increase in its volume. In contrast, inspiration causes a decrease in venous return to the left ventricle and a reduction in its volume. These changes in venous return can alter the intensity of murmurs and heart sounds, primarily those that originate from the right side of the heart. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During inspiration there is an increase in the splitting of S2 as A2 and P2 are separated.",
"     </li>",
"     <li>",
"      Third (S3) and fourth (S4) heart sounds of right ventricular origin usually diminish with expiration and increase with inspiration. An S3 and S4 originating from the left side of the heart may increase with expiration and decrease with inspiration.",
"     </li>",
"     <li>",
"      In tricuspid stenosis, the opening snap diminishes with expiration and increases with inspiration. In contrast, the opening snap of mitral stenosis increases with expiration and decreases with inspiration.",
"     </li>",
"     <li>",
"      Pulmonary ejection sound of valvular origin decreases in intensity during inspiration.",
"     </li>",
"     <li>",
"      Inspiration increases the intensity of murmurs originating from the right side of the heart, including the diastolic murmurs of tricuspid stenosis and pulmonary regurgitation, the systolic murmur of tricuspid regurgitation (Carvallo's sign), and the presystolic murmur of Ebstein's anomaly.",
"     </li>",
"     <li>",
"      In mitral valve prolapse, the inspiratory decrease in venous return to the left side of the heart reduces left ventricular volume; the murmur and click occur earlier and may diminish.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ABRUPT STANDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abrupt standing from the supine position decreases venous return to the heart and, consequently, right and left ventricular diastolic volumes and stroke volumes decline. There also may be a fall in arterial pressure and a reflex increase in heart rate. These hemodynamic changes are associated with changes in the following murmurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Decrease in the intensity of the murmurs of pulmonary and aortic stenosis",
"     </li>",
"     <li>",
"      Decrease in the intensity of the murmurs of mitral and tricuspid regurgitation",
"     </li>",
"     <li>",
"      Earlier onset of the click and prolongation of systolic murmur of mitral valve prolapse",
"     </li>",
"     <li>",
"      Decrease in the intensity of the systolic murmur in ventricular septal defect without significant pulmonary hypertension",
"     </li>",
"     <li>",
"      In hypertrophic cardiomyopathy, a decrease in left ventricular outflow size is associated with an increase in the intensity of the ejection systolic murmur along with a decrease or unchanged carotid pulse volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SQUATTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Squatting from a standing position is associated with a simultaneous increase in venous return (preload) and systemic vascular resistance (afterload) and a rise in arterial pressure. This causes changes in the following murmurs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased intensity of the murmur of mitral regurgitation due to the rise in afterload, which favors the movement of blood in the left ventricle across the insufficient mitral valve rather than entering the systemic circulation across the aortic valve.",
"     </li>",
"     <li>",
"      In patients with mitral valve prolapse there is a delay in the onset of the click and a shortening of the late systolic murmur. These changes reflect the delay in prolapse induced by the increase in preload. However, as mitral regurgitation becomes more severe, the murmur may increase in intensity with squatting because of the increase in afterload.",
"     </li>",
"     <li>",
"      Increase in the magnitude of the left-to-right shunt in ventricular septal defect associated with an increased intensity of the systolic murmur.",
"     </li>",
"     <li>",
"      In patients with tetralogy of Fallot, the net effect of squatting is usually an increase in pulmonary flow, which is associated with increased intensity of the pulmonary ejection systolic murmur. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13752?source=see_link&amp;anchor=H11#H11\">",
"       \"Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot\", section on 'Cardiac auscultation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intensity of the diastolic murmur of aortic regurgitation increases due to augmented regurgitation; intensity of the Austin-Flint murmur also may increase.",
"     </li>",
"     <li>",
"      In hypertrophic cardiomyopathy, intensity of the ejection systolic murmur promptly declines because of an increased left ventricular volume and arterial pressure, which increase the effective orifice size of the outflow tract; the carotid pulse upstroke remains sharp, and the volume may increase.",
"     </li>",
"     <li>",
"      Intensity of the murmur of valvular aortic stenosis shows variable changes, depending upon the type of hemodynamic response; a significant increase in systemic vascular resistance is associated with a decreased intensity of the murmur, an increased left ventricular volume with increased intensity of the murmur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     VALSALVA MANEUVER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hemodynamic changes resulting from a Valsalva maneuver vary with the different phases.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During phase 1, with the onset of the maneuver, there is a transient increase in left ventricular output.",
"     </li>",
"     <li>",
"      During the straining phase, phase 2, there is a decrease in venous return, right and left ventricular volumes, stroke volumes, mean arterial pressure, and pulse pressure; this is associated with a reflex increase in heart rate.",
"     </li>",
"     <li>",
"      During phase 3 (release of Valsalva), which only lasts for a few cardiac cycles, there is a further reduction in left ventricular volume.",
"     </li>",
"     <li>",
"      Phase 4 is characterized by an increase in stroke volume and arterial pressure and reflex slowing of heart rate (the overshoot).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Analysis of changes in the intensity and character of the murmur during phase 2 of the Valsalva maneuver is most useful and practical for the differential diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intensity of flow murmurs, murmurs of aortic and pulmonary stenosis, tricuspid and mitral regurgitation, aortic and pulmonary regurgitation, and mitral and tricuspid stenosis decreases. The volume of the carotid pulse also decreases.",
"     </li>",
"     <li>",
"      The murmur of hypertrophic cardiomyopathy increases in intensity as the left ventricular outflow size decreases with a decreased venous return. The carotid pulse volume also declines.",
"     </li>",
"     <li>",
"      In mitral valve prolapse there is an early onset of the click and murmur due to the decrease in left ventricular volume. The opposite effects are observed during phase 4.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     HAND GRIP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained hand grip for 20 to 30 seconds leads to an increase in systemic vascular resistance, arterial pressure, cardiac output, and left ventricular volume and filling pressure. Hemodynamic changes during hand grip are variable and not always similar in all patients. As an example, the increase in arterial pressure may be relatively greater than the increase in heart rate or cardiac output. Thus, changes in intensity of murmurs are not always predictable.",
"   </p>",
"   <p>",
"    Hand grip is most useful in differentiating between the ejection systolic murmur of aortic stenosis and the regurgitant murmur of mitral insufficiency. Intensity of the murmur of aortic stenosis tends to decrease along with a decreased transvalvular pressure gradient, while the severity and murmur of mitral regurgitation increase. Other murmurs change as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased severity and murmur of aortic regurgitation",
"     </li>",
"     <li>",
"      Increased left-to-right shunt in ventricular septal defect with an increased intensity of the murmur",
"     </li>",
"     <li>",
"      The diastolic murmur of mitral stenosis becomes accentuated because of an increased heart rate",
"     </li>",
"     <li>",
"      In hypertrophic cardiomyopathy, intensity of the ejection systolic murmur softens due to an increased left ventricular volume and arterial pressure",
"     </li>",
"     <li>",
"      The click and the murmur of mitral valve prolapse are delayed because of the increased left ventricular volume",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     POSTEXTRASYSTOLIC POTENTIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If premature beats occur during the clinical examination, analysis of changes in the intensity and character of the murmur during the postextrasystolic (postectopic) beat can provide clues to the diagnosis of valvular heart disease. The postectopic pause is associated with an increased ventricular volume; however, myocardial contractility also increases due to postextrasystolic potentiation. In most circumstances, the effect of increased contractility supersedes the effect of an increased ventricular volume, resulting in the following changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensity of the ejection systolic murmur increases in aortic stenosis and hypertrophic cardiomyopathy. Carotid pulse volume increases in the former and decreases or remains unchanged in the latter. These findings in patients with hypertrophic cardiomyopathy reflect the Brockenbrough sign (postextrasystolic potentiation resulting in increased left ventricular outflow gradient and decreased or unchanged pulse pressure). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=see_link&amp;anchor=H8#H8\">",
"       \"Hemodynamics of valvular disorders as measured by cardiac catheterization\", section on 'Hypertrophic cardiomyopathy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The murmur of aortic regurgitation also may increase due to an increased arterial pressure that augments the regurgitant flow.",
"     </li>",
"     <li>",
"      Tricuspid regurgitation murmurs increase due to an increased right ventricular volume",
"     </li>",
"     <li>",
"      The pansystolic murmur of mitral regurgitation, particularly of rheumatic origin, does not usually change.",
"     </li>",
"     <li>",
"      In mitral valve prolapse, postextrasystolic potentiation causes a rapid rate of ejection and, therefore, an earlier onset of the click and the murmur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     AMYL NITRITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/1/33813?source=see_link\">",
"     Amyl nitrite",
"    </a>",
"    (a predominantly arteriolar dilator) was previously used as a bedside pharmacologic maneuver [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41876/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], but its use is no longer recommended given the utility of echocardiography for distinguishing various cardiac lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=see_link\">",
"       \"Patient information: Heart murmurs (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/17/33042?source=see_link\">",
"       \"Patient information: Vagal maneuvers and their responses (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28053883\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic venous return and pulmonary venous return change reciprocally with inspiration and expiration. These changes alter certain heart sounds and murmurs, primarily those that originate from the right side of the heart. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Respiration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic venous return and systemic arterial pressure change reciprocally with abrupt standing and squatting. These changes alter certain heart sounds and murmurs such as the click and murmur of mitral valve prolapse and the ejection systolic murmur in hypertrophic cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Abrupt standing'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Squatting'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The straining phase of the Valsalva maneuver induces a decrease in intensity of the murmur of aortic stenosis and an increase in the intensity of the systolic ejection murmur of hypertrophic cardiomyopathy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Valsalva maneuver'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hand grip induces an increase in systemic vascular resistance and tends to decrease the intensity of the murmur of aortic stenosis and increase the intensity of the murmur of mitral regurgitation. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Hand grip'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41876/abstract/1\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41876/abstract/2\">",
"      BECK W, SCHRIRE V, VOGELPOEL L, et al. Hemodynamic effects of amyl nitrite and phenylephrine on the normal human circulation and their relation to changes in cardiac murmurs. Am J Cardiol 1961; 8:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41876/abstract/3\">",
"      PERLOFF JK, CALVIN J, DELEON AC, BOWEN P. SYSTEMIC HEMODYNAMIC EFFECTS OF AMYL NITRITE IN NORMAL MAN. Am Heart J 1963; 66:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41876/abstract/4\">",
"      de Leon AC Jr, Perloff JK. The pulmonary hemodynamic effects of amyl nitrite in normal man. Am Heart J 1966; 72:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41876/abstract/5\">",
"      Asymmetric septal hypertrophy. Ann Intern Med 1974; 81:650.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1080 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-190.102.30.19-0FE0C5A6F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41876=[""].join("\n");
var outline_f40_57_41876=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28053883\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RESPIRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ABRUPT STANDING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SQUATTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      VALSALVA MANEUVER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      HAND GRIP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      POSTEXTRASYSTOLIC POTENTIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      AMYL NITRITE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28053883\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1080\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1080|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/62/17391\" title=\"figure 1\">",
"      Systolic murmurs and S2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1080|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?25/56/26508\" title=\"table 1\">",
"      ACC AHA murmurs interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/4/36939\" title=\"table 2\">",
"      Echo asymptomatic murmurs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/27/13752?source=related_link\">",
"      Pathophysiology, clinical features, and diagnosis of tetralogy of Fallot",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/42/36514?source=related_link\">",
"      Patient information: Heart murmurs (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/17/33042?source=related_link\">",
"      Patient information: Vagal maneuvers and their responses (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_57_41877="Erlotinib: Patient drug information";
var content_f40_57_41877=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Erlotinib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     see \"Erlotinib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tarceva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3011589\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tarceva&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10027440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10027442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691944",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat lung cancer.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat pancreatic cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10027441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702044",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to erlotinib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10027446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697041",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are dehydrated, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take good care of your teeth. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2762179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC drugs that are used to lower stomach acid (eg, Pepcid&reg; AC, Prilosec OTC&reg;).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take St John's wort with this drug. This drug may not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696639",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid cigarette smoking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2762180",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use an alcohol-free lotion or cream to help with pimple-like skin effects or dry skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697737",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for at least 2 weeks after stopping the drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10027447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698315",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may have more chance of getting an infection. Wash hands often. Stay away from people with infections, colds, or flu.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698227",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the lungs may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10027449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10027444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10027445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10027450\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10027451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11364 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-189.41.172.26-BFFD0AA7E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41877=[""].join("\n");
var outline_f40_57_41877=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166466\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011589\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027440\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027442\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027441\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027446\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027447\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027449\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027444\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027445\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027450\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10027451\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=related_link\">",
"      Erlotinib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_57_41878="Thyroid nerves normal";
var content_f40_57_41878=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F82397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F82397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Nerve supply of the thyroid gland",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 527px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    It is critical that the superior and recurrent laryngeal nerves be routinely identified and protected in thyroid surgery to reduce the risk of injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41878=[""].join("\n");
var outline_f40_57_41878=null;
var title_f40_57_41879="Pterygium";
var content_f40_57_41879=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pterygium",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41879/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41879/contributors\">",
"     Deborah S Jacobs, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41879/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41879/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41879/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41879/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/57/41879/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pterygium is a triangular wedge of fibrovascular conjunctival tissue that typically starts medially on the nasal conjunctiva and extends laterally onto the cornea (",
"    <a class=\"graphic graphic_picture graphicRef72309 \" href=\"mobipreview.htm?32/3/32831\">",
"     picture 1",
"    </a>",
"    ). \"Pterygium\" refers to the shape of the tissue, which looks like an insect wing. The plural form of pterygium is pterygia.",
"   </p>",
"   <p>",
"    A pterygium is sometimes thought of as a trivial problem, because it is unlikely to threaten visual acuity unless it approaches the visual axis. Nevertheless, it can be a cause of concern to patients because of the abnormal appearance it confers upon the eye and the irritation that is often associated with it. Although benign in the sense that pterygium is not cancerous, it can have important adverse effects on vision if proliferation approaches or reaches the visual axis.",
"   </p>",
"   <p>",
"    This topic will focus on the clinical presentation, diagnosis, and treatment of pterygium. Some conditions that may occasionally be confused with pterygium are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15396?source=see_link\">",
"     \"Photokeratitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Worldwide prevalence of pterygium varies from 1 to 25 percent, depending on the population studied [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Pterygium occurs more commonly in tropical regions, although the exact mechanisms for this are not well-known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The prevalence of pterygium is associated with chronic sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/10\">",
"     10",
"    </a>",
"    ] and specifically to ultraviolet (UV) light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], which may partly explain the geographic variation in prevalence.",
"   </p>",
"   <p>",
"    Several population-based studies have found higher rates of pterygium to be associated with older age, male sex, fewer years of education, and outdoor job location [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/2,6,14-16\">",
"     2,6,14-16",
"    </a>",
"    ]. In the Barbados Eye Study, approximately one-fourth of the black participants had pterygium, a frequency that was 2.5 to 3 times higher than among whites in this study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/1\">",
"     1",
"    </a>",
"    ]. Among black participants, lower rates of pterygium were associated with darker skin complexion. Lower rates were also associated with always using sunglasses outdoors and using prescription glasses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/1,16\">",
"     1,16",
"    </a>",
"    ]. One study in Australia found a higher rate of pterygium in rural areas compared to urban areas (6.7 and 1.7 percent, respectively), partly as a result of ocular sun exposure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 2001 report estimated the direct medical costs of pterygium in Australia to be AUD $8.3 million annually [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although pterygium is classified as a corneal degenerative disorder, it may be considered more of a proliferative condition that has several possible inciting factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/12\">",
"     12",
"    </a>",
"    ]. UV light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/10\">",
"     10",
"    </a>",
"    ], abnormal conjunctival expression of tumor suppressor gene p53 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/18\">",
"     18",
"    </a>",
"    ], presence of angiogenesis-related factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/19\">",
"     19",
"    </a>",
"    ], human papillomavirus infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/20\">",
"     20",
"    </a>",
"    ], and abnormal HLA antigen expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/21\">",
"     21",
"    </a>",
"    ] have all been proposed as pathogenic factors. In particular, UV radiation may trigger events that produce damage to cellular DNA, RNA, and extracellular matrix composition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. There are conflicting data on whether UV exposure early in life is more important than exposure later in life for pterygium proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Hereditary factors may also contribute to pathogenesis and therefore to varying prevalence rates among populations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One model of epithelial cell production suggests that light-induced alteration of limbal stem cell function can account for the classic wedge shape of pterygium, which starts at the limbus (junction of the cornea and sclera) (",
"    <a class=\"graphic graphic_figure graphicRef62615 \" href=\"mobipreview.htm?8/23/8561\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of pterygium is poorly understood. One general observation is that pterygium, when active, can grow over a period of several months to years. Activity is marked clinically by redness and localized thickening, which probably represent active inflammation. When inactive (white and flat), pterygium may remain static for decades with no measurable increase in size or clinical significance. It is unclear how pterygium converts from active to inactive, or if it can be reactivated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common symptoms caused by pterygium are redness and irritation. Visual impairment is less common. In the absence of symptoms, patients may also report a change in the appearance of their eye, or pterygium may be noted incidentally on physical examination.",
"   </p>",
"   <p>",
"    Although common, most redness and irritation associated with pterygium are reportedly mild. Most patients may not seek treatment initially. When patients seek treatment for these irritative symptoms, the symptoms are generally significant, impairing their daily activities.",
"   </p>",
"   <p>",
"    Similarly, mild visual impairment caused by pterygium may be ignored initially, and patients presenting with visual blurriness due to pterygium indicates that visual impairment may be significantly affecting daily function. A pterygium extending more than a few millimeters onto the cornea can impair vision on the basis of induced astigmatism. Astigmatism is a refractive error in which a warped corneal surface causes light rays entering the eye along different planes to be focused unevenly. At low magnitude, astigmatism causes little subjective blur. A pterygium larger than 3.5 mm, and therefore more than halfway to the center of the pupil in a typical cornea of 11 to 12 mm, is likely to cause blurring of vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/25\">",
"     25",
"    </a>",
"    ]. Once a threshold is crossed of 45 percent of the corneal radius, or within 3.2 mm of the visual axis, there is an increasing degree of induced astigmatism with increasing pterygium size [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/26\">",
"     26",
"    </a>",
"    ]. A pterygium that extends further centrally may affect the visual axis, and the resultant opacity may directly impair visual acuity (",
"    <a class=\"graphic graphic_picture graphicRef77243 \" href=\"mobipreview.htm?43/16/44290\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef63403 \" href=\"mobipreview.htm?0/23/370\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=see_link&amp;anchor=H8#H8\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\", section on 'Astigmatism'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An uncommon manifestation of pterygium is restricted eye movement. This occurs when the inflammation over the pterygium causes the conjunctiva and overlying eyelid to stick together, preventing the eye from moving properly. This occurs only following multiple surgical excisions.",
"   </p>",
"   <p>",
"    In the absence of symptoms, patients may report a growth over the clear cornea, which sits anterior to the iris (",
"    <a class=\"graphic graphic_figure graphicRef62615 \" href=\"mobipreview.htm?8/23/8561\">",
"     figure 1",
"    </a>",
"    ). Pterygium is often unnoticed by the patient or clinician until the pterygium appears white against the colored iris (",
"    <a class=\"graphic graphic_picture graphicRef72309 \" href=\"mobipreview.htm?32/3/32831\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef54754 \" href=\"mobipreview.htm?2/60/3013\">",
"     picture 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77243 \" href=\"mobipreview.htm?43/16/44290\">",
"     picture 2",
"    </a>",
"    ), or unless there is a significant vascular component causing redness of the pterygium to contrast with the conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef77243 \" href=\"mobipreview.htm?43/16/44290\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef56287 \" href=\"mobipreview.htm?35/1/35860\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of pterygium is made by the classic clinical appearance of a wedge-shaped growth extending onto the cornea (",
"    <a class=\"graphic graphic_picture graphicRef72309 \" href=\"mobipreview.htm?32/3/32831\">",
"     picture 1",
"    </a>",
"    ). However, pterygium does not always manifest in its classic form, and other conditions may have a similar appearance. It is important to distinguish pterygium from these other conditions, particularly neoplastic lesions.",
"   </p>",
"   <p>",
"    Pterygium is typically soft, varying from nearly flat, white, and amorphous to thick,",
"    <span class=\"nowrap\">",
"     pink/red,",
"    </span>",
"    and fibrovascular. Pterygium is also more likely to be bilateral than unilateral. In contrast, neoplastic lesions are usually more vascular, irregular in both consistency and shape, and typically unilateral (",
"    <a class=\"graphic graphic_picture graphicRef70085 \" href=\"mobipreview.htm?24/31/25073\">",
"     picture 6",
"    </a>",
"    ). Conjunctival neoplasms often occur in axes other than the horizontal axis, in contrast to pterygium.",
"   </p>",
"   <p>",
"    Pinguecula is a degenerative eye condition that is often confused with pterygium. A pinguecula is a yellowish, slightly raised conjunctival lesion arising at the limbal conjunctiva (",
"    <a class=\"graphic graphic_picture graphicRef51561 \" href=\"mobipreview.htm?23/63/24563\">",
"     picture 7",
"    </a>",
"    ). Unlike a pterygium that arises from the limbus and progresses onto the cornea, a pinguecula arises from the limbus and remains confined to the conjunctiva without corneal involvement. The tendency to extend onto the corneal surface is the main distinguishing factor of a pterygium, compared to a pinguecula. There is usually space between the pinguecula and the edge of the cornea (",
"    <a class=\"graphic graphic_picture graphicRef72441 \" href=\"mobipreview.htm?5/31/5617\">",
"     picture 8",
"    </a>",
"    ). Unlike pterygium that more likely appears on the nasal conjunctiva, a pinguecula is more likely to arise from the temporal conjunctiva.",
"   </p>",
"   <p>",
"    Other conditions that can mimic pterygium include localized conjunctivitis, pseudo-pterygium (corneal pannus from chronic blepharitis) (",
"    <a class=\"graphic graphic_picture graphicRef81259 \" href=\"mobipreview.htm?9/30/9711\">",
"     picture 9",
"    </a>",
"    ), and episcleritis (",
"    <a class=\"graphic graphic_picture graphicRef77801 \" href=\"mobipreview.htm?1/42/1699\">",
"     picture 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76962 \" href=\"mobipreview.htm?16/25/16799\">",
"     picture 11",
"    </a>",
"    ). Other clinical findings for these conditions will help distinguish from pterygium. These conditions can also cause lesions outside the horizontal axis, unlike pterygium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=see_link\">",
"     \"Conjunctivitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=see_link\">",
"     \"Blepharitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/80?source=see_link\">",
"     \"Episcleritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a small pterygium can be treated symptomatically for redness and irritation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    or other ocular lubricants. The management of patients with larger lesions that impair visual acuity or eye movement usually involves surgical excision of the pterygium. The decision to perform surgical excision also varies based on the rate of documented growth and degree of induced astigmatism. Surgery should be avoided for cosmetic reasons alone, as pterygium is likely to recur, often times with irritative symptoms.",
"   </p>",
"   <p>",
"    Correction of visual impairment due to refractive error, including astigmatism, is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=see_link&amp;anchor=H19#H19\">",
"     \"Visual impairment in adults: Refractive disorders and presbyopia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are few randomized trials of pterygium that help to direct management, particularly for medical treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/27\">",
"     27",
"    </a>",
"    ]. Clinical practice varies widely based on individual patient and clinician preferences.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical treatments are for symptomatic relief and have not been shown to stop progression or cause regression of a pterygium. Patients with pterygium that does not affect vision or eye movement may be treated symptomatically with topical lubricants including drops, ointments, and gels, all of which are available over-the-counter.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     Artificial tears",
"    </a>",
"    are the most frequently utilized topical lubricant for pterygium and may help to reduce symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/28\">",
"     28",
"    </a>",
"    ]. They can be given 1 to 2 drops to affected area three to four times daily. Preservative-free preparations should be used in patients who have irritative symptoms with preservatives or who need to use lubrication more than four times per day. Preservative-free preparations are more expensive.",
"   </p>",
"   <p>",
"    Treatment with topical decongestants, non-steroidal anti-inflammatory drugs (NSAIDs), and glucocorticoids may also be effective for symptomatic relief of pterygium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/29,30\">",
"     29,30",
"    </a>",
"    ], but are all associated with adverse effects which limit their use. Topical decongestants can be used to treat redness and irritation not relieved by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"     artificial tears",
"    </a>",
"    (eg, Naphcon-A or Visine 1 to 2 drops up to four times daily). The most common side effects of topical decongestants are increased intraocular pressure, high systemic blood pressure, palpitations, and headache. Topical NSAIDs should be prescribed by an ophthalmologist as they can cause keratitis, as well as increased lacrimation and a transient burning sensation. Topical glucocorticoids should also be prescribed only by an ophthalmologist because these can exacerbate infection and cause glaucoma and cataracts with long-term use. These agents should be avoided if the patient is asymptomatic. Any of these medications taken chronically can lead to tachyphylaxis, as well as cause \"rebound\" symptoms when discontinued.",
"   </p>",
"   <p>",
"    Vascular endothelial growth factor (VEGF) inhibitors have been proposed to block angiogenesis responsible for pterygium formation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/31\">",
"     31",
"    </a>",
"    ]. Small cases series found that intralesional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/40/33413?source=see_link\">",
"     ranibizumab",
"    </a>",
"    , injections help to decrease size of primary pterygium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. It is unclear whether VEGF inhibitors improve symptoms related to pterygium or affect long-term prognosis.",
"   </p>",
"   <p>",
"    Follow-up of pterygium with medical management varies based on the degree of pterygium inflammation, growth, and proximity to the visual axis. If there is no visual impairment, restriction of eye movement, encroachment on the pupil, or other concerning",
"    <span class=\"nowrap\">",
"     signs/symptoms,",
"    </span>",
"    monitoring at 6 to 12 month intervals is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery generally involves excision of pterygium, often with adjuvant medical and surgical treatments to help lower rates of recurrence. Limited data are available on surgical outcomes for pterygium, as there are few randomized trials with large numbers of patients and long-term follow-up. Excision usually corrects pterygium-induced astigmatism and visual impairment from a visual axis opacity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/25\">",
"     25",
"    </a>",
"    ]. However, recurrence of pterygium is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for pterygium is indicated in the following situations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Induced astigmatism that causes visual impairment",
"     </li>",
"     <li>",
"      Opacity in the visual axis",
"     </li>",
"     <li>",
"      Documented growth that is threatening to affect the visual axis via astigmatism or opacity",
"     </li>",
"     <li>",
"      Restriction of eye movement",
"     </li>",
"     <li>",
"      Significant cosmetic impact or intractable irritation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent pterygium, which is not uncommon after surgery, can be more symptomatic and problematic to eliminate than primary pterygium. These are factors that should be taken into consideration when surgery is contemplated for small pterygium, irritation, or for cosmetic reasons alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Operative approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical excision is straightforward from a technical perspective. The excision procedure typically lasts about half an hour and is done on an outpatient basis under local anesthesia, with or without IV sedation.",
"   </p>",
"   <p>",
"    Simple &ldquo;bare sclera&rdquo; excision may be associated with higher recurrence rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/36,37\">",
"     36,37",
"    </a>",
"    ], so adjunctive measures including the following are often employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/27,36,38-48\">",
"     27,36,38-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Conjunctival autograft &ndash; Healthy conjunctival tissue from the same eye is onto the bare scleral defect (the area from which the pterygium was removed). Conjunctival autografts are safe and effective in helping to reduce recurrence. There are several variations of this procedure including flaps, rotations, and narrow strips.",
"     </li>",
"     <li>",
"      Limbal conjunctival autograft &ndash; Limbal conjunctival autograft involves including limbal tissue in the strip of conjunctiva which theoretically provides stem cells promoting normal corneal versus conjunctival epithelial regeneration, and acts a better barrier to conjunctival fibrovascular migration. Recurrence rates with limbal conjunctival autograft are similar to conventional conjunctival autograft.",
"     </li>",
"     <li>",
"      Amniotic membrane transplantation &ndash; Amniotic membrane from placental tissue possesses antiangiogenic properties that can be used over a bare scleral defect. Recurrence rates are higher compared to conventional conjunctival autograft, but amniotic membrane transplantation is an important alternative to conjunctival autografts when a pterygium is large, and there is insufficient healthy conjunctiva elsewhere to graft over bare sclera.",
"     </li>",
"     <li>",
"      Fibrin glue to affix grafts or amniotic membrane, in place of sutures, to minimize inflammation",
"     </li>",
"     <li>",
"      Preoperative, intraoperative, or postoperative topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      C",
"     </li>",
"     <li>",
"      Intraoperative topical chemotherapeutic agents (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/15/43254?source=see_link\">",
"       daunorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      , 5-fluorouracil)",
"     </li>",
"     <li>",
"      Preoperative or postoperative topical or subconjunctival VEGF inhibitors",
"     </li>",
"     <li>",
"      Postoperative topical",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      A",
"     </li>",
"     <li>",
"      Beta irradiation",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H850619\">",
"    <span class=\"h3\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ophthalmologist typically follows the patient closely after surgery, treating pain, monitoring for ocular complications, and documenting visual outcome. The progression of pterygium can be documented photographically or with video keratography, which is a form of topographic mapping of the corneal surface.",
"   </p>",
"   <p>",
"    Postoperative pain due to the surgical abrasion of the corneal surface typically requires opioids for several days after surgery, and photophobia usually lasts a few weeks. Pain and photophobia, rather than any anatomic healing complications, limit patient activity in the early postoperative period. Patients are typically prescribed postoperative topical antibiotics for a few days or weeks, and topical glucocorticoids for a few weeks or months. Patients should be monitored by the ophthalmologist while glucocorticoids are prescribed due to possible side effects, including infection and secondary glaucoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative complications are rare for pterygium removal as the procedure is extraocular; however, complications include ocular perforation, as well as possible retinal detachment or endophthalmitis that might occur as a result of inadvertent perforation of the globe.",
"   </p>",
"   <p>",
"    Corneal ulceration is a rare complication associated with the use of adjuncts that have anti-metabolic effect.",
"   </p>",
"   <p>",
"    Repeated excisions tend to lead to corneal scarring, irregular astigmatism, fibrotic restriction of extraocular movements leading to diplopia, and formation of symblepharon (adhesions of eyelid to ocular surface of globe). All of these can contribute to an abnormal appearance of the globe and can interfere with visual function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H491371941\">",
"    <span class=\"h3\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrence rates for simple surgical excision to bare sclera are high, varying between 30 to 80 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/36\">",
"     36",
"    </a>",
"    ], and reported as high as 90 percent in certain subpopulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/37\">",
"     37",
"    </a>",
"    ]. Use of adjunctive measures (eg, conjunctival autograft,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C) decreases recurrences rates substantially, but reported rates vary widely. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Operative approach'",
"    </a>",
"    above.) Regardless, the recurrence rate remains high and is the main reason that surgery is not recommended for a small pterygium, for irritation, or for cosmetic reasons alone.",
"   </p>",
"   <p>",
"    The recurrent lesion may also be more inflamed or grow larger than the initial lesion. Recurrent pterygium has a higher rate of recurrence after excision than primary pterygium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/49\">",
"     49",
"    </a>",
"    ], creating a vicious cycle of excision and recurrence. Recurrences and repeated excisions can lead to disruption of the ocular surface and subsequent complications. Increasing patient age is associated with lower risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/37\">",
"     37",
"    </a>",
"    ]. When there is recurrence, it is typically apparent by four months after surgery. If the pterygium has not recurred after one year, it is not likely to recur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/50\">",
"     50",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of prevention measures for pterygium is unknown. Exposure to UV light is an important risk factor for development of pterygium. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Pathogenesis'",
"    </a>",
"    above.) Several population-based studies suggest that the use of sunglasses and hats may help prevent primary pterygium and that outdoor work is contributory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41879/abstract/1,51,52\">",
"     1,51,52",
"    </a>",
"    ]. It is not yet established that any specific measures reduce rate or progression once pterygium, primary or recurrent, has appeared. Lubrication and protection with a hat",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    UV blocking spectacles that fit closely, wrap around, or have side shields against potentially adverse factors of UV exposure are sensible approaches in the absence of more specific evidence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/40/41601?source=see_link\">",
"       \"Patient information: Pterygium (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A pterygium is a triangular wedge of fibrovascular conjunctival tissue that extends onto the corneal surface (",
"      <a class=\"graphic graphic_picture graphicRef72309 \" href=\"mobipreview.htm?32/3/32831\">",
"       picture 1",
"      </a>",
"      ). Pterygium can cause local symptoms of redness and irritation and can also impair vision by inducing astigmatism or by directly affecting the visual axis. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pterygium should be differentiated from other ocular conditions, including conjunctival neoplasia and pinguecula, as treatments differ. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms including redness and irritation should be treated with topical ophthalmologic lubricants, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/41/24211?source=see_link\">",
"       artificial tears",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Medical therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Indications for surgical removal of pterygium include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Astigmatism leading to visual impairment",
"     </li>",
"     <li>",
"      Opacity in the visual axis",
"     </li>",
"     <li>",
"      Documented growth that is threatening to affect the visual axis via astigmatism or opacity",
"     </li>",
"     <li>",
"      Restriction of eye movement",
"     </li>",
"     <li>",
"      Significant cosmetic impact or intractable irritation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Recurrent pterygium, which is not uncommon after surgery, can be more symptomatic and problematic to eliminate than primary pterygium. These factors should be taken into consideration when surgery is contemplated for small pterygium, irritation, or for cosmetic reasons alone. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Indications'",
"    </a>",
"    above.).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperatively, the patient should be treated for pain, monitored for ocular complications, and visual outcome should be documented. (See",
"      <a class=\"local\" href=\"#H850619\">",
"       'Follow-up'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not yet established that any specific measures reduce rate or progression once pterygium has appeared. Lubrication and protection with a hat",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      UV blocking spectacles that fit closely, wrap around, or have side shields are sensible approaches in the absence of more specific evidence. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/1\">",
"      Luthra R, Nemesure BB, Wu SY, et al. Frequency and risk factors for pterygium in the Barbados Eye Study. Arch Ophthalmol 2001; 119:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/2\">",
"      Cajucom-Uy H, Tong L, Wong TY, et al. The prevalence of and risk factors for pterygium in an urban Malay population: the Singapore Malay Eye Study (SiMES). Br J Ophthalmol 2010; 94:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/3\">",
"      West S, Mu&ntilde;oz B. Prevalence of pterygium in Latinos: Proyecto VER. Br J Ophthalmol 2009; 93:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/4\">",
"      Viso E, Gude F, Rodr&iacute;guez-Ares MT. Prevalence of pinguecula and pterygium in a general population in Spain. Eye (Lond) 2011; 25:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/5\">",
"      Fotouhi A, Hashemi H, Khabazkhoob M, Mohammad K. Prevalence and risk factors of pterygium and pinguecula: the Tehran Eye Study. Eye (Lond) 2009; 23:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/6\">",
"      Ma K, Xu L, Jie Y, Jonas JB. Prevalence of and factors associated with pterygium in adult Chinese: the Beijing Eye Study. Cornea 2007; 26:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/7\">",
"      Anderson JR. A pterygium map. Acta Ophthalmol 1954; 3:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/8\">",
"      Singh G. Pterygium in the tropics. Ophthalmology 1990; 97:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/9\">",
"      Wiwanitkit V. Tropical pterygium. Bull Soc Belge Ophtalmol 2009; :7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/10\">",
"      Threlfall TJ, English DR. Sun exposure and pterygium of the eye: a dose-response curve. Am J Ophthalmol 1999; 128:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/11\">",
"      Mackenzie FD, Hirst LW, Battistutta D, Green A. Risk analysis in the development of pterygia. Ophthalmology 1992; 99:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/12\">",
"      Bradley JC, Yang W, Bradley RH, et al. The science of pterygia. Br J Ophthalmol 2010; 94:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/13\">",
"      Liang QF, Xu L, Jin XY, et al. Epidemiology of pterygium in aged rural population of Beijing, China. Chin Med J (Engl) 2010; 123:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/14\">",
"      Wong TY, Foster PJ, Johnson GJ, et al. The prevalence and risk factors for pterygium in an adult Chinese population in Singapore: the Tanjong Pagar survey. Am J Ophthalmol 2001; 131:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/15\">",
"      McCarty CA, Fu CL, Taylor HR. Epidemiology of pterygium in Victoria, Australia. Br J Ophthalmol 2000; 84:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/16\">",
"      Nemesure B, Wu SY, Hennis A, et al. Nine-year incidence and risk factors for pterygium in the barbados eye studies. Ophthalmology 2008; 115:2153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/17\">",
"      Wlodarczyk J, Whyte P, Cockrum P, Taylor H. Pterygium in Australia: a cost of illness study. Clin Experiment Ophthalmol 2001; 29:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/18\">",
"      Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997; 123:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/19\">",
"      Aspiotis M, Tsanou E, Gorezis S, et al. Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye (Lond) 2007; 21:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/20\">",
"      Piras F, Moore PS, Ugalde J, et al. Detection of human papillomavirus DNA in pterygia from different geographical regions. Br J Ophthalmol 2003; 87:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/21\">",
"      Tsironi S, Ioachim E, Machera M, et al. Immunohistochemical HLA-DR antigen expression with lymphocyte subsets and proliferative activity in pterygium. In Vivo 2002; 16:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/22\">",
"      Solomon AS. Pterygium. Br J Ophthalmol 2006; 90:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/23\">",
"      Tsai YY, Cheng YW, Lee H, et al. Oxidative DNA damage in pterygium. Mol Vis 2005; 11:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/24\">",
"      Kwok LS, Coroneo MT. A model for pterygium formation. Cornea 1994; 13:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/25\">",
"      Fong KS, Balakrishnan V, Chee SP, Tan DT. Refractive change following pterygium surgery. CLAO J 1998; 24:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/26\">",
"      Lin A, Stern G. Correlation between pterygium size and induced corneal astigmatism. Cornea 1998; 17:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/27\">",
"      Todani A, Melki SA. Pterygium: current concepts in pathogenesis and treatment. Int Ophthalmol Clin 2009; 49:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/28\">",
"      Hoffman RS, Power WJ. Current options in pterygium management. Int Ophthalmol Clin 1999; 39:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/29\">",
"      Frucht-Pery J, Siganos CS, Solomon A, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol 1999; 127:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/30\">",
"      Frucht-Pery J, Solomon A, Siganos CS, et al. Treatment of inflamed pterygium and pinguecula with topical indomethacin 0.1% solution. Cornea 1997; 16:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/31\">",
"      Hosseini H, Nejabat M, Khalili MR. Bevacizumab (Avastin) as a potential novel adjunct in the management of pterygia. Med Hypotheses 2007; 69:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/32\">",
"      Fallah Tafti MR, Khosravifard K, Mohammadpour M, et al. Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 2011; 30:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/33\">",
"      Saxena S, Vishwkarma K, Khattri M, Kishore P. Multiple subconjunctival bevacizumab for advanced primary pterygium. Ann Ophthalmol (Skokie) 2010; 42 Spec No:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/34\">",
"      Mandalos A, Tsakpinis D, Karayannopoulou G, et al. The effect of subconjunctival ranibizumab on primary pterygium: a pilot study. Cornea 2010; 29:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/35\">",
"      Hirst LW. The treatment of pterygium. Surv Ophthalmol 2003; 48:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/36\">",
"      Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol 2007; 18:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/37\">",
"      Chen PP, Ariyasu RG, Kaza V, et al. A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 1995; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/38\">",
"      S&aacute;nchez-Thorin JC, Rocha G, Yelin JB. Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol 1998; 82:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/39\">",
"      K&uuml;&ccedil;&uuml;kerd&ouml;nmez C, Akova YA, Altin&ouml;rs DD. Comparison of conjunctival autograft with amniotic membrane transplantation for pterygium surgery: surgical and cosmetic outcome. Cornea 2007; 26:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/40\">",
"      Luanratanakorn P, Ratanapakorn T, Suwan-Apichon O, Chuck RS. Randomised controlled study of conjunctival autograft versus amniotic membrane graft in pterygium excision. Br J Ophthalmol 2006; 90:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/41\">",
"      Amano S, Motoyama Y, Oshika T, et al. Comparative study of intraoperative mitomycin C and beta irradiation in pterygium surgery. Br J Ophthalmol 2000; 84:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/42\">",
"      J&uuml;rgenliemk-Schulz IM, Hartman LJ, Roesink JM, et al. Prevention of pterygium recurrence by postoperative single-dose beta-irradiation: a prospective randomized clinical double-blind trial. Int J Radiat Oncol Biol Phys 2004; 59:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/43\">",
"      Yalcin Tok O, Burcu Nurozler A, Ergun G, et al. Topical cyclosporine A in the prevention of pterygium recurrence. Ophthalmologica 2008; 222:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/44\">",
"      Khakshoor H, Razavi ME, Daneshvar R, et al. Preoperative subpterygeal injection vs intraoperative mitomycin C for pterygium removal: comparison of results and complications. Am J Ophthalmol 2010; 150:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/45\">",
"      Sodhi PK, Verma L, Pandey RM, Ratan S. Comparison between the role of intraoperative mitomycin C and doxorubicin in preventing the recurrence of primary pterygium. Ophthalmic Res 2005; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/46\">",
"      Dadeya S. Intraoperative daunorubicin to prevent the recurrence of pterygium after excision. Cornea 2001; 20:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/47\">",
"      Bekibele CO, Baiyeroju AM, Olusanya BA, et al. Pterygium treatment using 5-FU as adjuvant treatment compared to conjunctiva autograft. Eye (Lond) 2008; 22:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/48\">",
"      Pan HW, Zhong JX, Jing CX. Comparison of fibrin glue versus suture for conjunctival autografting in pterygium surgery: a meta-analysis. Ophthalmology 2011; 118:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/49\">",
"      Solomon A, Pires RT, Tseng SC. Amniotic membrane transplantation after extensive removal of primary and recurrent pterygia. Ophthalmology 2001; 108:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/50\">",
"      Hirst LW, Sebban A, Chant D. Pterygium recurrence time. Ophthalmology 1994; 101:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/51\">",
"      Lu P, Chen X, Kang Y, et al. Pterygium in Tibetans: a population-based study in China. Clin Experiment Ophthalmol 2007; 35:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41879/abstract/52\">",
"      Al-Bdour M, Al-Latayfeh MM. Risk factors for pterygium in an adult Jordanian population. Acta Ophthalmol Scand 2004; 82:64.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6899 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-8913731101-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41879=[""].join("\n");
var outline_f40_57_41879=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Operative approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H850619\">",
"      - Follow-up",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H491371941\">",
"      - Recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6899\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6899|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/23/8561\" title=\"figure 1\">",
"      Eye anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6899|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/3/32831\" title=\"picture 1\">",
"      Pterygium 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/16/44290\" title=\"picture 2\">",
"      Inflamed pterygium extending toward visual axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/23/370\" title=\"picture 3\">",
"      Pterygium crossing visual axis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/60/3013\" title=\"picture 4\">",
"      Pterygium 2 and 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/1/35860\" title=\"picture 5\">",
"      Pterygium with vascularity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?24/31/25073\" title=\"picture 6\">",
"      Conjunctival neoplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/63/24563\" title=\"picture 7\">",
"      Pinguecula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/31/5617\" title=\"picture 8\">",
"      Inflamed pinguecula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/30/9711\" title=\"picture 9\">",
"      Corneal pannus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/42/1699\" title=\"picture 10\">",
"      Mild episcleritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?16/25/16799\" title=\"picture 11\">",
"      Diffuse episcleritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/38/19048?source=related_link\">",
"      Blepharitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/17/20760?source=related_link\">",
"      Conjunctivitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/5/80?source=related_link\">",
"      Episcleritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?40/40/41601?source=related_link\">",
"      Patient information: Pterygium (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/2/15396?source=related_link\">",
"      Photokeratitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/17/2329?source=related_link\">",
"      Visual impairment in adults: Refractive disorders and presbyopia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_57_41880="Age nomogram";
var content_f40_57_41880=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DRUG%2F78350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DRUG%2F78350&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Age nomogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 482px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41880=[""].join("\n");
var outline_f40_57_41880=null;
var title_f40_57_41881="Doppler LA appendage flow during atrial fib and atrial flutter";
var content_f40_57_41881=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78275&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Doppler interrogation of LA appendage flow during atrial fibrillation and atrial flutter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 415px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed-Doppler tracing of LAA flow in atrial fibrillation is seen in panel A. Note the rapid fibrillatory flow waves, which are of higher velocity during ventricular diastole than systole (arrows). Pulsed-Doppler tracing of LAA flow in atrial flutter (with a 2:1 ventricular response) is seen in panel B. Flutter flow waves are, in general, slower and of higher velocity than fibrillatory flow waves.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from the American College of Cardiology. Agmon, Y, Khandheria, BK, Gentile, F, Seward, JB. J Am Coll Cardio, 1999; 34:1867.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.elsevier.com/locate/jacc\">",
"      file://www.elsevier.com/locate/jacc",
"     </a>",
"     <br/>",
"     <a href=\" file://www.sciencedirect.com\">",
"      file://www.sciencedirect.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41881=[""].join("\n");
var outline_f40_57_41881=null;
var title_f40_57_41882="Clinical manifestations and diagnosis of the myelodysplastic syndromes";
var content_f40_57_41882=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Richard M Stone, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Richard A Larson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/57/41882/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/57/41882/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production and a variable risk of transformation to acute leukemia. These disorders may occur de novo or arise years after exposure to potentially mutagenic therapy (eg, radiation exposure, chemotherapy).",
"   </p>",
"   <p>",
"    Patients with MDS have a variable reduction in the production of normal red blood cells, platelets, and mature granulocytes. This often results in a variety of systemic consequences including anemia, bleeding, and an increased risk of infection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link\">",
"     \"Management of the complications of the myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis, epidemiology, clinical manifestations, pathologic features, and diagnosis of MDS will be reviewed here. The cytogenetics, prognosis, and treatment of this syndrome are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=see_link\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link\">",
"     \"Overview of the treatment of myelodysplastic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=see_link\">",
"     \"Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4008903\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of MDS is poorly understood. MDS is a clonal process that is thought to develop from a single transformed hematopoietic progenitor cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Studies suggest that the cell of origin has acquired multiple mutations resulting in dysplasia and ineffective hematopoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the inciting mutation is unknown for the majority of cases, recurrent mutations in genes involved in the RNA splicing machinery (eg, SF3B1, U2AF1, SRSF2, ZRSR2, and U2AF35) have been identified in a subset of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. In particular, somatic mutations in the SF3B1 gene that encodes components of the RNA splicing machinery occurs in 60 to 80 percent of the MDS subtype refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/4,8-13\">",
"     4,8-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H256819286#H256819286\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on 'Gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SF3B1 knockout mice develop ring sideroblasts; SF3B1 mutant patients have mitochondria that have more coarse mitochondrial deposits than in RARS patients with the wild type version of the gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/11\">",
"     11",
"    </a>",
"    ]. In contrast to the favorable prognosis of RARS, another splicing factor mutation (SRSF2) occurs in approximately 15 percent of MDS patients, and this &ldquo;founder&rdquo; mutation carries a negative prognostic impact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Haploinsufficiency of ribosomal proteins, particularly RPS14, has been linked to the anemia seen in MDS cases with deletion of the long arm of chromosome 5 (5q-) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/15\">",
"     15",
"    </a>",
"    ]. Telomere disruption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/16,17\">",
"     16,17",
"    </a>",
"    ] and aberrant or absent expression of microRNA species may be important in MDS pathophysiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MDS genomes are characterized by global DNA hypomethylation with concomitant hypermethylation of gene-promoter regions relative to normal controls. These hypermethylated genes are not expressed (ie, they are silenced). As such, DNA methylation provides an epigenetic mechanism for controlling gene expression. While the underlying mechanism of altered-DNA methylation in MDS genomes is unclear, several studies have implicated mutations in genes that encode enzymes, such as TET2 (ten-eleven translocation), IDH1, and IDH2 (isocitrate dehydrogenase-1 and -2, respectively), that influence DNA methylation directly or indirectly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/19-24\">",
"     19-24",
"    </a>",
"    ]. RUNX1 mutations may disturb expression of genes related to normal hematopoietic aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/25\">",
"     25",
"    </a>",
"    ]. The role of DNA methylation in the pathobiology of MDS is also supported by studies that have demonstrated disease response to hypomethylating agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H2446335#H2446335\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Azacitidine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H2446356#H2446356\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Decitabine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Factors extrinsic to the hematopoietic cell, such as stromal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/26\">",
"     26",
"    </a>",
"    ] and T cell dysregulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/27\">",
"     27",
"    </a>",
"    ], may occur causally or secondarily to the primary genetic lesions. Studies demonstrating the response of MDS to treatment with immunosuppressive agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , antithymocyte globulin) in some patients with MDS, suggest that abnormalities of the immune system may also be responsible for the myelosuppression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    marrow hypocellularity seen in patients with MDS, especially younger subjects with lower-risk disease and presence of HLA-DR15 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Aplastic anemia'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H2447560#H2447560\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The precise incidence of de novo MDS is not known; however, estimates from cancer databases indicate that there are approximately 10,000 cases diagnosed annually in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. One series, for example, reported a crude annual incidence rate of 4.1 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/31\">",
"     31",
"    </a>",
"    ]. A similar incidence rate has been reported in the United Kingdom and Ireland [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In comparison, lower incidence rates of 0.27 per 100,000 have been reported in Eastern Europe, perhaps related to patterns in hospital use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/33\">",
"     33",
"    </a>",
"    ]. The actual incidence of MDS may be higher than that predicted by cancer databases since the nonspecific symptoms may evade detection in early stages of the disease and suspected cases may not undergo definitive testing (ie, bone marrow biopsy) due to comorbidities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MDS occurs most commonly in older adults with a median age at diagnosis in most series of &ge;65 years and a male predominance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/30,34,37-46\">",
"     30,34,37-46",
"    </a>",
"    ]. Onset of the disease earlier than age 50 is unusual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/47,48\">",
"     47,48",
"    </a>",
"    ], with the exception of treatment-induced MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/45,49\">",
"     45,49",
"    </a>",
"    ], but rare cases of MDS have been reported in children at a median age of six years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. The risk of developing MDS increases with age. In one study, the annual incidence per 100,000 was estimated to be 0.5, 5.3, 15, 49, and 89 for individuals &lt;50 years of age; 50 to 59; 60 to 69; 70 to 79; and &gt;80 years, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MDS has been associated with environmental factors (eg, exposure to chemicals, particularly benzene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/54\">",
"     54",
"    </a>",
"    ], radiation, tobacco, or chemotherapy drugs), genetic abnormalities (eg, trisomy 21, Fanconi's anemia, Bloom's syndrome, ataxia telangiectasia), and other benign hematologic diseases (eg, paroxysmal nocturnal hemoglobinuria, congenital neutropenia) (",
"    <a class=\"graphic graphic_table graphicRef72951 \" href=\"mobipreview.htm?22/45/23260\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/55\">",
"     55",
"    </a>",
"    ]. In addition, a rare autosomal dominant condition has been described associated with monocytopenia, susceptibility to infection with mycobacteria, fungi, and papillomaviruses, and the development of myelodysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/56\">",
"     56",
"    </a>",
"    ]. Familial MDS, while rare, has been associated with germ line RUNX1, CEBPA, TERC, TERT, and GATA2 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. &nbsp;Although connective tissue disorders such as relapsing polychondritis, polymyalgia rheumatica, Raynaud phenomenon and Sj&ouml;gren's syndrome, inflammatory bowel disease, pyoderma gangrenosum, Beh&ccedil;et's disease, and glomerulonephritis have been reported in association with MDS, a causal relationship has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/59-64\">",
"     59-64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs and symptoms at presentation of MDS are non-specific. Many patients are asymptomatic at diagnosis and only come to the physician's attention based upon abnormalities found on routine blood counts (eg, anemia, neutropenia, and thrombocytopenia). Others present with symptoms or complications resulting from a previously unrecognized cytopenia (eg, infection, fatigue).",
"   </p>",
"   <p>",
"    Anemia is the most common cytopenia and can manifest as fatigue, weakness, exercise intolerance, angina, dizziness, cognitive impairment, or an altered sense of well being [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/39,65-67\">",
"     39,65-67",
"    </a>",
"    ]. Less commonly, infection, easy bruising, or bleeding precipitate a hematologic evaluation. Systemic symptoms such as fever and weight loss are uncommon, and generally represent late manifestations of the disease or its attendant complications.",
"   </p>",
"   <p>",
"    Physical findings in MDS are non-specific. Sixty percent of patients are pale (reflecting anemia), and 26 percent have petechiae",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    purpura (due to thrombocytopenia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/39\">",
"     39",
"    </a>",
"    ]. Hepatomegaly, splenomegaly, and lymphadenopathy are uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/68\">",
"     68",
"    </a>",
"    ]. Sweet&rsquo;s syndrome (neutrophilic dermatosis) may be the presenting symptom.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2301298\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with MDS have a high incidence of infection related to neutropenia and granulocyte dysfunction (eg, impaired chemotaxis and microbial killing) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Bacterial infections predominate with the skin being the most common site involved. Although fungal, viral, and mycobacterial infections can occur, they are rare in the absence of concurrent administration of immunosuppressive agents. The evaluation and treatment of infections in patients with MDS are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=see_link&amp;anchor=H7196296#H7196296\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Infection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myeloperoxidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/70\">",
"     70",
"    </a>",
"    ] and alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/71\">",
"     71",
"    </a>",
"    ] activities may be diminished in myeloid elements, whereas monocyte-specific esterase may be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/72\">",
"     72",
"    </a>",
"    ]. As a consequence, granulocytes may be dysfunctional and display defective phagocytosis, bactericidal activity, adhesion, and chemotaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/70\">",
"     70",
"    </a>",
"    ], leading to impaired resistance to bacterial infections. Quantitative decreases in natural killer cells are routinely seen.",
"   </p>",
"   <p>",
"    Abnormalities of adaptive immune system may also be found in patients with MDS, although, in the majority of cases, lymphocytes are not derived from the malignant clone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/73\">",
"     73",
"    </a>",
"    ]. Lymphopenia, due largely to a reduced number of CD4+ cells, is inversely related to the number of transfusions received [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. However, CD8+ cells are normal or slightly increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/76\">",
"     76",
"    </a>",
"    ]. Immunoglobulin production is variably affected, with hypogammaglobulinemia, polyclonal hypergammaglobulinemia, and monoclonal gammopathy reported in 13, 30, and 12 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2301305\">",
"    <span class=\"h2\">",
"     Autoimmune abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune abnormalities, although uncommon, may complicate the course of MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/59-64\">",
"     59-64",
"    </a>",
"    ]. Among 221 cases reviewed in one series, 30 (14 percent) experienced autoimmune phenomena, most commonly cutaneous vasculitis and monoarticular arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/59\">",
"     59",
"    </a>",
"    ]. An acute clinical syndrome characterized by cutaneous vasculitis, fever, arthritis, peripheral edema, and pulmonary infiltrates was reported in seven patients. Other autoimmune abnormalities include pericarditis, pleural effusions, skin ulcerations, iritis, myositis, peripheral neuropathy, and pure red cell aplasia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=see_link&amp;anchor=H25#H25\">",
"     \"Diagnosis and differential diagnosis of rheumatoid arthritis\", section on 'Paraneoplastic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=see_link&amp;anchor=H2#H2\">",
"     \"Acquired pure red cell aplasia\", section on 'Etiology and pathogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4008672\">",
"    <span class=\"h2\">",
"     Acquired hemoglobin H disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acquired hemoglobin H disease (also called acquired alpha thalassemia, alpha thalassemia myelodysplastic syndrome) has been documented in approximately 8 percent of cases of MDS and 2.5 percent of those with various myeloproliferative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/79-82\">",
"     79-82",
"    </a>",
"    ], and results in a spectrum of red cell morphologic changes similar to those seen in patients with alpha thalassemia (eg, microcytosis, hypochromia, hemoglobin H-containing red cells) (",
"    <a class=\"graphic graphic_figure graphicRef50325 \" href=\"mobipreview.htm?7/33/7711\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef77536 \" href=\"mobipreview.htm?14/49/15123\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/83\">",
"     83",
"    </a>",
"    ]. An acquired somatic mutation of ATRX, an X-linked gene encoding a chromatin-associated protein, has been linked to this entity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/79\">",
"     79",
"    </a>",
"    ], as have acquired deletions of the alpha globin loci. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hemoglobin H disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=see_link&amp;anchor=H2#H2\">",
"     \"Molecular pathology of the thalassemic syndromes\", section on 'Globin gene anatomy and physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2301312\">",
"    <span class=\"h2\">",
"     Cutaneous manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin lesions are uncommon in patients with MDS; two syndromes occur with sufficient frequency to merit description:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sweet syndrome (acute febrile neutrophilic dermatosis), when complicating the course of MDS, may herald transformation to acute leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/84-87\">",
"       84-87",
"      </a>",
"      ]. Paracrine and autocrine elaboration of the cytokines interleukin-6 and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/13/23767?source=see_link\">",
"       granulocyte colony-stimulating factor",
"      </a>",
"      have been implicated in the pathogenesis of this condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/86\">",
"       86",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=see_link\">",
"       \"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Myeloid sarcoma (also called granulocytic sarcoma or chloroma) of the skin may also herald disease transformation into acute leukemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/88-90\">",
"       88-90",
"      </a>",
"      ]. Since myeloid sarcoma is now considered an extra-medullary presentation of AML, the approach to treatment of patients with myeloid sarcoma without evidence of AML on bone marrow biopsy is similar to that for patients with overt AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/91\">",
"       91",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Myeloid sarcoma'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDS is characterized by abnormal cell morphology (dysplasia) and quantitative changes in one or more of the blood and bone marrow elements (ie, red cells, granulocytes, platelets).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4008100\">",
"    <span class=\"h2\">",
"     Complete blood count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood count with leukocyte differential almost always demonstrates a macrocytic or normocytic anemia; neutropenia and thrombocytopenia are more variable. Pancytopenia (ie, anemia, leukopenia, and thrombocytopenia) is present at the time of diagnosis in up to 50 percent of patients. While isolated anemia is not uncommon, less than 5 percent of patients present with an isolated neutropenia, thrombocytopenia, or monocytosis in the absence of anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Anemia",
"      </strong>",
"      &mdash; Anemia is almost uniformly present and is generally associated with an inappropriately low reticulocyte response. The mean corpuscular volume (MCV) may be macrocytic (&gt;100 femtoliters) or normal. The red cell distribution width (RDW) is often increased reflecting the presence of increased variability in red cell size, also called anisocytosis. The mean corpuscular hemoglobin concentration (MCHC) is usually normal, reflecting a normal ratio of hemoglobin to cell size.",
"     </li>",
"     <li>",
"      <strong>",
"       Leukopenia",
"      </strong>",
"      &mdash; Approximately half of patients have a reduced total white blood cell count (ie, leukopenia), usually resulting from absolute neutropenia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/45\">",
"       45",
"      </a>",
"      ]. Circulating immature neutrophils (myelocytes and myeloblasts) may be identified, but constitute fewer than 20 percent of the leukocyte differential.",
"     </li>",
"     <li>",
"      <strong>",
"       Thrombocytopenia",
"      </strong>",
"      &mdash; Varying degrees of thrombocytopenia are present in roughly 25 percent of patients with MDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/45\">",
"       45",
"      </a>",
"      ]. Unlike anemia, isolated thrombocytopenia is not a common early manifestation of MDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/92\">",
"       92",
"      </a>",
"      ]. However, a thrombocytopenic presentation with minimal morphologic dysplasia has been described in patients in whom del(20q) was the sole karyotypic abnormality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/93\">",
"       93",
"      </a>",
"      ]. Such patients may be easily misdiagnosed as having immune thrombocytopenia (ITP). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Myelodysplasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Thrombocytosis",
"      </strong>",
"      &mdash; Thrombocytosis is less commonly seen in MDS than thrombocytopenia. In one report, of the 388 patients diagnosed with MDS from 1980 to 2006 at a single institution, 31 (8 percent) presented with a high platelet count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/94\">",
"       94",
"      </a>",
"      ]. Among these patients, there was a low incidence of spontaneous bleeding or thromboembolic events. Thrombocytosis has been described in 5q- syndrome, 3q21q26 syndrome, and refractory anemia with ringed sideroblasts with thrombocytosis (RARS-T), which is often associated with activating mutations in JAK2. (See",
"      <a class=\"local\" href=\"#H359933\">",
"       'MDS with isolated del(5q)'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H1583841\">",
"       'RARS with thrombocytosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33613152\">",
"    <span class=\"h2\">",
"     Peripheral blood smear",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood smear usually demonstrates evidence of dysplasia in the red and white blood cell series. Platelets are usually morphologically normal. Less commonly, platelets may be smaller or larger than normal or hypergranular. Megakaryocytic fragments are not seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4010436\">",
"    <span class=\"h3\">",
"     Red blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following erythroid findings have been noted in the peripheral blood of patients with MDS (",
"    <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Erythrocytes are usually normocytic or macrocytic [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/71,95\">",
"       71,95",
"      </a>",
"      ], although patients with refractory anemia with ringed sideroblasts (RARS) may present with a variable population of hypochromic, microcytic red cells [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/96\">",
"       96",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link\">",
"       \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ovalomacrocytosis is the best-recognized morphologic abnormality of erythrocytes. In some cases, however, elliptocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/97,98\">",
"       97,98",
"      </a>",
"      ], teardrops, stomatocytes, or acanthocytes (Spur cells) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/99\">",
"       99",
"      </a>",
"      ] may predominate, reflecting intrinsic alterations in cytoskeletal proteins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/98,100\">",
"       98,100",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Basophilic stippling, Howell-Jolly bodies, and megaloblastoid nucleated red cells may also be found in the peripheral smear (",
"      <a class=\"graphic graphic_picture graphicRef85882 \" href=\"mobipreview.htm?4/39/4722\">",
"       picture 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef85883 \" href=\"mobipreview.htm?32/12/32961\">",
"       picture 3",
"      </a>",
"      ). These peripheral blood findings are associated with dyserythropoietic features in bone marrow precursors, characterized by delayed and distorted nuclear and cytoplasmic maturation, erythroid hyperplasia with megaloblastoid features, nuclear budding, multinucleation, karyorrhexis, and cytoplasmic vacuolization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/71,101\">",
"       71,101",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The presence of reticulocytosis may be indicative of a superimposed autoimmune hemolytic anemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/102\">",
"       102",
"      </a>",
"      ] or may be a marker of delayed reticulocyte maturation, so-called pseudoreticulocytosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/103,104\">",
"       103,104",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4010760\">",
"    <span class=\"h3\">",
"     White blood cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplastic neutrophils are commonly found in the peripheral blood smear. These cells may demonstrate increased size, abnormal nuclear lobation, and abnormal granularity (",
"    <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"     table 2",
"    </a>",
"    ). Monocytes may also demonstrate immature characteristics.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Granulocytes commonly display reduced segmentation, the so-called pseudo-Pelger-Huet (Pelgeroid) abnormality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/42\">",
"       42",
"      </a>",
"      ], often accompanied by reduced or absent granulation (",
"      <a class=\"graphic graphic_picture graphicRef71990 \" href=\"mobipreview.htm?4/45/4816\">",
"       picture 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef85881 \" href=\"mobipreview.htm?40/58/41890\">",
"       picture 5",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/105,106\">",
"       105,106",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occasionally, granulocytes have a clumped chromatin pattern in which blocks of chromatin are separated by a void in nuclear material, creating an appearance of nuclear fragmentation associated with loss of segmentation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/107,108\">",
"       107,108",
"      </a>",
"      ]. Ring-shaped nuclei and nuclear sticks may be identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/109\">",
"       109",
"      </a>",
"      ], particularly in therapy-related MDS. Rarely, a pseudo-Chediak-Higashi anomaly (",
"      <a class=\"graphic graphic_picture graphicRef71313 \" href=\"mobipreview.htm?37/52/38722\">",
"       picture 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/110\">",
"       110",
"      </a>",
"      ] or myelokathexis-like features (",
"      <a class=\"graphic graphic_picture graphicRef78993 \" href=\"mobipreview.htm?29/7/29809\">",
"       picture 7",
"      </a>",
"      ) may be evident [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/111\">",
"       111",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=see_link&amp;anchor=H2#H2\">",
"       \"Congenital neutropenia\", section on 'Severe congenital neutropenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Auer rods within leukemic blasts (",
"      <a class=\"graphic graphic_picture graphicRef78291 \" href=\"mobipreview.htm?17/50/18214\">",
"       picture 8",
"      </a>",
"      ) are rare. The presence of Auer rods in a patient with a prior diagnosis of MDS is often a harbinger of transformation to AML [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47639590\">",
"    <span class=\"h2\">",
"     Bone marrow aspirate and biopsy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4009096\">",
"    <span class=\"h3\">",
"     Bone marrow aspirate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow aspirate provides material for a 500 cell differential count to determine the percentage of blasts in the marrow; it also allows for a detailed cytologic evaluation of the blasts and other cells. Impaired myeloid maturation is often readily apparent. The percentage of granulocytic precursors may be increased and a maturation arrest seen at the myelocyte stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/38\">",
"     38",
"    </a>",
"    ]. Maturation of the cytoplasm may progress more rapidly than the nucleus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The myeloid:erythroid ratio is variable, but often decreased. There is a shift towards more immature precursors, but the blast percentage, by definition, is less than 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. Morphologic abnormalities in the erythroid precursors include large size, nuclear multilobation, nuclear budding, and other abnormal forms. The cytoplasm may show eosinophilia, basophilia, vacuolization, coarse or fine periodic acid-Schiff-positive granules, or a &ldquo;necklace&rdquo; of iron-laden mitochondria surrounding the nuclei (ie, ring sideroblasts detected with Prussian blue staining) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/114,115\">",
"     114,115",
"    </a>",
"    ]. Granulocytic precursors may also demonstrate dysplastic features, such as abnormally large size, abnormal nuclear shape, and increased or decreased cytoplasmic granularity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4009103\">",
"    <span class=\"h3\">",
"     Bone marrow biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bone marrow biopsy gives a general overview of the degree of involvement and specific histologic features associated with the process (eg, fibrosis). Cellularity is usually increased, but may be normal or decreased. Other features include reactive lymphocytosis and mastocytosis, lymphoid aggregates, fibrosis, increased histiocytes, pseudo-Gaucher histiocytes, and hemophagocytic syndrome. In addition, clusters of immature cells may locate centrally in the marrow space rather than along the endosteal surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/114,116\">",
"     114,116",
"    </a>",
"    ]. Special techniques can reveal increased apoptosis in lower risk MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The bone marrow is usually hypercellular and accompanied by single- or multi-lineage dysplasia (",
"    <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/116,118,119\">",
"     116,118,119",
"    </a>",
"    ]. The classic paradox of peripheral pancytopenia despite the presence of a hypercellular bone marrow reflects premature cell loss via intramedullary cell death (apoptosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/120,121\">",
"     120,121",
"    </a>",
"    ]. Although hypocellularity is uncommon, it is found with greatest frequency in therapy-related MDS and must be distinguished from aplastic anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/49\">",
"     49",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Aplastic anemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Red blood cells",
"      </strong>",
"      &mdash; Specific erythroid findings in the bone marrow include (",
"      <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"       table 2",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Ring sideroblasts containing mitochondria laden with iron may be evident on bone marrow specimens stained for the presence of iron (",
"      <a class=\"graphic graphic_picture graphicRef65887 \" href=\"mobipreview.htm?0/44/705\">",
"       picture 9",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H359898\">",
"       'Refractory anemia with ring sideroblasts'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Internuclear bridging characterized by chromatin threads tethering dissociated nuclei reflects impaired mitosis and may contribute to the addition and deletion of genetic material characteristic of MDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although erythroid hyperplasia may represent the predominant finding in association with ineffective erythropoiesis, red cell aplasia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoplasia rarely occur [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Megakaryocytes",
"      </strong>",
"      &mdash; Megakaryocytes are normal or increased in number, and sometimes occur in clusters. Abnormal megakaryocytes, including micromegakaryocytes, large mononuclear forms, megakaryocytes with multiple dispersed nuclei (\"Pawn ball\" changes), and hypogranular megakaryocytes are common bone marrow findings (",
"      <a class=\"graphic graphic_picture graphicRef59897 \" href=\"mobipreview.htm?14/52/15173\">",
"       picture 10",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/42,124,125\">",
"       42,124,125",
"      </a>",
"      ]. Nonlobulated or mononuclear megakaryocytes may be identified, particularly in association with the 5q- syndrome. Antibodies to von Willebrand factor and Ulex europaeus agglutinin-1 may be used to identify these atypical megakaryocytes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/126\">",
"       126",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H359933\">",
"       'MDS with isolated del(5q)'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Abnormal localization of immature precursors",
"      </strong>",
"      &mdash; Granulopoiesis may be displaced from its normal paratrabecular location to more central marrow spaces [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/116,127\">",
"       116,127",
"      </a>",
"      ]. This displacement of granulocyte precursors has been termed \"abnormal localization of immature precursors\" [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/116,127,128\">",
"       116,127,128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Fibrosis",
"      </strong>",
"      &mdash; Mild to moderate degrees of myelofibrosis are reported in up to 50 percent of patients with MDS, and marked fibrosis is found in 10 to 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/129-132\">",
"       129-132",
"      </a>",
"      ]. While myelofibrosis occurs in all subtypes of MDS, it is most common in therapy-related MDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/49\">",
"       49",
"      </a>",
"      ]. Importantly, deposition of mature collagen (detected with a trichrome stain) is uncommon in MDS. Instead, fibrosis takes the form of increases in the number and thickness of reticulin fibers, best detected with a silver impregnation stain [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/133\">",
"       133",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Cytochemistry and immunophenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytochemical stains and immunophenotyping studies may demonstrate a decrease or loss of normal myeloid maturation antigens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/74\">",
"     74",
"    </a>",
"    ], or the presence of antigens not normally expressed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/134\">",
"     134",
"    </a>",
"    ]. Myeloperoxidase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/70\">",
"     70",
"    </a>",
"    ] and alkaline phosphatase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/71\">",
"     71",
"    </a>",
"    ] activities may be diminished in myeloid elements, whereas monocyte-specific esterase may be increased [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Useful cytochemical methods include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Iron stains for identification of ring sideroblasts",
"     </li>",
"     <li>",
"      PAS staining of erythroblasts to assess dyserythropoiesis",
"     </li>",
"     <li>",
"      Peroxidase or Sudan black B staining to confirm the myeloid lineage of blasts",
"     </li>",
"     <li>",
"      Nonspecific or double esterase stains to discern abnormal granulocytic and monocytic forms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Immunocytochemistry may be helpful in order to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Exclude lymphoid origin of primitive blasts",
"     </li>",
"     <li>",
"      Distinguish erythroid precursors via a glycophorin-A-reactive antibody",
"     </li>",
"     <li>",
"      Quantify myeloid progenitors and blasts using antibodies to CD34, CD117, CD13, CD14, and CD33 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/135\">",
"       135",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Detect dysplastic or immature megakaryocytes via antibodies with specificity for von Willebrand factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/126\">",
"       126",
"      </a>",
"      ], factor VIII [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/136\">",
"       136",
"      </a>",
"      ], CD41 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/137\">",
"       137",
"      </a>",
"      ], or the HPI-ID monoclonal antibody [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/138\">",
"       138",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Detect lineage infidelity (eg, myeloid lineage cells expressing nonmyeloid antigens) and confirm the presence of bi- or tri-lineage dysplasia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/139,140\">",
"       139,140",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Automated flow cytometric systems (multiparameter flow cytometry) for scoring dyspoiesis in MDS have been developed and are in the process of being standardized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/141\">",
"     141",
"    </a>",
"    ]. These systems appear to have both diagnostic and prognostic value in patients with MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/141-146\">",
"     141-146",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5152246\">",
"    <span class=\"h3\">",
"     Genetic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MDS is made based upon an evaluation of the bone marrow and peripheral smear in the appropriate clinical context. Detection of certain chromosomal abnormalities by routine cytogenetic analysis, reverse transcriptase polymerase chain reaction (RT-PCR), or fluorescent in situ hybridization (FISH) distinguishes between MDS and acute myeloid leukemia (AML) in some cases, aids in the classification of MDS, and is a major factor in determining prognostic risk group and therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/147\">",
"     147",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H516641#H516641\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Importantly, the following cytogenetic abnormalities, if found, result in the diagnosis of AML, regardless of blast count [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H17#H17\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Bone marrow infiltration'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      t(8;21)(q22;q22); RUNX1-RUNX1T1 (previously AML1-ETO) &nbsp;",
"     </li>",
"     <li>",
"      inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 &nbsp;",
"     </li>",
"     <li>",
"      t(15;17)(q22;q21.1); PML-RARA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similarly, the presence of one of the following chromosomal abnormalities is presumptive evidence of MDS in patients with otherwise unexplained refractory cytopenia and no morphologic evidence of dysplasia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       -7/del(7q)",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       -5/del(5q)",
"      </span>",
"     </li>",
"     <li>",
"      del(13q)",
"     </li>",
"     <li>",
"      del(11q)",
"     </li>",
"     <li>",
"      del(12p) or t(12p)",
"     </li>",
"     <li>",
"      del(9q)",
"     </li>",
"     <li>",
"      idic(X)(q13)",
"     </li>",
"     <li>",
"      t(17p) (unbalanced translocations) or i(17q) (ie, loss of 17p)",
"     </li>",
"     <li>",
"      t(11;16)(q23;p13.3)",
"     </li>",
"     <li>",
"      t(3;21)(q26.2;q22.1)",
"     </li>",
"     <li>",
"      t(1;3)(p36.3;q21)",
"     </li>",
"     <li>",
"      t(2;11)(p21;q23)",
"     </li>",
"     <li>",
"      inv(3)(q21q26.2)",
"     </li>",
"     <li>",
"      t(6;9)(p23;q34)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether other methods to detect chromosomal abnormalities such as FISH, flow-FISH, comparative genomic hybridization (CGH), single nucleotide polymorphism array, and loss of heterozygosity (uniparental disomy) are superior prognostically or may be used to direct therapy remains to be determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/148,149\">",
"     148,149",
"    </a>",
"    ]. Further details regarding cytogenetic changes in patients with MDS are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H303969\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MDS should be considered in any patient with unexplained cytopenia(s) or monocytosis. A careful history should elicit details regarding nutritional status, alcohol and drug use, medications, occupational exposure to toxic chemicals, prior treatment with antineoplastic agents or radiotherapy, and risk factors for",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treatment of human immunodeficiency virus (HIV) infection. Evaluation of the peripheral blood smear and a unilateral bone marrow biopsy and aspirate are key components to the diagnosis of MDS. Common conditions that present with features similar to MDS must be ruled out (eg, HIV; vitamin B12, folate, and copper deficiencies; zinc excess). In addition, clinicians may wish to perform some of the tests recommended for the pretreatment evaluation of patients with MDS in concert with the initial evaluation. These are described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=see_link&amp;anchor=H516641#H516641\">",
"     \"Overview of the treatment of myelodysplastic syndromes\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Even in the setting of neutropenia, thrombocytopenia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    coagulopathy, it is unusual for bleeding or infection to develop at the site of marrow",
"    <span class=\"nowrap\">",
"     aspiration/biopsy",
"    </span>",
"    as a complication of the procedure. The preferred biopsy location in adults is the posterior superior iliac crest and spine, although a different site should be used if the patient has received prior irradiation to this area. The sternum is a reasonable alternative site for bone marrow aspiration, although bone marrow biopsy",
"    <strong>",
"     cannot",
"    </strong>",
"    be performed at this site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5482?source=see_link&amp;anchor=H6#H6\">",
"     \"Bone marrow aspiration and biopsy: Indications and technique\", section on 'Choice of aspiration or biopsy site'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasional patients may have a \"dry tap\" on aspiration, due to the presence of extensive fibrosis. An adequate bone marrow biopsy with touch preparations should provide sufficient material for diagnostic purposes in situations when the marrow cannot be aspirated. A portion of the biopsy can be submitted in saline or, preferably, culture medium (eg, Roswell Park Memorial Institute culture medium, RPMI) and teased apart in the flow cytometry laboratory in an attempt to isolate a cell suspension for analysis.",
"   </p>",
"   <p>",
"    Careful inspection of the peripheral blood smear and bone marrow aspirate is necessary to document the requisite dysplastic cytologic features identifiable in any or all of the hematopoietic lineages. The bone marrow biopsy gives a general overview of the degree of involvement and specific histologic features associated with the process (eg, fibrosis). Since the diagnosis relies heavily on morphologic changes, the quality of the smears is of the utmost importance. Slides should be made from freshly obtained specimens; slides made from specimens exposed to anticoagulants for two or more hours are not satisfactory.",
"   </p>",
"   <p>",
"    To determine the blast percentage in the peripheral blood, a 200 leukocyte differential is recommended; Buffy coat smears may be necessary in severely cytopenic patients. The percentage of blasts in the marrow should be calculated from a 500 cell differential count performed on the bone marrow aspirate. Blast counts from the aspirate are superior to those calculated from a flow specimen since the latter may be influenced by hemodilution and artifacts produced by specimen preparation (eg, red cell lysis techniques, density gradient centrifugation) and the approach through which different cell populations are selected for gating.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of MDS is made based upon findings in the peripheral blood and bone marrow as interpreted within the clinical context. Most cases of MDS are diagnosed based upon the presence of the three main features outlined below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. While most cases of MDS will have these three features, some will not, as clarified in the caveats presented.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otherwise unexplained quantitative changes in one or more of the blood and bone marrow elements (ie, red cells, granulocytes, platelets). The values used to define cytopenia are: hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       g/L);",
"      </span>",
"      absolute neutrophil count &lt;1.8 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (&lt;1800/microL);",
"      </span>",
"      platelets &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (&lt;100,000/microL).",
"      </span>",
"      However, failure to meet the threshold for cytopenia does not exclude the diagnosis of MDS if there is definite morphologic evidence of dysplasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Morphologic evidence of significant dysplasia (ie, &ge;10 percent of erythroid precursors, granulocytes, or megakaryocytes) upon visual inspection of the peripheral blood smear, bone marrow aspirate, and bone marrow biopsy in the absence of other causes of dysplasia (",
"      <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"       table 2",
"      </a>",
"      ). In the absence of morphologic evidence of dysplasia, a presumptive diagnosis of MDS can be made in patients with otherwise unexplained refractory cytopenia in the presence of certain genetic abnormalities. (See",
"      <a class=\"local\" href=\"#H5152246\">",
"       'Genetic features'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blast forms account for less than 20 percent of the total cells of the bone marrow aspirate and peripheral blood. Cases with higher blast percentages are considered to have acute myeloid leukemia (AML). In addition, the presence of myeloid sarcoma or certain genetic abnormalities, such as those with t(8;21), inv(16), or t(15;17), are considered diagnostic of AML, irrespective of the blast cell count. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\", section on 'Blast count'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDS must be distinguished from other entities that may also present with cytopenias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysplasia. The entities considered in a specific case depend largely upon the presenting features. As examples, in cases presenting with cytopenias, circulating blasts, or significant fibrosis, it is important to consider idiopathic cytopenia of undetermined significance, acute myeloid leukemia, and myelofibrosis, respectively, as well as other entities. The following sections describe the most common entities that should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64020980\">",
"    <span class=\"h2\">",
"     Idiopathic cytopenia of undetermined significance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term &ldquo;idiopathic cytopenia of undetermined significance&rdquo; (ICUS) is used to classify cases of persistent cytopenia without significant dysplasia, without any of the specific cytogenetic abnormalities considered as presumptive evidence of MDS, and without a potentially related hematologic or non-hematologic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113,150-153\">",
"     113,150-153",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5152246\">",
"     'Genetic features'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The natural history of ICUS is not well known. A retrospective analysis of 67 patients with ICUS evaluated evidence of clonality at diagnosis, as well as patient outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/154\">",
"     154",
"    </a>",
"    ]. In this population, 67 percent of patients presented with anemia. Cytopenias involved one, two, and three myeloid cell lines in 66, 18, and 12 percent, respectively. Eight patients developed acute myeloid leukemia (AML). The median overall survival of all patients with ICUS was 44 months. Clonality studies using human androgen receptor gene-based assays (HUMARA) were performed on 23 patients and identified clonal populations in six patients, two of whom developed AML.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64020408\">",
"    <span class=\"h2\">",
"     Acute myeloid leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDS and acute myeloid leukemia (AML) lie along a disease continuum with distinction between the two largely made based upon the blast percentage. In the current WHO classification system, blast forms must account for at least 20 percent of the total cellularity in AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/155\">",
"     155",
"    </a>",
"    ]. In addition, the presence of myeloid sarcoma or any one of the following genetic abnormalities is considered diagnostic of AML without regard to the blast count:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 (previously AML1-ETO)",
"     </li>",
"     <li>",
"      AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11",
"     </li>",
"     <li>",
"      APL with t(15;17)(q24.1;q21.1); PML-RARA",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It may not be possible to distinguish refractory anemia with excess blasts (RAEB) from early, evolving AML. This distinction can be made reliably only after at least 30 days of observation; in general, the peripheral blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    bone marrow blast percentage should continue to rise in evolving AML and remain relatively stable in RAEB. (See",
"    <a class=\"local\" href=\"#H359912\">",
"     'Refractory anemia with excess blasts'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Previously in the French-American-British (FAB) classification system, cases of MDS with Auer rods or with 21 to 30 percent blasts in the bone marrow or &ge;5 percent blasts in the blood were classified as refractory anemia with excess blasts in transformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/156\">",
"     156",
"    </a>",
"    ]. However, in the WHO classification system such cases are considered AML [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ], although biologic differences between RAEB-T and AML have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/157\">",
"     157",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64021188\">",
"    <span class=\"h2\">",
"     MDS/MPN syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDS is characterized by dysplasia and cytopenias. In contrast, the",
"    <span class=\"nowrap\">",
"     myelodysplastic/myeloproliferative",
"    </span>",
"    neoplasms",
"    <span class=\"nowrap\">",
"     (MDS/MPN)",
"    </span>",
"    include disorders where both dysplastic and proliferative features coexist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic myelomonocytic leukemia (CMML) &mdash; CMML is characterized by the overproduction of maturing monocytic cells and sometimes dysplastic neutrophils, often accompanied by anemia",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia (",
"      <a class=\"graphic graphic_table graphicRef85786 \" href=\"mobipreview.htm?43/38/44651\">",
"       table 3",
"      </a>",
"      ). This entity was previously considered to be a subtype of MDS, but is currently classified as a",
"      <span class=\"nowrap\">",
"       MDS/MPN.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H64021195\">",
"       'Chronic myelomonocytic leukemia'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Atypical chronic myeloid leukemia, BCR-ABL negative &mdash; Cases are usually characterized by marked neutrophilia with accompanying dysgranulopoiesis (",
"      <a class=\"graphic graphic_table graphicRef85787 \" href=\"mobipreview.htm?26/40/27275\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H13#H13\">",
"       \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on '\"Atypical CML\"'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Juvenile myelomonocytic leukemia &mdash; This rare disorder of infancy and early childhood is characterized by hepatosplenomegaly and lymphadenopathy, with or without evidence of dysgranulopoiesis (",
"      <a class=\"graphic graphic_table graphicRef85788 \" href=\"mobipreview.htm?23/19/23867\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Juvenile myelomonocytic leukemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       MDS/MPN,",
"      </span>",
"      unclassifiable (including refractory anemia with ring sideroblasts with thrombocytosis) (",
"      <a class=\"graphic graphic_table graphicRef85789 \" href=\"mobipreview.htm?41/43/42683\">",
"       table 6",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Isolated isochromosome 17p &mdash; Patients with this abnormality have a high risk of transformation to AML. Findings on examination of the peripheral blood and bone marrow include leukocytosis, anemia, thrombocytopenia, splenomegaly, micromegakaryocytes, and fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/158\">",
"       158",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases with prominent dysplastic and myeloproliferative features should be classified as",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    rather than MDS. Myeloproliferative features include significant thrombocytosis (eg, platelet count &ge;450",
"    <span class=\"nowrap\">",
"     x10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    associated with megakaryocytic proliferation and leukocytosis (white blood cell count &ge;13",
"    <span class=\"nowrap\">",
"     x10",
"     <sup>",
"      9",
"     </sup>",
"     /L)",
"    </span>",
"    with or without prominent splenomegaly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64021195\">",
"    <span class=\"h3\">",
"     Chronic myelomonocytic leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic myelomonocytic leukemia (CMML) is a",
"    <span class=\"nowrap\">",
"     MDS/MPN",
"    </span>",
"    characterized by the overproduction of maturing monocytic cells and sometimes dysplastic neutrophils, often accompanied by anemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef85786 \" href=\"mobipreview.htm?43/38/44651\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/159-161\">",
"     159-161",
"    </a>",
"    ]. Splenomegaly is massive in up to 25 percent of patients with CMML and is often accompanied by hepatomegaly, lymphadenopathy, and nodular cutaneous leukemic infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/162-166\">",
"     162-166",
"    </a>",
"    ]. Pleural and pericardial effusions and ascites can occur in CMML patients with exceedingly high or uncontrolled monocytosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/167\">",
"     167",
"    </a>",
"    ], but will often resolve with antileukemic therapy.",
"   </p>",
"   <p>",
"    Serologic polyclonal gammopathy was found in 47 percent of patients in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/163\">",
"     163",
"    </a>",
"    ]. Muramidase (lysozyme) activity may be increased in the blood or urine, reflecting heightened monocytopoiesis and cell turnover [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/168\">",
"     168",
"    </a>",
"    ]. Lysozymuria may be associated with urinary potassium wasting, hypokalemia, and elevated serum creatinine levels. A coagulopathy may be present due to binding of Factor X to abnormal monocytes, leading to an acquired Factor X deficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=see_link&amp;anchor=H16897924#H16897924\">",
"     \"Causes of hypokalemia\", section on 'Salt-wasting nephropathies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Borderline or relative elevations in the monocyte count are common in MDS. In contrast, cases of CMML have a peripheral blood monocyte count",
"    <span class=\"nowrap\">",
"     &gt;1000/microL",
"    </span>",
"    (",
"    <a class=\"graphic graphic_picture graphicRef85880 \" href=\"mobipreview.htm?27/46/28388\">",
"     picture 11",
"    </a>",
"    ). The bone marrow is uniformly hypercellular, with mononuclear cells exhibiting features intermediate between myelocytes and monocytes, which are termed paramyeloid cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/162\">",
"     162",
"    </a>",
"    ]. Cells of the monocytic line can be distinguished from myeloid precursors using a combined esterase stain. There are &lt;20 percent blasts in the bone marrow or peripheral blood. Blasts include myeloblasts, monoblasts, and promonocytes. Monocytes displaying atypical cytologic features are common and are excluded from the blast count. Auer rods are absent and ring sideroblasts may or may not be present. Cases must not exhibit the Philadelphia chromosome, the BCR-ABL1 fusion gene, or rearrangements of platelet derived growth factor receptor (PDGFRA or PDGFRB).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1583841\">",
"    <span class=\"h3\">",
"     RARS with thrombocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with the clinical and morphologic features of RARS (refractory anemia with ring sideroblasts) also have thrombocytosis (RARS-T) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/169-171\">",
"     169-171",
"    </a>",
"    ]. These patients demonstrate features of MDS (eg, ring sideroblasts) as well as MPN (eg, megakaryocytes resembling those seen in essential thrombocythemia, thrombocytosis), and have been provisionally designated by the WHO as RARS-T within the category of",
"    <span class=\"nowrap\">",
"     MDS/MPD,",
"    </span>",
"    unclassifiable",
"    <span class=\"nowrap\">",
"     (MDS/MPD-U)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/172\">",
"     172",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=see_link\">",
"     \"Diagnosis and clinical manifestations of essential thrombocythemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Alternative possibilities are that these patients represent the simultaneous occurrence of two separate disorders (eg, RARS and essential thrombocythemia) or that RARS-T represents patients with essential thrombocythemia who have ring sideroblasts secondary to a non-MDS-associated defect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/173\">",
"     173",
"    </a>",
"    ]. However, the finding of the JAK2 V617F mutation in up to two-thirds of patients with RARS-T and in only 2 of 89 cases of typical MDS, suggests that RARS-T is best considered another JAK2 mutation-associated chronic MPD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/174-176\">",
"     174-176",
"    </a>",
"    ]. In one instructive report, three patients with RARS, who initially had low to normal platelet counts, progressed to RARS-T [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/177\">",
"     177",
"    </a>",
"    ]. Two of the three acquired the JAK2 mutation at this time, suggesting that RARS-T may evolve from RARS through the acquisition of somatic mutations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most patients with MDS have normal or increased bone marrow cellularity, a minority have cellularity that is lower than expected based upon the patient's age (ie, cellularity &lt;30 percent in patients &lt;60 years or &lt;20 percent in patients &gt;60 years), termed hypoplastic MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. Hypocellularity is found with greatest frequency in therapy-related MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/49\">",
"     49",
"    </a>",
"    ]. Marrow cells in these patients are as a rule morphologically and karyotypically abnormal, features that enable distinction from aplastic anemia (AA). Many patients with both AA and MDS have small populations of glycosylphosphatidyl inositol-anchor deficient cells characteristic of paroxysmal nocturnal hemoglobinuria (PNH), but few patients with MDS alone either develop PNH or display typical PNH clinical manifestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/178\">",
"     178",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=see_link&amp;anchor=H19#H19\">",
"     \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\", section on 'Diagnostic criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Presence of a clonal chromosomal abnormality (eg, 5q-, monosomy 7) confirms the diagnosis of MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/179\">",
"     179",
"    </a>",
"    ]. Expression of the tumor necrosis factor (TNF) receptor on bone marrow stem cells by flow cytometry may discriminate AA from MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/180\">",
"     180",
"    </a>",
"    ]. Patients with AA have a markedly greater TNF receptor expression than those with MDS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Myelofibrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate degrees of bone marrow fibrosis are common in patients with MDS, and a small percentage will display marked fibrosis similar to that seen in patients with primary myelofibrosis (PMF). Patients with hyperfibrotic MDS are often pancytopenic, with trilineage dysplasia and atypical megakaryocytic proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/131,132,181\">",
"     131,132,181",
"    </a>",
"    ]. Most cases of hyperfibrotic MDS can be distinguished from PMF by the absence of splenomegaly (",
"    <a class=\"graphic graphic_table graphicRef51995 \" href=\"mobipreview.htm?24/59/25531\">",
"     table 7",
"    </a>",
"    ). In complicated cases, evaluation for the JAK2V617F mutation may be of benefit. This mutation is evident in approximately 50 percent of cases of PMF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/182,183\">",
"     182,183",
"    </a>",
"    ], but is present in only 5 percent of patients with MDS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/184\">",
"     184",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=see_link\">",
"     \"Clinical manifestations and diagnosis of primary myelofibrosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64021958\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysplastic hematopoiesis and variable degrees of cytopenia are common findings accompanying human immunodeficiency virus (HIV) infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/185,186\">",
"     185,186",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3098?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Anemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44039?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14522?source=see_link\">",
"     \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, a detailed morphologic review was performed in a blinded fashion on 216 bone marrow specimens from 178 patients with HIV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/185\">",
"     185",
"    </a>",
"    ]. Among the most common bone marrow findings were hypercellularity (53 percent of specimens), myelodysplasia (69 percent), increased marrow iron stores (65 percent), megaloblastic hematopoiesis (38 percent), fibrosis (20 percent), plasmacytosis (25 percent), lymphocytic aggregates (36 percent), and granulomas (13 percent).",
"   </p>",
"   <p>",
"    Hematopoietic dysplasia in such patients may result from medications, opportunistic infection,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a direct effect of HIV on hematopoietic progenitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/187,188\">",
"     187,188",
"    </a>",
"    ]. Thus, serologic screening for HIV should be considered in patients with unexplained cytopenia(s)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    myelodysplasia. MDS that occurs in patients with HIV infection are more likely to have complex cytogenetics (including",
"    <span class=\"nowrap\">",
"     7q-/7-)",
"    </span>",
"    and shorter survival than non-HIV infected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/189\">",
"     189",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64021769\">",
"    <span class=\"h2\">",
"     Poor nutritional status",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with MDS have macrocytic red cells, reduced reticulocyte percentage, and pancytopenia (anemia, leukopenia, and thrombocytopenia), findings that may also be present in the megaloblastic anemias, copper deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/190,191\">",
"     190,191",
"    </a>",
"    ], and zinc excess [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/192\">",
"     192",
"    </a>",
"    ]. While reduced neutrophil lobulation is characteristic of MDS, the combination of increased neutrophil lobulation along with macrocytosis is pathognomonic of megaloblastic anemia. Accordingly, zinc excess and vitamin B12, folate, and copper deficiencies should be excluded in all patients. It is important to distinguish MDS from the other causes of anemia in the elderly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/193\">",
"     193",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=see_link&amp;anchor=H2127027#H2127027\">",
"     \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnosis and treatment of vitamin B12 and folate deficiency\", section on 'Initial diagnostic strategy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical aspects, diagnosis, and treatment of the sideroblastic anemias\", section on 'Copper deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/0/22538?source=see_link\">",
"     \"Anemia in the older adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a number of medications, including granulocyte colony stimulating factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/194\">",
"     194",
"    </a>",
"    ], valproic acid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/195\">",
"     195",
"    </a>",
"    ], mycophenolate mofetil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/196,197\">",
"     196,197",
"    </a>",
"    ], ganciclovir [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/197,198\">",
"     197,198",
"    </a>",
"    ], and alemtuzumab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/199\">",
"     199",
"    </a>",
"    ], has been associated with acquired dysplastic changes, including macrocytosis, abnormal (reduced) neutrophil lobulation, neutropenia, thrombocytopenia, and dysplastic changes in all three cell lines on bone marrow examination. Methotrexate or alkylating agents such as cyclophosphamide, sometimes used to treatment autoimmune disorders, can cause dysplasia. In most of the reported cases these changes were reversible on reduction or discontinuation of these medications, usually over a period of several weeks. Repeat bone marrow examinations may be necessary in complicated cases to confirm the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359854\">",
"    <span class=\"h1\">",
"     WHO CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;MDS is classified using the WHO classification system based upon a combination of morphology, immunophenotype, genetics, and clinical features (",
"    <a class=\"graphic graphic_table graphicRef85790 \" href=\"mobipreview.htm?24/28/25037\">",
"     table 8",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/200\">",
"     200",
"    </a>",
"    ]. This classification attempts to identify biologic entities in the hopes that future work will elucidate molecular pathways that might be amenable to targeted therapies. The WHO classification system was built upon the French American British (FAB) Cooperative Group classification, which continues in the vernacular (",
"    <a class=\"graphic graphic_table graphicRef51895 \" href=\"mobipreview.htm?20/33/21020\">",
"     table 9",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/156\">",
"     156",
"    </a>",
"    ]. These classification systems are complicated and require morphologic evaluation by an expert hematopathologist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/201\">",
"     201",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO classification system distinguishes six general entities with the following estimated percentages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113,202\">",
"     113,202",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Refractory cytopenia with unilineage dysplasia (refractory anemia, refractory neutropenia, or refractory thrombocytopenia) &mdash; &lt;5 percent",
"     </li>",
"     <li>",
"      Refractory anemia with ring sideroblasts &mdash; &lt;5 percent",
"     </li>",
"     <li>",
"      Refractory anemia with multilineage dysplasia &mdash; 70 percent",
"     </li>",
"     <li>",
"      Refractory anemia with excess blasts &mdash; 25 percent",
"     </li>",
"     <li>",
"      MDS with isolated del(5q) &mdash; 5 percent",
"     </li>",
"     <li>",
"      MDS, unclassified &mdash; &lt;5 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Childhood MDS is considered a distinct entity in the WHO classification system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. Refractory cytopenia of childhood accounts for approximately half of childhood MDS and is the most common subtype in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359891\">",
"    <span class=\"h2\">",
"     Refractory cytopenia with unilineage dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory cytopenia with unilineage dysplasia (RCUD) is characterized by &lt;5 percent blasts in the bone marrow and &le;1 percent blasts in the peripheral blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. Monocytosis, significant numbers of ringed sideroblasts, and Auer rods are absent. The recommended level for defining dysplasia is &ge;10 percent in the affected cell lineage, and the recommended values for defining cytopenia are [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/203\">",
"     203",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Refractory anemia &mdash; hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Refractory thrombocytopenia &mdash; platelet count",
"      <span class=\"nowrap\">",
"       &lt;100,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Refractory neutropenia &mdash; absolute neutrophil count (ANC)",
"      <span class=\"nowrap\">",
"       &lt;1800/microL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Values above these levels do not exclude MDS if there are definitive morphologic or cytogenetic features of MDS. While the majority of patients with refractory cytopenia with unilineage dysplasia will demonstrate a single cytopenia (usually corresponding to the dysplastic line), patients with two cytopenias but with unilineage dysplasia are also included in this classification. In contrast, patients with refractory pancytopenia and unilineage dysplasia are",
"    <strong>",
"     not",
"    </strong>",
"    considered to have RCUD, and are instead included in the category of MDS, unclassifiable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359898\">",
"    <span class=\"h2\">",
"     Refractory anemia with ring sideroblasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory anemia with ring sideroblasts (RARS) fulfills all of the criteria for refractory anemia, but also demonstrates &gt;15 percent ring sideroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. Pathologic sideroblasts containing more than five iron-laden mitochondria per cell may be evident on bone marrow specimens stained for the presence of iron (",
"    <a class=\"graphic graphic_picture graphicRef65887 \" href=\"mobipreview.htm?0/44/705\">",
"     picture 9",
"    </a>",
"    ). Sideroblasts in which 10 or more iron-laden mitochondria occupy more than one-third of the nuclear rim are termed \"ring\" sideroblasts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/204\">",
"     204",
"    </a>",
"    ]. Ring sideroblasts and increased storage iron can be found in any of the MDS subtypes; however, the former is characteristic of RARS.",
"   </p>",
"   <p>",
"    RARS is usually associated with a good prognosis. However, the 15 percent cutoff value used to define RARS is somewhat arbitrary and has been questioned. In a study of 200 patients with MDS without excess blasts who had &gt;1 percent ring sideroblasts, the percentage of ring sideroblasts was not an independent predictor of leukemia-free or overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/205\">",
"     205",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=see_link&amp;anchor=H14168401#H14168401\">",
"     \"Prognosis of the myelodysplastic syndromes in adults\", section on 'FAB classification'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359905\">",
"    <span class=\"h2\">",
"     Refractory cytopenia with multilineage dysplasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory cytopenia with multilineage dysplasia (RCMD) is characterized by less than 5 percent BM blasts and severe dysplasia in two or more cell lineages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. Some patients with RCMD have increased ring sideroblasts, a condition referred to as RCMD-RS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359912\">",
"    <span class=\"h2\">",
"     Refractory anemia with excess blasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refractory anemia with excess blasts (RAEB) is characterized by 5 to 19 percent bone marrow blasts and is further subdivided into RAEB-I (5 to 9 percent blasts) and RAEB-II (10 to 19 percent blasts) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/113\">",
"     113",
"    </a>",
"    ]. In a study of 558 patients who met these WHO criteria for RAEB, there were no significant differences (other than blast count) between those with RAEB-I or RAEB-II with respect to their clinical, morphologic, hematologic, or cytogenetic parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/206\">",
"     206",
"    </a>",
"    ]. However, RAEB-II was associated with a shorter median survival (9 versus 16 months) and an increased risk of developing acute myeloid leukemia (40 versus 22 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H359933\">",
"    <span class=\"h2\">",
"     MDS with isolated del(5q)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 5 percent of patients with MDS present with &ldquo;5q- syndrome&rdquo; characterized by severe anemia, preserved platelet counts, and an interstitial deletion of the long arm of chromosome 5 as the sole cytogenetic abnormality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/124,207,208\">",
"     124,207,208",
"    </a>",
"    ]. 5q- syndrome may follow a relatively benign course that extends over several years. It has a low incidence of transformation into acute leukemia and is well known for its responsiveness to treatment with novel agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=see_link&amp;anchor=H2443602#H2443602\">",
"     \"Treatment of intermediate, low, or very low risk myelodysplastic syndromes\", section on 'Patients with 5q deletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The 5q- syndrome is a distinctive type of primary MDS that primarily occurs in older women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/207-209\">",
"     207-209",
"    </a>",
"    ]. The median age at diagnosis is 65 to 70 years, with a female predominance of 7:3 (in contrast to a male predominance in other forms of MDS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/210\">",
"     210",
"    </a>",
"    ]. Affected patients typically present with a refractory macrocytic anemia, normal or elevated platelet counts, and the absence of significant neutropenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/209\">",
"     209",
"    </a>",
"    ]. Because of the typical absence of thrombocytopenia and significant neutropenia, there is a low incidence of bleeding and infection in these patients, but red blood cell transfusions are frequently required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H256828282#H256828282\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on 'Deletions of chromosome 5'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The bone marrow in 5q- syndrome is characterized by the presence of micromegakaryocytes with monolobulated and bilobulated nuclei. There are less than 5 percent blasts in the marrow in approximately 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/209,210\">",
"     209,210",
"    </a>",
"    ]. The del(5q) is typically interstitial. Approximately 75 percent of cases have a del(5)(q13q33); other interstitial deletions include del(5)(q15q33) and del(5)(q22q33) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/57/41882/abstract/211-213\">",
"     211-213",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H256828282#H256828282\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on 'Deletions of chromosome 5'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=see_link&amp;anchor=H256821606#H256821606\">",
"     \"Cytogenetics and molecular genetics of myelodysplastic syndromes\", section on '5q- syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/1/9234?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/26/6564?source=see_link\">",
"       \"Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The myelodysplastic syndromes (MDS) comprise a heterogeneous group of malignant hematopoietic stem cell disorders characterized by dysplastic and ineffective blood cell production. MDS occurs most commonly in older adults and may occur de novo or arise years after exposure to potentially mutagenic therapy (eg, radiation exposure, chemotherapy). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4008903\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The diagnosis of MDS should be considered in any patient with unexplained cytopenia(s) or monocytosis. Careful inspection of the peripheral blood smear and bone marrow aspirate is necessary to document the requisite dysplastic cytologic features identifiable in any or all of the hematopoietic lineages (",
"      <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"       table 2",
"      </a>",
"      ). Detection of certain chromosomal abnormalities distinguishes between MDS and acute myeloid leukemia (AML) in some cases, aids in the classification of MDS, and is a major factor in determining prognostic risk group and therapy. (See",
"      <a class=\"local\" href=\"#H303969\">",
"       'Evaluation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The diagnosis of MDS requires",
"      <strong>",
"       both",
"      </strong>",
"      of the following:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Otherwise unexplained quantitative changes in one or more of the blood and bone marrow elements (ie, red cells, granulocytes, platelets). The values used to define cytopenia are: hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      (100",
"      <span class=\"nowrap\">",
"       g/L);",
"      </span>",
"      absolute neutrophil count &lt;1.8 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (&lt;1800/microL);",
"      </span>",
"      and platelets &lt;100 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L",
"      </span>",
"      <span class=\"nowrap\">",
"       (&lt;100,000/microL).",
"      </span>",
"      However, failure to meet the threshold for cytopenia does not exclude the diagnosis of MDS if there is definite morphologic evidence of dysplasia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Morphologic evidence of significant dysplasia (ie, &ge;10 percent of erythroid precursors, granulocytes, or megakaryocytes) upon visual inspection of the peripheral blood smear, bone marrow aspirate, and bone marrow biopsy in the absence of other causes of dysplasia (",
"      <a class=\"graphic graphic_table graphicRef82345 \" href=\"mobipreview.htm?24/15/24828\">",
"       table 2",
"      </a>",
"      ). In the absence of morphologic evidence of dysplasia, a presumptive diagnosis of MDS can be made in patients with otherwise unexplained refractory cytopenia in the presence of certain genetic abnormalities. (See",
"      <a class=\"local\" href=\"#H5152246\">",
"       'Genetic features'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Importantly, blast forms must account for less than 20 percent of the total cells of the bone marrow aspirate and peripheral blood. In addition, the presence of myeloid sarcoma or certain genetic abnormalities, such as those with t(8;21), inv(16), or t(15;17), are considered diagnostic of acute myeloid leukemia, irrespective of the blast cell count. (See",
"      <a class=\"local\" href=\"#H64020408\">",
"       'Acute myeloid leukemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MDS must be distinguished from other entities that may also present with cytopenias",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dysplasia. Common conditions that present with features similar to MDS include HIV infection, deficiencies of vitamin B12, folate, or copper, and zinc excess. Other entities considered in a specific case depend largely upon the presenting features. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MDS is classified using the WHO classification system based upon a combination of morphology, immunophenotype, genetics, and clinical feature (",
"      <a class=\"graphic graphic_table graphicRef85790 \" href=\"mobipreview.htm?24/28/25037\">",
"       table 8",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H359854\">",
"       'WHO Classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5937816\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate would like to acknowledge Donald C Doll, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/1\">",
"      Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366:1090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/2\">",
"      Will B, Zhou L, Vogler TO, et al. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood 2012; 120:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/3\">",
"      Pang WW, Pluvinage JV, Price EA, et al. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 2013; 110:3011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/4\">",
"      Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/5\">",
"      Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet 2012; 44:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/6\">",
"      Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood 2012; 119:3203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/7\">",
"      Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood 2012; 119:3211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/8\">",
"      Visconte V, Makishima H, Jankowska A, et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts. Leukemia 2012; 26:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/9\">",
"      Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood 2011; 118:6239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/10\">",
"      Patnaik MM, Lasho TL, Hodnefield JM, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/11\">",
"      Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood 2012; 120:3173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/12\">",
"      Cazzola M, Rossi M, Malcovati L, Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative. Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood 2013; 121:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/13\">",
"      Thol F, Kade S, Schlarmann C, et al. Frequency and prognostic impact of mutations in SRSF2, U2AF1, and ZRSR2 in patients with myelodysplastic syndromes. Blood 2012; 119:3578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/14\">",
"      Wu SJ, Kuo YY, Hou HA, et al. The clinical implication of SRSF2 mutation in patients with myelodysplastic syndrome and its stability during disease evolution. Blood 2012; 120:3106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/15\">",
"      Payne EM, Virgilio M, Narla A, et al. L-Leucine improves the anemia and developmental defects associated with Diamond-Blackfan anemia and del(5q) MDS by activating the mTOR pathway. Blood 2012; 120:2214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/16\">",
"      Gadji M, Adebayo Awe J, Rodrigues P, et al. Profiling three-dimensional nuclear telomeric architecture of myelodysplastic syndromes and acute myeloid leukemia defines patient subgroups. Clin Cancer Res 2012; 18:3293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/17\">",
"      Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 2012; 12:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/18\">",
"      Rhyasen GW, Starczynowski DT. Deregulation of microRNAs in myelodysplastic syndrome. Leukemia 2012; 26:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/19\">",
"      Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/20\">",
"      Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116:3923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/21\">",
"      Cazzola M. IDH1 and IDH2 mutations in myeloid neoplasms--novel paradigms and clinical implications. Haematologica 2010; 95:1623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/22\">",
"      Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011; 364:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/23\">",
"      Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of &alpha;-ketoglutarate-dependent dioxygenases. Cancer Cell 2011; 19:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/24\">",
"      Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2012; 30:3376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/25\">",
"      Matsuura S, Komeno Y, Stevenson KE, et al. Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome. Blood 2012; 120:4028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/26\">",
"      Aanei CM, Flandrin P, Eloae FZ, et al. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes. Stem Cells Dev 2012; 21:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/27\">",
"      Fozza C, Longinotti M. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes? Eur J Haematol 2012; 88:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/28\">",
"      Sloand EM, Wu CO, Greenberg P, et al. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008; 26:2505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/29\">",
"      Kordasti SY, Afzali B, Lim Z, et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009; 145:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/30\">",
"      Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007; 109:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/31\">",
"      Aul C, Gattermann N, Schneider W. Age-related incidence and other epidemiological aspects of myelodysplastic syndromes. Br J Haematol 1992; 82:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/32\">",
"      Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/33\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/34\">",
"      Smith A, Howell D, Patmore R, et al. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. Br J Cancer 2011; 105:1684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/35\">",
"      De Roos AJ, Deeg HJ, Onstad L, et al. Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005-2006. Am J Hematol 2010; 85:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/36\">",
"      Cogle CR, Craig BM, Rollison DE, List AF. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood 2011; 117:7121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/37\">",
"      Greenberg PL. The smoldering myeloid leukemic states: clinical and biologic features. Blood 1983; 61:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/38\">",
"      Doll DC, List AF. Myelodysplastic syndromes. West J Med 1989; 151:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/39\">",
"      Foucar K, Langdon RM 2nd, Armitage JO, et al. Myelodysplastic syndromes. A clinical and pathologic analysis of 109 cases. Cancer 1985; 56:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/40\">",
"      Vallespi T, Torrabadella M, Julia A, et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 1985; 61:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/41\">",
"      Tricot G, Vlietinck R, Boogaerts MA, et al. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis. Br J Haematol 1985; 60:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/42\">",
"      Kuriyama K, Tomonaga M, Matsuo T, et al. Diagnostic significance of detecting pseudo-Pelger-Hu&euml;t anomalies and micro-megakaryocytes in myelodysplastic syndrome. Br J Haematol 1986; 63:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/43\">",
"      Knapp RH, Dewald GW, Pierre RV. Cytogenetic studies in 174 consecutive patients with preleukemic or myelodysplastic syndromes. Mayo Clin Proc 1985; 60:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/44\">",
"      Jacobs RH, Cornbleet MA, Vardiman JW, et al. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes. Blood 1986; 67:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/45\">",
"      French registry of acute leukemia and myelodysplastic syndromes. Age distribution and hemogram analysis of the 4496 cases recorded during 1982-1983 and classified according to FAB criteria. Groupe Francais de Morphologie Hematologique. Cancer 1987; 60:1385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/46\">",
"      Sekeres MA, Schoonen WM, Kantarjian H, et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008; 100:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/47\">",
"      Beris P. Primary clonal myelodysplastic syndromes. Semin Hematol 1989; 26:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/48\">",
"      Kuendgen A, Strupp C, Aivado M, et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006; 24:5358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/49\">",
"      Michels SD, McKenna RW, Arthur DC, Brunning RD. Therapy-related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 1985; 65:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/50\">",
"      Bader-Meunier B, Mi&eacute;lot F, Tchernia G, et al. Myelodysplastic syndromes in childhood: report of 49 patients from a French multicentre study. French Society of Paediatric Haematology and Immunology. Br J Haematol 1996; 92:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/51\">",
"      Passmore SJ, Hann IM, Stiller CA, et al. Pediatric myelodysplasia: a study of 68 children and a new prognostic scoring system. Blood 1995; 85:1742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/52\">",
"      Hasle H. Myelodysplastic syndromes in childhood--classification, epidemiology, and treatment. Leuk Lymphoma 1994; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/53\">",
"      Williamson PJ, Kruger AR, Reynolds PJ, et al. Establishing the incidence of myelodysplastic syndrome. Br J Haematol 1994; 87:743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/54\">",
"      Schnatter AR, Glass DC, Tang G, et al. Myelodysplastic syndrome and benzene exposure among petroleum workers: an international pooled analysis. J Natl Cancer Inst 2012; 104:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/55\">",
"      Ma X, Lim U, Park Y, et al. Obesity, lifestyle factors, and risk of myelodysplastic syndromes in a large US cohort. Am J Epidemiol 2009; 169:1492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/56\">",
"      Vinh DC, Patel SY, Uzel G, et al. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood 2010; 115:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/57\">",
"      B&ouml;d&ouml;r C, Renneville A, Smith M, et al. Germ-line GATA2 p.THR354MET mutation in familial myelodysplastic syndrome with acquired monosomy 7 and ASXL1 mutation demonstrating rapid onset and poor survival. Haematologica 2012; 97:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/58\">",
"      Holme H, Hossain U, Kirwan M, et al. Marked genetic heterogeneity in familial myelodysplasia/acute myeloid leukaemia. Br J Haematol 2012; 158:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/59\">",
"      Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: response to immunosuppressive therapy. Br J Haematol 1995; 91:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/60\">",
"      Green AR, Shuttleworth D, Bowen DT, Bentley DP. Cutaneous vasculitis in patients with myelodysplasia. Br J Haematol 1990; 74:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/61\">",
"      Savige JA, Chang L, Smith CL, Duggan JC. Myelodysplasia, vasculitis and anti-neutrophil cytoplasm antibodies. Leuk Lymphoma 1993; 9:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/62\">",
"      Shirota T, Hayashi O, Uchida H, et al. Myelodysplastic syndrome associated with relapsing polychondritis: unusual transformation from refractory anemia to chronic myelomonocytic leukemia. Ann Hematol 1993; 67:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/63\">",
"      Castro M, Conn DL, Su WP, Garton JP. Rheumatic manifestations in myelodysplastic syndromes. J Rheumatol 1991; 18:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/64\">",
"      Giannouli S, Voulgarelis M, Zintzaras E, et al. Autoimmune phenomena in myelodysplastic syndromes: a 4-yr prospective study. Rheumatology (Oxford) 2004; 43:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/65\">",
"      Jansen AJ, Essink-Bot ML, Beckers EA, et al. Quality of life measurement in patients with transfusion-dependent myelodysplastic syndromes. Br J Haematol 2003; 121:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/66\">",
"      Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005; 104:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/67\">",
"      Goldberg SL, Chen E, Corral M, et al. Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. J Clin Oncol 2010; 28:2847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/68\">",
"      Koeffler HP, Golde DW. Human preleukemia. Ann Intern Med 1980; 93:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/69\">",
"      Pomeroy C, Oken MM, Rydell RE, Filice GA. Infection in the myelodysplastic syndromes. Am J Med 1991; 90:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/70\">",
"      Boogaerts MA, Nelissen V, Roelant C, Goossens W. Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 1983; 55:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/71\">",
"      Linman JW, Bagby C Jr. The preleukemic syndrome: clinical and laboratory features, natural course, and management. Nouv Rev Fr Hematol Blood Cells 1976; 17:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/72\">",
"      Scott CS, Cahill A, Bynoe AG, et al. Esterase cytochemistry in primary myelodysplastic syndromes and megaloblastic anaemias: demonstration of abnormal staining patterns associated with dysmyelopoiesis. Br J Haematol 1983; 55:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/73\">",
"      Prchal JT, Throckmorton DW, Carroll AJ 3rd, et al. A common progenitor for human myeloid and lymphoid cells. Nature 1978; 274:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/74\">",
"      Hokland P, Kerndrup G, Griffin JD, Ellegaard J. Analysis of leukocyte differentiation antigens in blood and bone marrow from preleukemia (refractory anemia) patients using monoclonal antibodies. Blood 1986; 67:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/75\">",
"      Bynoe AG, Scott CS, Ford P, Roberts BE. Decreased T helper cells in the myelodysplastic syndromes. Br J Haematol 1983; 54:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/76\">",
"      Anderson RW, Volsky DJ, Greenberg B, et al. Lymphocyte abnormalities in preleukemia--I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk Res 1983; 7:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/77\">",
"      Mufti GJ, Figes A, Hamblin TJ, et al. Immunological abnormalities in myelodysplastic syndromes. I. Serum immunoglobulins and autoantibodies. Br J Haematol 1986; 63:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/78\">",
"      Pardanani A, Lasho TL, Finke CM, et al. Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms. J Clin Oncol 2012; 30:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/79\">",
"      Steensma DP, Higgs DR, Fisher CA, Gibbons RJ. Acquired somatic ATRX mutations in myelodysplastic syndrome associated with alpha thalassemia (ATMDS) convey a more severe hematologic phenotype than germline ATRX mutations. Blood 2004; 103:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/80\">",
"      Steensma DP, Gibbons RJ, Higgs DR. Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies. Blood 2005; 105:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/81\">",
"      Steensma DP, Porcher JC, Hanson CA, et al. Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders. Br J Haematol 2007; 139:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/82\">",
"      Steensma DP, Viprakasit V, Hendrick A, et al. Deletion of the alpha-globin gene cluster as a cause of acquired alpha-thalassemia in myelodysplastic syndrome. Blood 2004; 103:1518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/83\">",
"      Higgs DR. Gene regulation in hematopoiesis: new lessons from thalassemia. Hematology Am Soc Hematol Educ Program 2004; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/84\">",
"      Soppi E, Nousiainen T, Seppa A, Lahtinen R. Acute febrile neutrophilic dermatosis (Sweet's syndrome) in association with myelodysplastic syndromes: a report of three cases and a review of the literature. Br J Haematol 1989; 73:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/85\">",
"      Cohen PR, Talpaz M, Kurzrock R. Malignancy-associated Sweet's syndrome: review of the world literature. J Clin Oncol 1988; 6:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/86\">",
"      Reuss-Borst MA, Pawelec G, Saal JG, et al. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol 1993; 84:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/87\">",
"      Vignon-Pennamen MD, Juillard C, Rybojad M, et al. Chronic recurrent lymphocytic Sweet syndrome as a predictive marker of myelodysplasia: a report of 9 cases. Arch Dermatol 2006; 142:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/88\">",
"      List AF, Gonzalez-Osete G, Kummet T, Doll DC. Granulocytic sarcoma in myelodysplastic syndromes: clinical marker of disease acceleration. Am J Med 1991; 90:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/89\">",
"      Lin CK, Liang R, Ma L, et al. Myelodysplastic syndrome presenting with generalized cutaneous granulocytic sarcomas. Acta Haematol 1990; 83:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/90\">",
"      da Silva MA, Moriarty A, Schultz S, Tricot G. Extramedullary disease in myelodysplastic syndromes. Am J Med 1988; 85:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/91\">",
"      Tsimberidou AM, Kantarjian HM, Wen S, et al. Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia. Cancer 2008; 113:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/92\">",
"      Najean Y, Lecompte T. Chronic pure thrombocytopenia in elderly patients. An aspect of the myelodysplastic syndrome. Cancer 1989; 64:2506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/93\">",
"      Gupta R, Soupir CP, Johari V, Hasserjian RP. Myelodysplastic syndrome with isolated deletion of chromosome 20q: an indolent disease with minimal morphological dysplasia and frequent thrombocytopenic presentation. Br J Haematol 2007; 139:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/94\">",
"      Kodali D, Mesa H, Rawal A, et al. Thrombocytosis in myelodysplastic and myelodysplastic/myeloproliferative syndromes. Leuk Lymphoma 2007; 48:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/95\">",
"      MACGIBBON BH, MOLLIN DL. SIDEROBLASTIC ANAEMIA IN MAN: OBSERVATIONS ON SEVENTY CASES. Br J Haematol 1965; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/96\">",
"      Tulliez M, Testa U, Rochant H, et al. Reticulocytosis, hypochromia, and microcytosis: an unusual presentation of the preleukemic syndrome. Blood 1982; 59:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/97\">",
"      Rummens JL, Verfaillie C, Criel A, et al. Elliptocytosis and schistocytosis in myelodysplasia: report of two cases. Acta Haematol 1986; 75:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/98\">",
"      Ideguchi H, Yamada Y, Kondo S, et al. Abnormal erythrocyte band 4.1 protein in myelodysplastic syndrome with elliptocytosis. Br J Haematol 1993; 85:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/99\">",
"      Doll DC, List AF, Dayhoff DA, et al. Acanthocytosis associated with myelodysplasia. J Clin Oncol 1989; 7:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/100\">",
"      de Cataldo F, Cairoli R, Baudo F, et al. Abnormalities of cytoskeletal proteins of the red blood cells in myelodysplastic syndromes. Int J Hematol 1994; 59:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/101\">",
"      Dreyfus B. Preleukemic states. I. Definition and classification. II. Refractory anemia with an excess of myeloblasts in the bone marrow (smoldering acute leukemia). Nouv Rev Fr Hematol Blood Cells 1976; 17:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/102\">",
"      Sokol RJ, Hewitt S, Booker DJ. Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes. J Clin Pathol 1989; 42:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/103\">",
"      Hertenstein B, Kurrle E, Redenbacher M, et al. Pseudoreticulocytosis in a patient with myelodysplasia. Ann Hematol 1993; 67:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/104\">",
"      Sher GD, Pinkerton PH, Ali MA, Senn JS. Myelodysplastic syndrome with prolonged reticulocyte survival mimicking hemolytic disease. Am J Clin Pathol 1994; 101:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/105\">",
"      Hast R, Nilsson I, Widell S, Ost A. Diagnostic significance of dysplastic features of peripheral blood polymorphs in myelodysplastic syndromes. Leuk Res 1989; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/106\">",
"      Davey FR, Erber WN, Gatter KC, Mason DY. Abnormal neutrophils in acute myeloid leukemia and myelodysplastic syndrome. Hum Pathol 1988; 19:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/107\">",
"      Felman P, Bryon PA, Gentilhomme O, et al. The syndrome of abnormal chromatin clumping in leucocytes: a myelodysplastic disorder with proliferative features? Br J Haematol 1988; 70:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/108\">",
"      Ja&eacute;n A, Irriguible D, Milla F, et al. Abnormal chromatin clumping in leucocytes: a clue to a new subtype of myelodysplastic syndrome. Eur J Haematol 1990; 45:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/109\">",
"      Langenhuijsen MM. Neutrophils with ring-shaped nuclei in myeloproliferative disease. Br J Haematol 1984; 58:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/110\">",
"      Gallardo R, Kranwinkel RN. Pseudo-Ch&eacute;diak-Higashi anomaly. Am J Clin Pathol 1985; 83:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/111\">",
"      Rassam SM, Roderick P, al-Hakim I, Hoffbrand AV. A myelokathexis-like variant of myelodysplasia. Eur J Haematol 1989; 42:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/112\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/114\">",
"      Matsushima T, Murakami H, Sawamura M, et al. Myelodysplastic syndrome with eosinophilia in bone marrow. Gunma Haematology Study Group. Br J Haematol 1993; 84:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/115\">",
"      Matsushima T, Handa H, Yokohama A, et al. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia. Blood 2003; 101:3386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/116\">",
"      Tricot G, De Wolf-Peeters C, Vlietinck R, Verwilghen RL. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984; 58:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/117\">",
"      P&uuml;lhorn H, Herrmann M, Harms H, et al. Apoptotic cells and clonally expanded cytotoxic T cells in bone marrow trephines of patients with myelodysplastic syndrome. Histopathology 2012; 61:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/118\">",
"      R&iacute;os A, Ca&ntilde;izo MC, Sanz MA, et al. Bone marrow biopsy in myelodysplastic syndromes: morphological characteristics and contribution to the study of prognostic factors. Br J Haematol 1990; 75:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/119\">",
"      Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/120\">",
"      Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/121\">",
"      Shetty V, Hussaini S, Broady-Robinson L, et al. Intramedullary apoptosis of hematopoietic cells in myelodysplastic syndrome patients can be massive: apoptotic cells recovered from high-density fraction of bone marrow aspirates. Blood 2000; 96:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/122\">",
"      Head DR, Kopecky K, Bennett JM, et al. Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study. Cancer 1989; 64:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/123\">",
"      Williamson PJ, Oscier DG, Bell AJ, Hamblin TJ. Red cell aplasia in myelodysplastic syndrome. J Clin Pathol 1991; 44:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/124\">",
"      Mathew P, Tefferi A, Dewald GW, et al. The 5q- syndrome: a single-institution study of 43 consecutive patients. Blood 1993; 81:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/125\">",
"      Wong KF, Chan JK. Are 'dysplastic' and hypogranular megakaryocytes specific markers for myelodysplastic syndrome? Br J Haematol 1991; 77:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/126\">",
"      Chuang SS, Jung YC, Li CY, Yung YC. von Willebrand factor is the most reliable immunohistochemical marker for megakaryocytes of myelodysplastic syndrome and chronic myeloproliferative disorders. Am J Clin Pathol 2000; 113:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/127\">",
"      Yunis JJ, Rydell RE, Oken MM, et al. Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes. Blood 1986; 67:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/128\">",
"      Verburgh E, Achten R, Maes B, et al. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol 2003; 21:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/129\">",
"      Sultan C, Sigaux F, Imbert M, Reyes F. Acute myelodysplasia with myelofibrosis: a report of eight cases. Br J Haematol 1981; 49:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/130\">",
"      Pagliuca A, Layton DM, Manoharan A, et al. Myelofibrosis in primary myelodysplastic syndromes: a clinico-morphological study of 10 cases. Br J Haematol 1989; 71:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/131\">",
"      Lambertenghi-Deliliers G, Orazi A, Luksch R, et al. Myelodysplastic syndrome with increased marrow fibrosis: a distinct clinico-pathological entity. Br J Haematol 1991; 78:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/132\">",
"      Ohyashiki K, Sasao I, Ohyashiki JH, et al. Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis. Cancer 1991; 68:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/133\">",
"      Manoharan A, Horsley R, Pitney WR. The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979; 43:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/134\">",
"      Clark RE, Smith SA, Jacobs A. Myeloid surface antigen abnormalities in myelodysplasia: relation to prognosis and modification by 13-cis retinoic acid. J Clin Pathol 1987; 40:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/135\">",
"      Kristensen JS, Hokland P. Monoclonal antibody ratios in malignant myeloid diseases: diagnostic and prognostic use in myelodysplastic syndromes. Br J Haematol 1990; 74:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/136\">",
"      Thiele J, Krech R, Wienhold S, et al. The use of the anti-factor VIII method on trephine biopsies of the bone marrow for the identification of immature and atypical megakaryocytes in myeloproliferative diseases and allied disorders. A morphometric study. Virchows Arch B Cell Pathol Incl Mol Pathol 1987; 54:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/137\">",
"      Kawaguchi M, Nehashi Y, Aizawa S, Toyama K. Comparative study of immunocytochemical staining versus Giemsa stain for detecting dysmegakaryopoiesis in myelodysplastic syndromes (MDS). Eur J Haematol 1990; 44:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/138\">",
"      Seo IS, Li CY, Yam LT. Myelodysplastic syndrome: diagnostic implications of cytochemical and immunocytochemical studies. Mayo Clin Proc 1993; 68:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/139\">",
"      Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood 2001; 98:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/140\">",
"      van de Loosdrecht AA, Westers TM, Westra AH, et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood 2008; 111:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/141\">",
"      van de Loosdrecht AA, Alhan C, B&eacute;n&eacute; MC, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica 2009; 94:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/142\">",
"      Wells DA, Benesch M, Loken MR, et al. Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation. Blood 2003; 102:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/143\">",
"      Scott BL, Wells DA, Loken MR, et al. Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome. Blood 2008; 112:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/144\">",
"      Kussick SJ, Fromm JR, Rossini A, et al. Four-color flow cytometry shows strong concordance with bone marrow morphology and cytogenetics in the evaluation for myelodysplasia. Am J Clin Pathol 2005; 124:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/145\">",
"      Kern W, Haferlach C, Schnittger S, Haferlach T. Clinical utility of multiparameter flow cytometry in the diagnosis of 1013 patients with suspected myelodysplastic syndrome: correlation to cytomorphology, cytogenetics, and clinical data. Cancer 2010; 116:4549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/146\">",
"      Westers TM, Ireland R, Kern W, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia 2012; 26:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/147\">",
"      Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012; 120:2454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/148\">",
"      Keyvanfar K, Weed J, Swamy P, et al. Interphase Chromosome Flow-FISH. Blood 2012; 120:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/149\">",
"      Jerez A, Sugimoto Y, Makishima H, et al. Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood 2012; 119:6109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/150\">",
"      Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Invest 2009; 39:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/151\">",
"      Valent P, Bain BJ, Bennett JM, et al. Idiopathic cytopenia of undetermined significance (ICUS) and idiopathic dysplasia of uncertain significance (IDUS), and their distinction from low risk MDS. Leuk Res 2012; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/152\">",
"      Pavlu J, Emmerson J, Marks AJ, Bain BJ. Idiopathic cytopenia of undetermined significance and the minimal criteria for a diagnosis of myelodysplastic syndrome. Leuk Lymphoma 2011; 52:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/153\">",
"      Ando K, Kodama A, Iwabuchi T, et al. Idiopathic neutropenia with fewer than 5% dysplasia may be a distinct entity of idiopathic cytopenia of undetermined significance. Ann Hematol 2010; 89:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/154\">",
"      Schroeder T, Ruf L, Bernhardt A, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol 2010; 21:2267.",
"     </a>",
"    </li>",
"    <li>",
"     Swerdlow SH, Campo E, Harris NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/156\">",
"      Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/157\">",
"      Albitar M, Beran M, O'Brien S, et al. Differences between refractory anemia with excess blasts in transformation and acute myeloid leukemia. Blood 2000; 96:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/158\">",
"      Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 2012; 118:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/159\">",
"      Breccia M, Cannella L, Frustaci A, et al. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems. Leuk Lymphoma 2008; 49:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/160\">",
"      Emanuel PD. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia. Leukemia 2008; 22:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/161\">",
"      Orazi A, Germing U. The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia 2008; 22:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/162\">",
"      Geary CG, Catovsky D, Wiltshaw E, et al. Chronic myelomonocytic leukaemia. Br J Haematol 1975; 30:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/163\">",
"      Tefferi A, Hoagland HC, Therneau TM, Pierre RV. Chronic myelomonocytic leukemia: natural history and prognostic determinants. Mayo Clin Proc 1989; 64:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/164\">",
"      Fenaux P, Beuscart R, Lai JL, et al. Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol 1988; 6:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/165\">",
"      Fenaux P, Jouet JP, Zandecki M, et al. Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors. Br J Haematol 1987; 65:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/166\">",
"      Duguid JK, Mackie MJ, McVerry BA. Skin infiltration associated with chronic myelomonocytic leukaemia. Br J Haematol 1983; 53:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/167\">",
"      Mufti GJ, Oscier DG, Hamblin TJ, et al. Serous effusions in monocytic leukaemias. Br J Haematol 1984; 58:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/168\">",
"      Youman JD 3rd, Saarni MI, Linman JW. Diagnostic value of muramidase (Lysozyme) in acute leukemia and preleukemia. Mayo Clin Proc 1970; 45:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/169\">",
"      Gupta R, Abdalla SH, Bain BJ. Thrombocytosis with sideroblastic erythropoiesis: a mixed myeloproliferative myelodysplastic syndrome. Leuk Lymphoma 1999; 34:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/170\">",
"      P&eacute;rez S&aacute;nchez I, P&eacute;rez Corrala A, Menarguez Palanca J, et al. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease. Leuk Lymphoma 2003; 44:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/171\">",
"      Cabello AI, Collado R, Ruiz MA, et al. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Leuk Res 2005; 29:365.",
"     </a>",
"    </li>",
"    <li>",
"     Bain B, Vardiman JW, Imbert M, Pierre R. Myelodysplastic/myeloproliferative disease, unclassifiable. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.58.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/173\">",
"      Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol 2009; 144:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/174\">",
"      Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood 2006; 108:2173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/175\">",
"      Gattermann N, Billiet J, Kronenwett R, et al. High frequency of the JAK2 V617F mutation in patients with thrombocytosis (platelet count&gt;600x109/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood 2007; 109:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/176\">",
"      Hussein K, Theophile K, Buhr T, et al. Different lineage involvement in myelodysplastic/myeloproliferative disease with combined MPLW515L and JAK2V617F mutation. Br J Haematol 2009; 145:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/177\">",
"      Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood 2009; 114:3538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/178\">",
"      Pu JJ, Hu R, Mukhina GL, et al. The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells. Haematologica 2012; 97:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/179\">",
"      Appelbaum FR, Barrall J, Storb R, et al. Clonal cytogenetic abnormalities in patients with otherwise typical aplastic anemia. Exp Hematol 1987; 15:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/180\">",
"      Kasahara S, Hara T, Itoh H, et al. Hypoplastic myelodysplastic syndromes can be distinguished from acquired aplastic anaemia by bone marrow stem cell expression of the tumour necrosis factor receptor. Br J Haematol 2002; 118:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/181\">",
"      Della Porta MG, Malcovati L, Boveri E, et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009; 27:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/182\">",
"      Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/183\">",
"      Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005; 352:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/184\">",
"      Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \"atypical\" myeloproliferative disorders and myelodysplastic syndromes. Blood 2005; 106:1207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/185\">",
"      Karcher DS, Frost AR. The bone marrow in human immunodeficiency virus (HIV)-related disease. Morphology and clinical correlation. Am J Clin Pathol 1991; 95:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/186\">",
"      Scadden DT, Zon LI, Groopman JE. Pathophysiology and management of HIV-associated hematologic disorders. Blood 1989; 74:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/187\">",
"      Sakaguchi M, Sato T, Groopman JE. Human immunodeficiency virus infection of megakaryocytic cells. Blood 1991; 77:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/188\">",
"      Chelucci C, Hassan HJ, Locardi C, et al. In vitro human immunodeficiency virus-1 infection of purified hematopoietic progenitors in single-cell culture. Blood 1995; 85:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/189\">",
"      Takahashi K, Yabe M, Shapira I, et al. Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection. Leuk Res 2012; 36:1376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/190\">",
"      Kumar N, Elliott MA, Hoyer JD, et al. \"Myelodysplasia,\" myeloneuropathy, and copper deficiency. Mayo Clin Proc 2005; 80:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/191\">",
"      Huff JD, Keung YK, Thakuri M, et al. Copper deficiency causes reversible myelodysplasia. Am J Hematol 2007; 82:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/192\">",
"      Willis MS, Monaghan SA, Miller ML, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol 2005; 123:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/193\">",
"      Pang WW, Schrier SL. Anemia in the elderly. Curr Opin Hematol 2012; 19:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/194\">",
"      Schmitz LL, McClure JS, Litz CE, et al. Morphologic and quantitative changes in blood and marrow cells following growth factor therapy. Am J Clin Pathol 1994; 101:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/195\">",
"      Singh NK, Nagendra S. Reversible neutrophil abnormalities related to supratherapeutic valproic acid levels. Mayo Clin Proc 2008; 83:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/196\">",
"      Banerjee R, Halil O, Bain BJ, et al. Neutrophil dysplasia caused by mycophenolate mofetil. Transplantation 2000; 70:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/197\">",
"      Kennedy GA, Kay TD, Johnson DW, et al. Neutrophil dysplasia characterised by a pseudo-Pelger-Huet anomaly occurring with the use of mycophenolate mofetil and ganciclovir following renal transplantation: a report of five cases. Pathology 2002; 34:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/198\">",
"      Taegtmeyer AB, Halil O, Bell AD, et al. Neutrophil dysplasia (acquired pseudo-pelger anomaly) caused by ganciclovir. Transplantation 2005; 80:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/199\">",
"      Gibbs SD, Westerman DA, McCormack C, et al. Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders. Br J Haematol 2005; 130:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/200\">",
"      Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/201\">",
"      Naqvi K, Jabbour E, Bueso-Ramos C, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood 2011; 118:4690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/202\">",
"      Wang XQ, Ryder J, Gross SA, et al. Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. Int J Hematol 2009; 90:361.",
"     </a>",
"    </li>",
"    <li>",
"     Brunning RD, Orazi A, Hasserjian RP, et al. Refractory cytopenia with unilineage dysplasia. In: World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al (Eds), IARC Press, Lyon 2008. p.94.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/204\">",
"      Hast R. Sideroblasts in myelodysplasia: their nature and clinical significance. Scand J Haematol Suppl 1986; 45:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/205\">",
"      Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119:5674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/206\">",
"      Germing U, Strupp C, Kuendgen A, et al. Refractory anaemia with excess of blasts (RAEB): analysis of reclassification according to the WHO proposals. Br J Haematol 2006; 132:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/207\">",
"      Nimer SD. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. J Clin Oncol 2006; 24:2576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/208\">",
"      Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010; 24:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/209\">",
"      Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994; 84:3253.",
"     </a>",
"    </li>",
"    <li>",
"     Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the myeloid neoplasms. In: WHO classification of tumors of hematopoietic and lymphoid tissues, Swerdlow SH, Campo E, Harris NL, et al (Eds), WHO press, 2008. p.18.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/211\">",
"      Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002; 99:4638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/212\">",
"      Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci U S A 1997; 94:6948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/57/41882/abstract/213\">",
"      Pedersen B. 5q(-)survival: importance of gender and deleted 5q bands and survival analysis based on 324 published cases. Leuk Lymphoma 1998; 31:325.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4492 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-122.72.76.133-CAE5397922-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41882=[""].join("\n");
var outline_f40_57_41882=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H47\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4008903\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2301298\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2301305\">",
"      Autoimmune abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4008672\">",
"      Acquired hemoglobin H disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2301312\">",
"      Cutaneous manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4008100\">",
"      Complete blood count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33613152\">",
"      Peripheral blood smear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4010436\">",
"      - Red blood cells",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4010760\">",
"      - White blood cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47639590\">",
"      Bone marrow aspirate and biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4009096\">",
"      - Bone marrow aspirate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4009103\">",
"      - Bone marrow biopsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Cytochemistry and immunophenotype",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5152246\">",
"      - Genetic features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H303969\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64020980\">",
"      Idiopathic cytopenia of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64020408\">",
"      Acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64021188\">",
"      MDS/MPN syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H64021195\">",
"      - Chronic myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1583841\">",
"      - RARS with thrombocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64021958\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H64021769\">",
"      Poor nutritional status",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H359854\">",
"      WHO CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359891\">",
"      Refractory cytopenia with unilineage dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359898\">",
"      Refractory anemia with ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359905\">",
"      Refractory cytopenia with multilineage dysplasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359912\">",
"      Refractory anemia with excess blasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H359933\">",
"      MDS with isolated del(5q)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5937816\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4492\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4492|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/33/7711\" title=\"figure 1\">",
"      Electrophoresis hgb H",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4492|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/49/15123\" title=\"picture 1\">",
"      Hgb H inclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/39/4722\" title=\"picture 2\">",
"      Dysplastic RBC in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/12/32961\" title=\"picture 3\">",
"      RBC dysplasia in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?4/45/4816\" title=\"picture 4\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/58/41890\" title=\"picture 5\">",
"      Dysplastic neutrophils MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?37/52/38722\" title=\"picture 6\">",
"      Giant granules in Chediak-Higashi syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?29/7/29809\" title=\"picture 7\">",
"      Myelokathexis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/50/18214\" title=\"picture 8\">",
"      Myeloblasts with Auer rod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/44/705\" title=\"picture 9\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/52/15173\" title=\"picture 10\">",
"      MDS abnormal megakaryocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/46/28388\" title=\"picture 11\">",
"      CMML peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4492|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/45/23260\" title=\"table 1\">",
"      Predisposing factors MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/15/24828\" title=\"table 2\">",
"      Morphologic abnormalities MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/38/44651\" title=\"table 3\">",
"      Diagnostic criteria for CMML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/40/27275\" title=\"table 4\">",
"      Diagnostic criteria aCML",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/19/23867\" title=\"table 5\">",
"      Diagnostic criteria juvenile myelomonocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/43/42683\" title=\"table 6\">",
"      Diagnostic criteria for MDS-MPN unclassifiable",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/59/25531\" title=\"table 7\">",
"      Diagnostic criteria MMM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/28/25037\" title=\"table 8\">",
"      Peripheral blood and BM findings in MDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/33/21020\" title=\"table 9\">",
"      FAB classification of MDS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/1/17433?source=related_link\">",
"      Acquired pure red cell aplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/0/22538?source=related_link\">",
"      Anemia in the older adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/22/5482?source=related_link\">",
"      Bone marrow aspiration and biopsy: Indications and technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/17/5402?source=related_link\">",
"      Causes of hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/63/6138?source=related_link\">",
"      Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/63/1018?source=related_link\">",
"      Clinical manifestations and diagnosis of primary myelofibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/35/14905?source=related_link\">",
"      Cytogenetics and molecular genetics of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/28/18890?source=related_link\">",
"      Diagnosis and clinical manifestations of essential thrombocythemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/55/6010?source=related_link\">",
"      Diagnosis and differential diagnosis of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/0/5130?source=related_link\">",
"      Diagnosis and treatment of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/1/3098?source=related_link\">",
"      Hematologic manifestations of HIV infection: Anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/0/44039?source=related_link\">",
"      Hematologic manifestations of HIV infection: Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=related_link\">",
"      Molecular pathology of the thalassemic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/26/19880?source=related_link\">",
"      Overview of the treatment of myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?9/1/9234?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?6/26/6564?source=related_link\">",
"      Patient information: Myelodysplastic syndromes (MDS) in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34425?source=related_link\">",
"      Prognosis of the myelodysplastic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40905?source=related_link\">",
"      Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/35/39480?source=related_link\">",
"      Therapy-related myeloid neoplasms: Acute myeloid leukemia and myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31210?source=related_link\">",
"      Treatment of intermediate, low, or very low risk myelodysplastic syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_57_41883="Arozullah index";
var content_f40_57_41883=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Arozullah respiratory failure index",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Preoperative predictor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Point value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Type of surgery",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Abdominal aortic aneurysm",
"       </td>",
"       <td class=\"sublist_other\">",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Thoracic",
"       </td>",
"       <td class=\"sublist_other\">",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neurosurgery, upper abdominal,",
"peripheral vascular",
"       </td>",
"       <td class=\"sublist_other\">",
"        14",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Neck",
"       </td>",
"       <td class=\"sublist_other\">",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emergency surgery",
"       </td>",
"       <td>",
"        11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Albumin &lt;3.0 g/dL",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        BUN &gt;30 mg/dL",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Partially or fully dependent functional status",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        History of chronic obstructive pulmonary disease",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        &gt;70 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        60 to 69 years",
"       </td>",
"       <td class=\"sublist_other\">",
"        4",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Arozullah, AM, Daley, J, Henderson, WG, Khuri, SF, Ann Surg 2000; 232:242.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41883=[""].join("\n");
var outline_f40_57_41883=null;
var title_f40_57_41884="Projected gender identity for DSDs";
var content_f40_57_41884=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57610&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Projected gender identity in individuals with disorders of sex development (DSD), by diagnosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Projected gender identity",
"       </td>",
"       <td class=\"subtitle1\">",
"        References",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        46XX DSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital adrenal hyperplasia",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        <p>",
"         Berenbaum 2003. J Clin Endocrinol Metab; 88:1102-6.",
"        </p>",
"        <p>",
"         Dessens.Arch Sex Behav 2005; 34:389.",
"        </p>",
"        <p>",
"         Lee. Pediatrics 2006; 118:e488.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        46XY DSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        5&alpha;-reductase-2 deficiency",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        <p>",
"         Imperato-McGinley. N Engl J Med, 1979. 300:1233-7.",
"        </p>",
"        <p>",
"         Imperato-McGinley. J Clin Endocrinol Metab 1979; 49:391.",
"        </p>",
"        <p>",
"         Cohen-Kettenis. Arch Sex Behav 2005; 34:399.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        17",
"        <sub>",
"        </sub>",
"        &beta; -hydroxysteriod dehydrogenase-3 deficiency",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        <p>",
"         Imperato-McGinley. N Engl J Med, 1979. 300:1233-7.",
"        </p>",
"        <p>",
"         Imperato-McGinley. J Clin Endocrinol Metab 1979; 49:391.",
"        </p>",
"        <p>",
"         Cohen-Kettenis. Arch Sex Behav 2005; 34:399.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complete androgen insensitivity syndrome",
"       </td>",
"       <td>",
"        Female",
"       </td>",
"       <td>",
"        <p>",
"         Hines. Arch Sex Behav 2003; 32:93.",
"        </p>",
"        <p>",
"         Wisniewski. Semin Reprod Med 2002; 20:297.",
"        </p>",
"        <p>",
"         Mazur. Arch Sex Behav 2005; 34:411.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Disorders of incomplete or unknown androgen synthesis or action:",
"        </p>",
"        <p>",
"         - Partial androgen insensitivity",
"        </p>",
"        <p>",
"         - Androgen biosynthetic defects",
"        </p>",
"        <p>",
"         - Incomplete gonadal dysgenesis",
"        </p>",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        <p>",
"         Reiner. J Pediatr Endocrinol Metab 2005; 18:549.",
"        </p>",
"        <p>",
"         Jurgensen. Horm Behav 2007; 51:443.",
"        </p>",
"        <p>",
"         Schober. J Urol 2001; 165:2350.",
"        </p>",
"        <p>",
"         Migeon. Pediatrics 2002; 110:e31.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         46XY with severe genital anomaly:",
"        </p>",
"        <p>",
"         - Micropenis",
"        </p>",
"        <p>",
"         - Penile agenesis (ablatio penis)",
"        </p>",
"        <p>",
"         - Cloacal exstrophy",
"        </p>",
"       </td>",
"       <td>",
"        Male",
"       </td>",
"       <td>",
"        <p>",
"         Meyer-Bahlburg. Arch Sex Behav 2005; 34:423.",
"        </p>",
"        <p>",
"         Reiner. N Engl J Med 2004; 350:333.",
"        </p>",
"        <p>",
"         Reiner. J Urol 2004; 172:2395.",
"        </p>",
"        <p>",
"         Zucker. Ann Rev Sex Res 1999; 10:1.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\">",
"        Ovotesticular DSD",
"       </td>",
"       <td>",
"        Unknown",
"       </td>",
"       <td>",
"        Lee. Pediatrics 2006; 118:e488.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Laurence Baskin, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41884=[""].join("\n");
var outline_f40_57_41884=null;
var title_f40_57_41885="Contents: Papulosquamous disorders";
var content_f40_57_41885=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"mobipreview.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"mobipreview.htm?2/59/3006\">",
"       Dermatology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Papulosquamous disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"mobipreview.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"mobipreview.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Papulosquamous disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Lichen planus",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?9/27/9656\">",
"           Lichen planus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?25/47/26361\">",
"           Oral lichen planus: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/11/41144\">",
"           Oral lichen planus: Pathogenesis, clinical features, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?36/5/36952\">",
"           Vulvar lichen planus",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other papulosquamous disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?16/61/17369\">",
"           Pityriasis lichenoides et varioliformis acuta (PLEVA)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?18/35/18999\">",
"           Pityriasis rosea",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?42/30/43497\">",
"           Pityriasis rubra pilaris",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Psoriasis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?41/63/43001\">",
"           Comorbid disease in psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?26/62/27625\">",
"           Epidemiology, clinical manifestations, and diagnosis of psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?31/29/32216\">",
"           Guttate psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?40/4/41030\">",
"           Management of psoriasis in pregnant women",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?0/45/729\">",
"           Pathophysiology of psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?3/11/3252\">",
"           Patient information: Psoriasis (Beyond the Basics)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?39/6/40042\">",
"           Treatment of psoriasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"mobipreview.htm?14/31/14842\">",
"           Treatment selection for moderate to severe plaque psoriasis in special populations",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-FB51CE221D-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f40_57_41885=[""].join("\n");
var outline_f40_57_41885=null;
var title_f40_57_41886="Epidemiology of yersiniosis";
var content_f40_57_41886=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 609px\">",
"   <div class=\"ttl\">",
"    Yersiniosis by month and ethnic group, FoodNet, United States (1996 to 1999)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 589px; height: 450px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Robert Tauxe, Centers for Disease Control. Originally published in: Schmitz AM, Tauxe RV. Yersinia enterocolitica Infections. In: Bacterial Infections of Humans: Epidemiology and Control, 4th Edition, Brachman PS, Abrutyn E (Eds), New York: Springer Science + Business Media, 2009.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41886=[""].join("\n");
var outline_f40_57_41886=null;
var title_f40_57_41887="NSCLC pleural met PETCT";
var content_f40_57_41887=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68407&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pleural metastasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 295px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEnAYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQAT0FABRS7T6GpYbWWUEohIFOzYENFWvsFx/c7Z61A0bqcMpBoswGUU7afQ/lRtPofyo5WA2inbD6H8qURsTgA01BsLjKKux6bcyAbI8596G0y5R9rpjHXmn7OXYVylRWmNOhC/NcgH0xSxWluikyNv547U/ZSC5l0VspHZkkeQTx/eoaKz2giEjt96l7OQXMaitKS1gdhsfyx78046dBjH2obuw20nBodzLoq8dLuijOqZQd81SZWUkEEYqbMBKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKVVLMAoyTQAlFX/7OKxgyuEkP8HtTooEiPzJvYc5q1TkxXKcMEkz7Y1JP5VZj09wW89hHj8auyO8xAkIUDpgYppXGecjpW0cPcVyGOCCJMOvmt2IOKkjaKMHyY9p755o2AnK9DxT4rV3OFUkmtlQSC4zzpD3XH+7Sh3Oe30rRttNncbFTHvitKLw+3/LScKcZ6VtGgK5zoMhO4E+9O3ymRgMHj0rpo9AUsB5wOe2K3rLwNNcBWjg3Z75rVYe4rnAB5NvAXIHpTVlfAyo4PpXp/wDwrW6YbgPLI/hqN/hzODtZ0BP+0OK0WFfYVzzZpnYZO0H/AHaHdyCPl5H92vRH+GF6BuhnjJ9NwqVfhndw7GkuYpAR8y5AxWqwb7BzHmwjmZFwWPpin/ZJGG5t+enevUh4W0e1j/0rVY4XU8rtzirdt4f0m5mjittVjlZ/4fLrRYJC5jylbCVgAsZIA9KZJp8gIzEQPSva7zw7YWytGsiiWMc8daxTY2Y3bgCcccVDwlh8x5S9oyhsKQT04qA2zKBuJGfavSGt4HkZW2nHtU8GhQXqkuyqo6cVhLDpDueYJGu7azcDpxRLAc7s/KK9Jv8AwG7xiW1TzFxkkdq5e88Nyxvs3uD1+6azlRC5zpyMMHOMZHNO8/zYglwgYHnAGKt3OnzQKcg7B7VTMe5sn5axlRQ7kM9lHOM2g2yA48snr71Qnt5YHKyoQRWqI8E4z/vCnLduFMUgDxE85HJrCWH7DuYVFa7WVtcT5R/s8fvzSXmizRIZLY+fCOrL2rCVGUeg7mTRSkEHB4NJWQwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiitXTLKMxG5uv9WPuL/eNNJt2QFa0sWmXzJG8uLpuNXVEdvxAnLcbj3p9xK1zJ0woHAA4pCh44ziu2lRtqS2KEZwWLYoKKFGGz60MVXGAeetOjgaVwsYLMew7VvZLYRGWUcJzU8Fq8zDAIJ4rc0/RxGFecAr6Vo5gt3/dKAfp0q4q4jN07RgieZcEA+hrQb7LajKqM1FPM8pJZuO+PSqxhZwcfrWyiBc/tNQchMe+Kr/2hLI5MbY9vWq0O/wCZHXPvSRyQqwEhBYnAFaJCNGzvdz4YYbPWu30DVrm0TMb8HjmvP5LYxJ5rsFXqOauaVrpRzFMwIxxVxlYR6xaa9JJBIlwdzvwpHGK828QXt1a37eXNICX4+Y1t6FqFvLcolw6qjHGS3SrerWvhlbqR77UkkK8hAOvtW695COBXUNUaZgss5Zj2Y1d+z6tNCwL3Gf8AeNXb3xPY2X7rRLRUiJyWb5smqi+MNS8tokeMKTn7oreMV1YiqmmammHljkcHjJJNdB4WS4tL8MY23diRjFZ1p441GAFGaMxr82Co61qL8RHl2efbIfdVAraCh3EdNqIuHcyTBiSMmuavb1AzYyCBVjVfiLFNEq21rsk2bCx5rlBrXmgtLy3biiSi3oBPNcqTuBIJ60xNZnt28uBsimm4S5iOUA4wD6VmO0IbDD51Hr1rlq0rFJnU6d40v7UjbLkLwUI6109n440jUkWDVbNIVPBfA5ry1JUJwRgNyfrVhLRQQ6A1zqLGepar4Qtrm3F1pDI8TjiPgkj1rznVfDRildCpSQHpWj4Z8R3Wh32yV3e2f5SCeldrqZs7+2SbepXH3h61M6V1cLniVzDLZz+Wy8Dj61C8LbgVGQRwa7jxHpLyRmdELKvAYDrXGNI6ttK8rwa5XHlZREsDOOAcrWvpMc1sRLyynqp71RtrrypV3DKk11UflTQo0ZHPXFawpxmJsxtc0aO+he5t02XA5cDoa4llwSMV6pKfswLAZwMmuM8R28c4W+tY8K3+tx0BrmxeDt7yHGRztFKwpK8lpp2ZoFFFFIAooooAKKKKACiiigAooooAKKKKACiinxRtK4RBlj0FG4FzTbRZT5s5xCv/AI97VrKrXkoY4RF4C1UVDHCkBcEKc8etW4JFiUN39K76NKyuyWx8+y2iMYALHvVMJld5P0FSSlpZNxHJ6CtnTNEe4WN5jtXP3cda6rdESUdM02W6IcDCZ6muq07SY7eB5QMbRkyEVuWOlQW0BkvGWCCJdxJ4wPX3rmPE3ja1mj+x6fb/ALlTgyA/fFXyKKuwG3t/vfZAuPRs8VmSXcUDlrq4UueNoFYN7qcs+Vj/AHcR/h71nkkn5iT9ahzsB0L6+qFlSLcOzZqjJrN2z7kfaPSsvNGaXtGFi8+pXLA7n59aha7mY5L81XJpKl1GOxck1C5kTY0pK+lQCV85DHNRU5QScDrQpNgTLNMxAEj57YY1qwqwUB3YkjJ3HNV7a1CgNuG4/pWna2DOwLyBQe5ruo02tWS2QpG3CpyGNWvsZDAk7ccZp7TRWh2x87TyfWopbkyMzeo6Vs6ltBWCRIlYkqWIGOtRxqvUIemaEd3C+Xyc9K3LXR3aLzZGxk0Rk7hYxSZQpPkFgelTJcKwVZYChxiuqhtY1UE4LgY6U29sIZowpQBjzmuuDe5JhIS1uQq5HYg9KpTwqcA5V+/vVy8tJLLLAlh/Kq/mrOipJwc5zSqTUtASKy537SMEV12nQh7ZCV521yUm5ZDgY2n866XQ9QFwqRvEQE469qmjBN6inJRV2Ty2UcikycL24qz4fg23wiklKwt0DHrXZ6PpEF5ETFIpB56dKbe+E9x3K+CORgYxXFPOMtU/ZOqub5/5WPPWZ0eblbHausFlobLcMm1nCKvcZ715f4m0J7O5dk+bPOcfeFegXWjpfQiwvp2jnJBhuD0X/ZxUmo2puLFdGu4vLvbdD5c56SKK3r4e+sdj0KdSM1eLPFGGCCBg9Melbuh3CJHtY5A607VtHaMGWMbWGd0eKxo5HtyrYOPSuKN4S1NTrpC0kLlRkEVzAWPdJayAmJsnAPVu1XLfWyIGTYeeB7VZ8K+FtZ8Y619h0G1aaYfPLKTtjhX+87dFH8+2TXoTlCVO7ZCvc4e5haGVo5F2sDyKgIrv/iZoOiaPfQ2uh60NXuYIgL2aOPERmyciNs/MoGOf/wBQ4JhXzuJp9UapjKKKK4igooooAKKKKACiiigAooooAKKKKACtXTIRFD579G4X61mxoXcKoyT2rYnCIqQxE7FGce/et6Mbu4mIBjJbk9afkvjcOB0qZUVkGOorT0XTWu7uJFjLvnpXoxi9kQP0TS3nmR5FJUH5Bjqa9L0/S4dOtmvL9ljWNd3zdE9/erWlaTFo9u9zdlUZFy0jDiEepHevKvHvi+XXro29oWh06I/KoP3z3Y+x9K3UVBXYiDx34ibWNSaO0lP2FPugcZPc1ytBpCawlLW4wJoptLms73GJRRRUjCjNFAqWAoq7YW5mccZycD61UiXc4UDOeMV1mj2O5VVRtc9/Su3C0udktkUGnmBgzN5kgOQoHSrU4nK5MLKT3rqbK2ht48ABnPBJFSXCjYThcjtivXVDTQzueeSK7sc9QaliXcwyOcV019pUdwoeEhZDyfesa4tJLSQSMpwvWsnQaY7mrolhHu3uRkDPSt8oNqBuc8jHaqujiJrAOeSx7VoD5jnqAMCumnR01JbIVIdimMDPPvSOuJMhsgcAVehtA6A4+Y84qvJD5cxB6/0rfkRmqik7Ip3MYlTYAMDkgiuOvoPIuZSDgE8V3eNwJ25A4WuX8SQhHBAyc847VhWppK5omYzkmJcnLVveEohNdhWUjPT6VjwxNI4AHFdNoiG2mQxjBPX2rHDu8rMmtHmg0eteEdPKTp/dHQV6DqWmRXNgHCASIuDivO9BmkiRGR9p7E+len6fHNcWK7j8rLgNX41xJhJYLHSSfU8nL+SfPhpxv1PLdUsFkmIkG1l+6arx2yagkcF6227i5gk/xrsL3R7n7TJ8u4pxnHWsq80K6jQS+UxxyWHavr8j4rpUaUcNinoupyYavVw7s4uy8jifEeiT3fmy+TsuUH7wAcSf7Qry7V7IAblOVJ9O9fR2h21zq97FpphMk8n3JMcIvct7V6m/gLw5B4bjsLjTrOeK2kN3uuBtVpsffcjt2I6YAHavpcZiqCUZ03fm7dj6HDVVXjzR2Pkfwd8On1HS/wC3/FV4NC8KxHLXcg/eXH+xCnVifXGPrgipvGPxCEmjv4d8FWJ0Pwyp+ZVP7+7P96Z+pz/dzjtyAMUfiR4h1jxDrs7a/cxSfZnaGGK2YG3hUHGIwCRt4HPOeOTXGTjAwf4unvWcU73n93Q3IFk2FSvVuOayruLyZmTOcd60pEZT16UzUIzNarMq8R8MayrLmQIyD1pKc1NryZKzNAoooqQCiiigAooooAKKKKACiinKORTSuwL2kxEyNMP+WQzj1qcrvk3Dkk9KldFtoEgRgzD5iw4zntUkA3BXK8jpXoUqdkQyzYx7gQ4xjoa9g+HuhwWNoupX5VWf/Vqe3vXlumx7pFZ/9Uhya6DxH4wms7MQ26ESOu1Gzwvviu6mlFXZLHfFfxkl9I2kaUcW6H97KD/rPavMOlOkdndnc5Zjkn1NRk1NSpzO41oBptKaQ1ztjEoooqBhRS0oFNIQ2inYoAo5QL+jQLLc5fog3D3rvNJgWK33AfM5/IVzfhm3ElpuOB8/Wu4sYgSqjoRg17uBpWhdmU5W3JLeJ2KnGUzya07izHkAjkn+VSWsI8tgvTpVkMSjRgDIX71eicE60m7IwWsh5JJ4IPSmNp0d1+4cgFxhc+tabOVGCPbNVrwMybRxngMOxpXKVWSE0fSX0+KSK8YKynC5HWrDRbBuPQNn61rmZby3tDIMPEgiJ9feory3+UqeV7GnbQz9s29SqkqtkqMMRVfyGJLOwJ7CmSwmI4L5JHapVmVEQt0UZ+tId7O6K8kDIuSODyPY1zviKMsAoXJPU+9b15q0ccRYKWLHP0NZlvb3epMZ/KIgDbSx6Upe8rHVSk2tTkldoZlUZOBz9a6/wyhvJ0zxiovE+mWuktFh1neVdxZf4farfgq4SO42Iu0k8Z9Kwow5ZFVpWg2j1DQbZ5JYVx8uQp+tek312un2kUO4IyAA+5rivC7K15EhI2/ez71q6/LJJdOB0z1PevxriSr9azOfN0f5aGXDlCNatOUzWOsKUw21WJ5461BJqx3bGUMM9PUVnabpk9yjO/EY43Gq+rXOnaTETLL57KOxxivFVGlzcsVdn0WJnl+ETVWR1lrfx6Vp89xoNrEb6YfO83O0egA7fjXkXju71/Xlk+36hcSR/wDPAnbGD2wo4rufDGq2N+scsEojc8hGOav61pEepszqFSU+g4r28p4hq5XXUaivBaWa2X+Z81Xp8/73AzvFdNv6fqfMM+nTIzxTr+8X261j31ntjyvzA9PavX/EWiNZa1DIRkodrLj72awvEvhtEa5vLbmDI8xcfcNfqilSxtGOJw7vGRthsQq0b9Tyh1xEec80kaBw8Lt+7YFsfStbU9PMKsYz8p9qxmBEqDOSO9cUotbnUYzDkimVe1FH88yMm1X5X3qkRXl1YNMtCUUUVgMKKKKACiiigAooooABWjpMJaVpsArFyQe9UFGTit+OP7NFHDwW6sR3zXTQp3ZLYxFErn86vRpuAEf3RVeFEywj++a2Y4RBCASMkV6cIklrSIFNsWJwOc5rjtYuzd38kmCFB2gfSun1KaO00aZGcrI4/d47muLOT1qqjskgQlGaKaa52xgaDSUVDYBRRRSGKKUUgoFUhC0opBTwPTrWkVdiOx8JQ/8AEtLt038V2+npmDK/e6Vh6JbeVpsCbcbwDW5bI9gSUbehHK96+jox5KaRyV3oaMClXCckHkkVOyqGbDYOOKghvbbK72CM3G01JdXNvEAJJFwehrY4lqytsBlBfnHI+tM+ztLcjbwOpNVkvYnkO6QEBugq69yWTZBGQp70kN6Mf5hVWVR8qnrVS81CS3RsNkY5p/lzuu2KNicdP602LwlrutFRFGI4s7TKSMChysiLXZixav56Mx4Knp61u6dYXOoWpuPLMdsvJZu9dBp3gPTdAGzV9QiklPzsQMfLWf4t8VQSeXaaUBFp0Y2bgMb/AHrOMrmyjfY5fU7uCAlLeMOvc4qvrOvS3Gl29pZrtYEEhRjNVLm4WRtiACPdktT1nto1ZYwMkfe9KqTsjspxsihfebOieYx345zzip9EMtnepKc7cfpU1vbeYfNY7sdD2qtrt4LOxZkH7xvl+lckanLK7LlHmVj07SfEEcZjkilAce/Su6s/E1ndqguot5A+8D1NfJ9lqdxbOGEjEema7ODx79nskjhiIlxyxr5fN+F6GZVXiIT5W9zy3hsRhpuWHla56/418dx6PbCNQd7j93EpwcetePa944uL6J0YkOT19q5jXdbudVuPNmckjp7VjM+T612ZdkmDy2KUY80u7NqWB5n7Su7yPSfA+vNDqkTmZgF4CZ6mvoLQfEhnEcdyQJCMD2r47tLlredJUJyhBr13wv4nOo24dW2yIQG56Vw51wzRzGDqYdWmunf/AIJjXo1MNP21D5roev8AjS2WfypYwGYL8xHc1l6lpwbQrSbKvashScAclz0zUmiam0tu8UxDntnmt/w+IZ4rvTp13CfLr6AjpXz3D2bVcpq/U8R8F9fI8/6641/ax0T3XZnz94j0uS1uZbKReUOQa4a+haGRyF/CveviJosg06O8ZcT2fyTgd89K8l1iz3ESqeB1FfouIpRlHnhsfRUaqqRUkcfcJ51rg5aRPuD0Hesk1vyHyZ8jqflPtWNeQ+RcPHuDY7ivErw6nQisaKU0lec1ZlhRRRSAKKKKAClFJTgKqMbsC5pUKy3SmVSYV5fHatgDJY556KfaqWlI6QSlkIjl4B9a0BASQc4SvVw9PQhst6XZYuCT8wHOa3dOsH1TUREgwicsewqHS4DHa567+K7fR7VNM8LXN45DPd4RQOq4NehGkRc8x+IMiJqS2UY4hFcma7H4q2623jCRF6GGNvzFccetclX4mUtgppp1NNYyGJRRRWYwooooAUUClApwFXGNxCAVq6DZNdX0RIxEpyxPel0TRLjVGOwiOIf8tGHFdZY2q6eVicBgONw7+9elg8O5PmexEpWOhtypYLGPkUYFXoJAJAHGW9Kz4J7cQgq464obVYIj8sZdumc9K9m6OGrJSZLrqoLVpThXQ7uK5gTSXBSRWOScAE5qxrF/NePsBwnak0eExrvfghsgmp3ZdKmrXNayGUCTqAa2LciMhVGUxxWfYRg3DM7A57VsxBFJ6cc1aRhXjZlhZSVCxjaO9NmvrqGAxW08keT2Y801ir9GyeuBU6Yd1DAEBcg07XMNUY/iPUryZrdhmRki8tjXNSp9rhaPHPcDjFdvJbrIHcrtPTmsWWxUuxj+9nqOBU2OqjNGBaWbPbvFt4WpINOVIy45zwc1dlie0bO7I74qWLBB2jOfmx6VMo3OtO5WgV4oihGIzyfauR8VTxgeSjZJOcV02rasmnQMZfm39AK87vZzc3LykEAngeleZX912RpHUjDYpd3tUeaM1zqo0VYeWzTc80hoqHO4DgcVp6PqMljcq0bEKT8wrKp6nBralVcXcUopqzPdvD/iBEks4t3+sXO7PWvTbO7P2QTxECVGBwOuK+VNEvHhnXLscEFeele7+B9fXUNPkVwfMBAc5618fxZlt5rG01vv6nzOYYd0JucVo/1PQtdaDVtKnGARcJukH90gcZrwGeBVmkik4OT1r03WbuS2V0s9yow5ya871JC10XUjcx4r6PhqvLE5fae60OnKajs4s8/1i3aO9dcYwaz7+AS2YmVgDFww7muo8Q2riYSMQd3OKwYyElJIHII2nvWtanq0e8mc8aYat3ls0DDJBVuQRVYivJqwaLQ2iiiucYUUUoppXYCgVfsLFpgZXGIV6n1qPTrU3M4B4jXlm9K15pfOcrGuyNeAB0NdtGnfVktirIZMADao4C1ahVmZUznPWm2tvJcTEp1UcDFXLS1K3hSTIK816lLQhm/CgRYs57DFeg6nZRFtC0sP8pJkcD0xmuBGC0OD8pYD9a9F1K4trHUvt130trcFRnrla7Y6ok8U+KGowap4xup7T/VIoiH1XiuSqzfyCW+uZR0eVmH4mq1eXUd5NloQ02l70lYMYUUUVNhhRRRQBJErOwVBlj0HrWnJpE8ap3LdvSneGrZZrsu4OEGQfeupCB5FO0kA5r0cLRU1dkN2NHTESz06OGJcAjLH3qR1LLnhlPGabbgyAgnCVp2sSlNjjHpXtxioqxz1JpGKtrK0ZWPgZzTlspgwDDAzmukigwMhQEHbvUdzHwDjHvRynFKepkppyyMAByTz7VZlgEEQ8sBiDg1cgKxoxz9KjZQ6MWyARzTWhdOo0N07KKWPJJrULqkYK889PWqdo6LH5YG4YzkVJcuMKHHTkYpjl78h5mO8bV2nPNXYpG2kkg88YrCWZ/OLtzjgVdguC3VhtzzTHOk2jVdmKHccDH61l3EgjXHQ1N9pTawOcdcVl38xmKhR8uMChkUqTuVtSucQyFiOF4rFsNSJixJlVHf1qbXJEWFY934Vz80gV04wqnkeorCpVUTujGxX8TTy3Myu/EYGFFYhq7rN6by64G2NPlUe1UK8qpU5pM2SCkJoNIRXLJjDNGaCMDkUlSwFBpwplOHSqg9QLNu5Rgw6ivQfh/qjx6pEiE7WHI9TXnMZ5xXQeFb1rTU4SOhYD9a71ThiabpVNmceLpKpBo9xuvMu5xAmS7dqy/FegXGmQxXBXdGByw7V2/gex8+a51NmU/ZYiApHXI61la3etqng28kk5KvgfnWuX4SOCp/V4bLf5nmYGPJKx5JrUWbcyE5I7Vy9zbNsWTOQa7O+tzJZyc8nqPSuQuAVcK2QFyMVniI6ntootG1xG0BwGPIJ7YrDYYJFbjqyuvJHNZ2qqPtbMq4Q9K8nER6miKB60UppK8tqzLCp7SEzzrGpwTUIra0yMw2xkypMvA45WtqMOZibJiVijEMCkIOvqTV2x06SbBHAPWrWlaU1y26QgDr9a6BZIbWMKy4A4r1acNCLkFrbx2UOU+Zj96s2+uN2oIIgQp+9W2CgUvvXb1NYq7bjVC3AUdfeuhIRqtIVKBOgwQKseN9aa80ovHlWCBT+FZ4ctKRjAX9ap62rHSbs4+ULxWzdouwjiCe/rTaKQmvNkyxO9GKKWswEpKU9KSkAUUUUhm74cvPJLxYHPeuhtp2D/IQc1xulqXvYo1O0s2M13NvamHBGN2cGvZwDvEykaNshZlO7HqK1YmGBu+XB4zVC16cY45q0kLXDhYgWb0r1bHPOHMzThclclgwz0FUry4RFbOT6c9KzNS1RdLfyJFLy4zhT0rKuNcWRcmF8Gk5WMXh3ctWuobrsqTwDxW9HIpiOWA3etcB5zMxkRSnOQDWnFqk0Uao8TO3XI7VCfcr2DOwB8tMgDpUTBpYvmJ3E5x7Vn2OqrLECw6HkVbGpQxjc3J64H8qu5FnEmKAqMY2jj61FJmFTj+L9KqXGtw+WxjgcHORWHqPiMFVVY2DE80c6NYScjoJ9RjKAFh8gx9awNQ19I3JztwPu+tYWq60XXybVdkZ5fdySfasF3LH5iSfeuHE4vl0idUYmvc6xHMWJjfceeT3rLmuZJfvMagNHevJnXlLctIeDkjJ/GrM1q0aK6kSIRnI7VVWtGwtbu6ic28bOifebsorSkuYGUMVd0qe1trjzLuBpgOgBqqwAYgEMB3HekNVy21AkvpVuLuWWNNiuchfSq5Ug4PWnhipyOtNzWUrXGJilHWiloUQHR9a1tCbZqMDEZ+cD9ay4xiux8CaFNqN4txkLHGwOCOtelhYt2sYV5KMG2fR/w7DPo+rBiCSmMj/drjY4ZLfwlq8cp3KsvB/GtzRNfHh4SrPC0sE4+YJ24qHxVNaR+EJ5IPkN4wdEPU10wqRdaaTvqjxsNNe0SPMGyYyvXrwO9cnqKMbxs9Rn5a64I4DMRkHk4rEjtRPqE0+fkXtXPiNz3Ecw6FQc5yKqasC1tbkL0Bya3NUiMUrMw+Vug9KzZEFxZzpGCX6qK8urG6sWjnjTaewwSDTK8iorMtD4vvrn1rpXVFnVI1wuBxXNx/fH1ropCFvR2JAxXXhVoJnX6Wm2xUZAI6VvWHgw6taXErzhZwu5Rn2zXP6co+xI5BJHvxXaW15JpmmaZqIbcjllkA9OlevCF0Z3PM7SGXz5owzfIxUhj6GtAWiRqWZwXPUCtnxTpsVpqSX1md1rc/MhU9+9ZBdBJgjlqOWwDEUoo+Vt2eTV3UrGddKDvEfJmBA4qmwYLuOfvDP0zXpfiW6tLOw0osga1ZVAx0yRzWtroD5zlXbK4xjBIqM12PxTsLbT/GE0NkmyFokkA+ozXHmvMqRs2ikNpc0lFZFBRQaBUtgFFFFNAXdIdI9Rt3lOI1bLH2rtrXVbSeVw06RoD95u4rz9KkBr0MLW9miGrnYXmvRQMyW5LjswNMh8Z6laQyRWflorjDFlyfwNc3YiJ7yFLhtkJbDn0FJclEuJVhOYwxCn1FdzxEmrpk8pdtZ3uLl2mkZpn5BY5yfSuysYtP0+ya41WRFmC5FufvN9K8/tpnguI5Y8b0OVz60+5mkuZmlnYu7HPJ6fSiFeyBo2ZNXin1DfFD5cPZWrY0xlvHOwZ54ri1B3DAyfSu/g1LT9E0+IwgTXjoCAP4D71vRm2m5ET0WhNdQfY1CxJ1+ZqlsbNZ1SRuSW4Wuel1u9uLjz5Sm/pgDiuj0DVbe9uYrdYnSduAT0J9q1jJSZxT5krst3GlJIXAXr6etctrnh+WMCSMHAOCPSvUk0uSI4mUqxOBn1rO1G0aNHjYd+9W4x26mNPFKMjxS/tzC/HI71TxmvRtTsYoJVJVXJ56d6bNpOm3zK11GVkC8eXwK4KmEcpNo9WFRSSaPOitJtrtJvBrOsk0V3FDAvZ+tc81tatKYVmClTzMfumuSphHEvmuZyitfw5by3WoC3jmaJWGWwcAimrol80gEMDSxt92RejD1rc07QZLNvMmk/engBeMCtaGHlfYTZzusJHFfyQxLhYzt+tUTWnrVv5F84Lbtxzms1hiorQcWxpjGptSKhbvhc4J9Kl8uCI/vH80f7Bria1GQZ/Or9ppd1ckbYyo9TRHfW9uv+jQfP6vzRJq13KOXC/wC7xVwcU9QOv0Tw7HbW8v23a7v93Hau48HwQ6fEkcRBLcgV4vHf3W0gzyHP+1XY/DW5mbxBArSswwSQxyK9ilVXJaK1OLGRbps9e1CBLhT5mRnnArB8VTu9vYW7EeVEpEYFemaP4YOpW/2ic+WrjMYNeaeMdsOpvasMvBkZr5PhyNeWKlUne1tTwsDeVZHO3Eh2nfkADGR0rFtzLDOuMMjZ7Vf1K4VdNZyDnPWobC4juLaLGA46g9a+kq6yZ9OipqcKyxttU7h0rnIcQXBIBDEELXc3EYKlVAJIrjL6Ix3ZG4Z3VyVIlI5q+ge2uXjk+8DzVatLXH8zUpWPU4rOxXkVo6loVOGB9DXQNKJNk23KsAK55a29OlWaz8kECSPlR/erbCvQTOz0RjJabQcgdq7Xw9DJq3hzU9KKgGNd0RPXNecaFeCEAE4J4xXW2WpTabcx3sBIdOSvZh717FFqxDKllaXMun3kFw5xYcgHvn0rNRDNEJFAAB5zXo1lcWPiU3U1hA0ErKBOh/j+lcVrukXOh3ToziWKT7rL0+lauKsIzHIiQ7+c9K66+gk1TwJpbqclJTXF3SiVQGJVhzXc+ANWtzpsml3+DHCN0eO5ogruwHnnxVtLm28Shrn5g0CBW9eOlcWa7j4lapLqdzEZlx5blV+griDXBiFabLWww0lKaaa4paDF70CkoqLjFoFJS007gOWn0xaf2rppiFzS5rRhvbX7CIJ7csQc7l4NPTRZ7i0a5syJoxyVXqv1roUW/hFcz4mIzjHIp4FLHDJsLbDgHBPpXQeD/Cl/4pvTBZERooy0rj5RXZSg2iZNLUz/AA9HG+t2QnIEPmDdnuK9O1PwjpF/dmeJZFJ6bTgYq7pHwXZJP+JnqUMgHTyuCK6v/hBrmIRxwahEsKDAz1rrpuKVpHHWqv7JwcPh+x0tGkSJpex3c4qSzvbZHDwWiq6n5Tt5zWr4nli8Lz/YL5vtUki+arR/yrgl1t4r1mijwGOQGHSt+aKSscvsZ1EdzZaleX1yFeQblfcQewrbZYSzh/nZxnNchpuo+RCzsmZJOSQKuRagZFwc5IyCOw9KyWGo+09rb3jP6lK9y7qenWtxHlcKyjHNc49hLDOjqysi8EYrcN0HEeRjFNuMFX5BBPBFbs6ablTVjhr/AF6CS5uLQq0UIyrZPX6VmSeGmmtDdWUimHqEPU0eNrQW2oRkAfvE3Egd63vCGpRXVktszKjxDAB7+9czSnLlmdyel0UPCd9Jb2E9q5cTeYMBv4R6V0Dlih4yxHWq+orDE4nfy4wONwHWlVt8Qk8weWBktnitoLlViZK5zeu2KxoLm4OVzjaOtc9dtbH/AI90df8AeNa3iLWEvAYIQSinlux+lc+7Zrz8TVjsjSKGsTjHb0phpSaQ15EndmgClpvpTqSYEkZ5r0L4L2Dah41tk3BY0+ZienHavO1r3H4G6WbXSL7UpR88nMRHYd69PBtvQyqxUotM9sfWWbWJIidkVqmFVeBjFeHeJ706h4g1C8AJjd8LjvXbQaibLRr/AFK6DMsuVHPPPFeZoMEkk7QSRk9a9CNKNK9jkoYZUtSnqzAwJbqM+aelbUHhhtP0eG8lYedMMqncD3qtNaRWsVvf3TrIj/MIl+8MVq3d1LNpb3l3uUXOPs0f90DrXM43dzsMdcMwBVgegNcprirHdsFBY55rqmmVY2TpgdfSuM1SQT3WFJBY/ePSueqtBo5/Uf8Aj7fNVDV7VozFfSITkjHNUTXj1viNENWrVnO1vcJKuMg96qinisKMrDZ0iOkc4eNhsbnPqa63T5xNb7eWyOTXC6XKZoDASu5OYxjk+tb2jXPlsEDe2K9alUM2jotB1GTStTSWEsRG33R3z616PqVrbapBGszK9pcr+6df+WbY5zXl1zc+RIjKoC/xGvQfA1/b39g2k3LqgHzRD+Jj7V2U5X0JZ59r1pNpk8trOuJVPykjqO1V9OkZTHIhxL3Ar07x54bW/tv7QiJE0K4dW6sB0xXmFk6tM8QGMH8RWqVmIzvEEH2q0lkZ+YPmx3Oa5E17PY+FTq2gLcxFTJIWVh/eAryDUbaWzvJoJ0MboxG0/WuTFQtqXEqGkNKetIa8yRQlFFFZjClpKWnEBy07NMFLmt1Kwh4NdD4T1n+y5Zo5OYZl2+wPrXOA1IpHeuqhUs7ieptSQwslyxmKybi4GeGFen/CDxRDptpHpLQZknfIdRyM+teObsrn8K9F+GFo17rts0a/6kBz9K9Wi1LQykr7nvFxN5KM0jYC/rWSNdhDku/yenesLxtrLx3DRW7qYsYIHUNXGy3TmSE5O7PI9a2il2Edd4k0y18Un7VazJ9piXb5bdWHoK8t1mxeykPmKVKnlT1FdvbagbO5W4hQr2Psa2PEelWvirR3ntwBexJvO3jd7fWtHHQLlfWtKtoPCml30aESyKoPPBzXOE/vz5bD5Rz9azNM1O4RFsb6VyIzxG5+6fStLaquWxkkdBTiDHiQ43D0xg06OYRqAxzmq3mAoQcA+tBb92Rt59fWhySFyoL2OG6BkukU7D8ua4O9u1s9YeaywBnkdqteJtWkmmW3hkIRR82Oua51m6nOTXJWrLZFxjYuanqU99Julc7R0UdKgW+uEhaJZW8tuozVZjTCa8+pWd73LSFJppNJmkJrjnO4wNFJmlrIYUCigU0DJ7SF7iZI41LFj0HpXuXwy1H+zsaUQXif7vtXk/haJAZrgn94nygfWu08L3y6XefapMkqDtB7mvWwceVXZnI7b4j3qRrbafbSLtIzJGOxrntDsPt8heY7LSH5pHPQEdqowTXPiDV5HADTytyAOg9a2tekW0sU0fTv3hBAlZP4ia7nJNElZNNl8R67ILQeXaFgSx+6oHWrPiS4je9jtLb5ra1G2PHf1ptxrMumWMWj2iqkqjEkgHLZrGnkENu5kcFhzkdRWUrJDM/VZhDA4GBIetcxGpnud7EEDnH0qzqd0ZZuG3A+lUdRk+x6eIwfnn546rXBWloUjI1O4N1eSTFduTjFUzTjTa8io7s0QynKabSg1xwfKyizaTtbXCSx43Ke9dBMyoY54T+6foR6965gGtPTb5YIpYpVLq+Av+zXo0ai2IZ22nkX9kYjycck1Np4mtgssbFZ4jkH0rH0ydrKby5AQCAeK6aMoGWVDuDdRXqU9VchnonhfxRBqVmYdUZIrlVwS33X47e9eU+IbBNP8STrbSZhZtwwfWtby1LnB245GeorL1SBvNSUtuIP51vzdGI7/R7i4svBVjeWqkeVIxf0A965L4u6NBqFha+JdMglZpfluyv3EA7+1dL4L1EXWmtoc4yk4wmOx962rvR1t/B1/o97cLHHOCFOcZrWrR9pCwk7M+ZiKZVu8t2trqWFs5RiBnuPWqxFeHUg0aoZRSmkrmasMKWkpacQHUUgoNa2FcKeDTM0CmpWAsRsFIJ5Fez/AAdh8vVpHjIAaDOPavFF6V6r8Jb50n3ANyPLB969bBz5nYiRra3GbnW7pQ427j07Gn6TYm3D3VwVKr8oBpurWU82sSlJFjyx3fWr9t5ew27yhwBzivWsctZvl0NOxtYru1c7VC/eHHU1Npiix1SGVspB3Ud6S3EcEcRAby84q7eX1qkQDLkv8oXvmrsmjzueaZwPxP0M2GvGe2wI7pfOU+hPauXs7+9tBvfBAHO6vXviGsUnh6xmmXEiEIufSvM55EcsSFwOtc+trnpUJOUdSOHUnuLZpJQiR55OK5zUvElwzvDasvkjjce/0qtr2qfaH+z23yQr97Hc1iE151bEa2TOlRHu5ZizHJPJppNNLU3NcUqpRZmWLyEeNvm/iU+tVyabmgmspTuAE0hxRSVk3cYUvpQBS4oSATvUsMbSyJGgyzEKPqaYor1v4X+DGtjDr+sIpt+kcLDkk9DXTQoupKyE3YzbTQJtGsYmuotruueR96qV6zAAuQGPb0r0X4pXHlGxjVDvlXKL/dFcPHp7MzNOwZiOBXruCgrIz3Oq8EQvpvhq+1RY99w/yQ+uDTIdJk8P6cdQ1CQ/brjLRxseg96boOv3WkWBtvJV4FPy7hkVm63rMuq3Ye6O92546LWbmlsOxCrby1zK2S/PPUViavfmVGWMYjPc96bqupMX8lNuF4+XvWXHGz28lxK+yJOobv8ASspVNLBYIFRS1xOQIk5B96wL65e7uXlkxk9h0FWdU1D7VtiiBS3j4Ve5+tZpNedWq82xaQhpppWNMzXmVJ6loKKKKwGKKeDUdKDWtOdhM6DS7m4ngIJDCDkE9TXS6TfooCSHr29K4Wwu5LOdZYiMjqD0NdEHR0FxbEbW+8D1Br18PV0IaO0i2ffJ+Y9P/r02aMum1sAjpWLpd3kqJGznge1bTSbcFwSOxFdydyBkDS29wsiExyLjBHFdxr95Fr3g83MUm25tVy0WfmNcPJiSTzVJGeBnpTluZrbcU+6wwwHcV0xndWFY4nWrf7TG10vEif6wH0rAIrub+KOWR3iAw33lrlNRtDbSkhSEPSuOtTvqUmZzCmmpGFNIrzZw1LG0UuKAKlRAUdKWpFiPk+Yfu5wKbitlB2EMxRin4oxS5GMRa7XwVdvaWaSBsKsua41VJICjJPQV1+nQrbabHFuGWbc2eoruwkWpXJkemzWjSlJJCW81d4K+9JHpzkqFidZN3X2rU0K0ll0a3kTMhXG3FXtR1ldFt9kqpLeSDIA/hFe5fQ5pq6K9nEwl8iVWc4yAK0bq3P2cH7MBInI3DmsGy8UywXsUssUflH7xxzXePcf2nYC6sNsqE9B1+lRKdmuxxSjd3OC+IZkXTrJJD94hsV5rq0brY3BjzgkkkV6D8TXlJh875ZFXIX0FcVdqkmnKd2EcYek9VY6cO+h5u3rUbVoatZmyudgOUYZQ+1UDXg14tNpnchhpCaUikrkYxKKKWpGJS0AU4CqURABSgetXdJ0+TUbsQxkL3LHpXbeFfh5Nq+pbXfFpGwLP2x6V10cNKepLaRD8L/CD69qK3NwhWzgYMWPQ4r28mC6mZ8+XYWQxtHCtj0qtJbRQWsOi6MPKhUDzJF7Adc1yvjTxHbQQjR9McfZ0/wBbJ3Y/WvYpUlSjYzbuUPEWs/25qTy7M28R2wnvis9AuTk5+nWqMMrSsXUCKEdAe9RTahFbs4hDO1ZVZpDSNCeRUjzI4APY1z17eR738okHufWqN1dSSzF5XPPIUHpUEaPdvtUY9W7AVwyqX2KsPgjMztPIwjgTlnb+VZOraibx9kQ2W6cKvr9adrN2zSfZo5Fa3j4BXo31rLrjq1b6FJAaQmgmmk1xVJlCGkoorkbuygooopAFFFFADgau6feNayZ+8h+8pqgKcDXTSq2JaOqhZJYvPsydg5K91+tbVhqgYhZT2xzXC2V3JaTCSI/VT0P1rcj1K1uLlERfK39XfoDXp0q6JaOwlYMu5OYz0x2qF5ioO9gQOwrIg1F7RvJf5kHcdxVyeW3vY0EJMb9ya7oTTJsPIBXzFHJ6gdqhnRAoaSMMrcZI4pISbT93KGZW/iHSuq8HLY30wsrkBklOFb0NdMUpaEnlurWLW9wxiRjCRnd2rOxXu+oeAZJbqS2t7y1WNvuxyferz7XPAep2BkKW0u1CdzkfLj2rmqYVt3RSkcTtoArat9AuZoywZFx/CetMj0O7csNuMevesPqsuw7ozUV2QhQSq8kelG2tO20+9R3jELKHG0s3SrI0CVGHmzRhO9dMcO7bCuYRXFJjJwOTXULYWEQCyb2YHPFWd1oEKQ26+xI5q3he7DmMXRrMFhNICGU/KDWzBF517uf7g5OKkt4QAshUlc42981oQ6ZfTF3iVIAwwFkHJrWEFBWRLZ2ng7xJLYaTeQrEzmMGSLPr7+1cv9uuLy4e9unzJI3zD0HoK9T8K6DBZ+H1geIl5VzIz9c+3tWJrXgESEHSJhGSfnEp4/CuhSSJOUlnVogq9z39K0/D/ii90EMtmyYJ+5L0+tWJfAWqsP3d3a7gPlzXQaf4HsY4omujJLdAfOQflJ9vam5RaszN0kzhtWv59XnlnuWDOzfh9BXOyPMGkikTMQ54HFeleJfAtzcTRnRZEhT+ISdM1x3iPw/qehwn7dtkhf8A5aR9M+lJzitiowUdjm72zivoVV88D5W7iubvdJubd8KhkU91rciSZ5MRFtudtasFq0YPmOS3QgVyVYRqmqdjz112sQwwR1FNIr0CaygeNtsCB89WFZc+gxM5kkDAHnCdK4p4RrYrmOTx9aMV0x0O3yCFlIxmnrolqeTHcAVCwkg5kcuMVYgt5Zv9UhYZ6jtXWJbQpCFjtQwHHI5rV03w3c3qhreJrdT3bgV00sHrqJyHfDvw417d/ZRIgZ/nZh2HcV7KyRadZJpulAGUrgn092rjvCenReFYp59QvbeS4k5jWM8gelV/EHi1XtDHp6NAz/6534c/Q+lenGCgkZNtsXxT4jNjbtpGlHzLx+J516D8a4uCxitstM5kkPJJPGarz6tbxbhApLtyWPU1mie4uGIRJWDHI21zVa6uWkX9Sv8ACrEhABHash5nJCL36Y6mkvJIbOQfaW8xm5KL1X60ybXbeGMfYYD5nrIM4+lebVrJvVlpE62aookv5BCg52twW+lUdR1oSQtbWKeVbnufvH8ay7u6lupN87lj2yelQZrknW7FWAmkJpCaaTXHOokOwpNNoormlLmKCiiipAKKKKACiiigAooooAUGng1HS5rWFRoVjZsNTRYRBeKXiH8S/e/Ota3RJMtaSh8/w5yR9a5IGpYpniOYnZD6g4r0KWItuS0dpBfKo8m6BYDrirESmF1n0x3XBzgnkfSuestaiYMuoRblxhTGMHPvWpCCAWtJhLxkKh5X613066ZLR694fvIfE+kxSz3KQa4nyJGDg8dCavR/29pmbW4QXkB5YsM59q8bt7t1nR9zQXI/jTg11mj+NNW0tPKEq3SHvJy1dtOtcho7x4NI1fFtNZG0cdSF25NQ6h4JsfsrNaSSLKoypY8Vz1t48unlBurS3Xn722t2Lx/prxbZYpN/QgdK6YzT2FY811eG7tb14ch1HUrWaLaaST5wwX3rq/EWrW19f+fCEiiIxjpWSHaR8KdyHpiqckBhzRLE5zgkVPpkIurqNIVLOTytaMtlDK43hgg6mrti8djcRy28WJgcZI7VzTmxo6fQPDyACS92Qwocs0n9Kmv/ABJp1m7Lo8AnnjP35hlMe1Yer6vf6iSsjxrGRtMa96zYoVi2xqmCevpisvaPoOxdfXNWubprj7Q4GP8AVoeK2YfG+qRrGpjhKLwwI+YiuNku1W48qBiXzj5e1SKJQWaZhjOOKOZvqB6VN41hGjveQ2c/mfdBI4De/tXCXfiLWr9mlkuPKTGT5ZxXW+G41n8EaoWVWADbd3Y+teewMqRiOWQcLk89aJOXcDRh127UKyX1xuB6O3WrOrazdz+Sl3L5qNj92Tx9axwiPCxBXH8JrHXzYL9Gll80g5654qedoLG3qVkgkV4iyKRkqvrUVrECrYMm3qS3WrhkF1MsjfKgGMVOyRAlATjGeKpMCvEgYdfbmntGBjngDFNAG0/MAAeKd8u8EsGXGcDrVKYWIH3qCCoCjuKbCxfBONtSy+YUbysYx/FWI88aHE0jEg/8szQ52CxpTFd2N4XB7VMNQuEXbFcSxqOgc8ViyaiCMRqpP9402Fbq4k+VHk9x0FT7fsFjUvdT8lNzFZZz1ZuQPpWU7T3/ACWIQdW7Coru6tLKXF2TLKBwqdB9axNQ1e4uyAuIUAxtTjI96zqYqysxqJry3Ol2DbXLXEuOGjPy5rLvNduZ4zGgWJc8FBg1kZpM15tSu2UkOkdpHLuxZj1J700mkJppNcs6hQuaCabmkrnlU7DsKTmkoorJu4wooopAFFFFABRRRQAUUUUAFFFFABRRRQAZpwNNoqlJoCQGpYJ5ISTDIyE9dpxVbNKDW8a9hWOgsdYQrtvkLBfusn3s+9bccsckava3MQ3fdQn5s1wwano5RgynDDoR2rtpYuxDidqWnhceasi7v+enSrH2iMRYCkseMiuUtNbu4C5dhPuGP3vOPpSrq8rTKzhQmeQtdtPFxJcTsbb7JPDsuTtftU8NsIspDIdvrnpXOw3lheMFDvE+PvOeKsJGqSH/AImUW3H96t3XT2Cx0KSTKwjYKR/nmnkyu5OBsAwD71iNdOB/x/WxAHHzc1NHdMFUfb7XaeSN1T7VMLGs0haPciHI4yarSJdtnBwCPxql9qcAj+0LPGcj5qIpQWDSanb7s9m4xS9pELD7bSXim83eNx/Orstg88RV5sA+h5qk8kTS4/tKADPJDVZgaxVzv1KIj/eq4yiwOs0LWbXSvC93pTCV55QdrHoPrXMq1pFJF9oCkhcH0NQSXFjuZft0RzxndTHk01QPMu4nIHY1bnEViS41C1jZ1VV254HtTGvrLIbyCG24zis641HSYs5+d8dqqyaxo7ADZc9P1rF1YrqOxurf2vlEsHXHpSHVrbAKqwrnTqejt95bvHfBqGXUNLBJhW5J7bjU+3j3Cx076nahCSrZz0pf7TgZgyL8oGOK4htWlyQqJtzkZFMOqz4wAg+gpfWIhY6y/wBSMqFIQ0an7xaqFtbvK52KMAcu33ayodeuIlwYoXH+0M1WvNWublvveUuMFY+AazniIsaR0U1zp+ngGZ1uJO3knj8axb/Xbu5ceU/kIOAI+OKyM4pN1c0q47EjszsWckseST3phNNLUm6sJVkOwpNJmm5pK5ZVb7FWFJpKKKybbGFFFFIAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApc0UU02gFDUoNFFaQkxCg0uaKK6VJiDIpc+1FFWpMQUUUU7sAozRRTuAcelHFFFO7AM0Z4ooqXJgJmjNFFRzsYmaM0UVLkwDNITRRWcpMBCaTNFFYykxiZoooqLjCiiigAooooAKKKKACiiigAooooAtafZSX0xjiKggZ5pEFso2zeZvBwcdKKKOgH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    PET-CT showing a left lung mass and adjacent pleural thickening that is metabolically active. CT guided pleural biopsy showed non-small cell lung cancer.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_57_41887=[""].join("\n");
var outline_f40_57_41887=null;
